| A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin | Phase 3 | Eli Lilly and Company | <1 mi |
| EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | Phase 3 | Boehringer Ingelheim | <1 mi |
| Study to Assess the Effects of Oral NMRA-335140 in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Study to Assess the Safety and Effectiveness of NMRA-335140-501 | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure and Impaired Kidney Function | Phase 3 | AstraZeneca | <1 mi |
| AN INTERNATIONAL, OBSERVATIONAL, BLINDED STUDY TO ASSESS THE PERFORMANCE OF THE CORDIO HEARO SYSTEM | — | Cordio Medical | <1 mi |
| A Study to Test Whether Vicadrostat (BI 690517) in Combination With Empagliflozin Helps People With Heart Failure and a Weak Pumping Function of the Left Side of the Heart | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Heart Failure | Phase 3 | Boehringer Ingelheim | <1 mi |
| Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin | Phase 3 | AstraZeneca | <1 mi |
| A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | <1 mi |
| Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76) | Phase 3 | Anthos Therapeutics, Inc. | <1 mi |
| Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7 | Phase 2/3 | Mirati Therapeutics Inc. | <1 mi |
| Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor | Phase 3 | OSE Immunotherapeutics | <1 mi |
| A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC | Phase 3 | AstraZeneca | <1 mi |
| The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma. | Phase 3 | Epizyme, Inc. | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007) | Phase 3 | AstraZeneca | <1 mi |
| ADSTILADRIN Early Utilization and Outcomes in the Real World Setting | — | Ferring Pharmaceuticals | <1 mi |
| A Study of JNJ-64042056 in Participants With Preclinical Alzheimer's Disease | Phase 2 | Janssen Pharmaceutica N.V., Belgium | <1 mi |
| A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2) | Phase 3 | Erasca, Inc. | <1 mi |
| A Study to Evaluate the Effect of Venetoclax on Participants Receiving a Covalent Bruton's Tyrosine Kinase Inhibitor (cBTKi) for First-line Chronic Lymphocytic Leukemia (1L CLL) to Achieve Deep Durable Remissions to Allow Off-treatment Period. | Phase 2 | Genentech, Inc. | <1 mi |
| RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis | Phase 1/2 | Cabaletta Bio | <1 mi |
| A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge) | Phase 3 | Definium Therapeutics US, Inc. | <1 mi |
| Symbiotic Use in Post-Bariatric Surgery Patients | N/A | University of North Florida | <1 mi |
| Study of GS-0272 in Participants With Rheumatoid Arthritis | Phase 1 | Gilead Sciences | <1 mi |
| Long Term Followup of Patients Enrolled in MC1137, BEAUTY Study | — | Mayo Clinic | <1 mi |
| DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy | Phase 1 | Boehringer Ingelheim | <1 mi |
| Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer | Phase 2 | Mayo Clinic | <1 mi |
| Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01) | Phase 3 | AstraZeneca | <1 mi |
| A Study to Test Long-term Treatment With Brigimadlin in People With Solid Tumours Who Took Part in a Previous Study With This Medicine | Phase 2 | Boehringer Ingelheim | <1 mi |
| Efficacy, Safety and Tolerability of AZD6234 in Participants Living With Overweight or Obesity With Type 2 Diabetes Who Are on a Stable Dose of GLP-1 Receptor Agonist | Phase 2 | AstraZeneca | <1 mi |
| 48-hour Ambulatory EEG Monitoring in Early Onset Alzheimer's Disease | N/A | Mayo Clinic | <1 mi |
| A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02) | Phase 3 | DualityBio Inc. | <1 mi |
| Study to Assess EN3835 in the Treatment of Plantar Fibromatosis (Also Known as Ledderhose Disease) | Phase 3 | Endo Pharmaceuticals | <1 mi |
| Study of ABBV-383 Assessing Adverse Events and Clinical Activity With Subcutaneous (SC) Injection in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | AbbVie | <1 mi |
| A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers | N/A | Integra LifeSciences Corporation | <1 mi |
| Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) | — | University of Southern California | <1 mi |
| Nipocalimab in Moderate to Severe Sjogren's Disease | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| CARE: Cancer Risk Perception and Women of Color | — | Mayo Clinic | <1 mi |
| Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs. | Phase 1/2 | RayzeBio, Inc. | <1 mi |
| An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies | Phase 1/2 | BeOne Medicines | <1 mi |
| Project: Every Child for Younger Patients With Cancer | — | Children's Oncology Group | <1 mi |
| Triptorelin for the Prevention of Ovarian Damage in Adolescents and Young Adults With Cancer | Phase 3 | Children's Oncology Group | <1 mi |
| A Trial of Robotic Versus Open Hysterectomy Surgery in Cervix Cancer | N/A | GOG Foundation | <1 mi |
| DCSZ11 as a Monotherapy and in Combination in Patients With Advanced or Metastatic Solid Tumors | Phase 1 | DynamiCure Biotechnology | <1 mi |
| Study of Acalabrutinib and Rituximab in Untreated Elderly and/or Frail Patients With DLBCL | Phase 2 | AstraZeneca | <1 mi |
| Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial | Phase 2 | Mayo Clinic | <1 mi |
| Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy | N/A | Proton Collaborative Group | <1 mi |
| A Culturally-Tailored Mobile Health and Social Media Physical Activity Intervention for Improving Physical Activity in Hispanic or Latino/Latina Adolescent and Young Adult Childhood Cancer Survivors, Walking Juntos Study | Phase 2 | Children's Oncology Group | <1 mi |
| Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | Phase 3 | Advenchen Laboratories, LLC | <1 mi |
| Alternate Doses and Dosing Schedules of Belantamab Mafodotin for Treatment of Triple-Class Refractory Multiple Myeloma | Phase 2 | Mayo Clinic | <1 mi |
| A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples | N/A | Mayo Clinic | <1 mi |
| A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial | Phase 2 | NRG Oncology | <1 mi |
| Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer | Phase 4 | Novartis Pharmaceuticals | <1 mi |
| ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study) | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| Evaluating a Mobile Health Application Intervention for Caregiver Instruction in Manual Therapy for Chemotherapy-Induced Peripheral Neuropathy | N/A | Mayo Clinic | <1 mi |
| An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| Evaluate the Safety and Clinical Activity of HH2853 | Phase 1/2 | Haihe Biopharma Co., Ltd. | <1 mi |
| A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations | Phase 3 | Children's Oncology Group | <1 mi |
| Fasting Mimicking Diet for Reducing Immune Related Adverse Events for Cancer Patients on Immune Checkpoint Inhibitors, FMD-ICI Trial | N/A | Mayo Clinic | <1 mi |
| A Study of Vibegron in Pediatric Participants 2 Years to Less Than (<) 18 Years of Age With NDO and on CIC | Phase 2/3 | Urovant Sciences GmbH | <1 mi |
| Study of Lurbinectedin in Combination With Doxorubicin Versus Doxorubicin Alone as First-line Treatment in Participants With Metastatic Leiomyosarcoma (SaLuDo) | Phase 3 | PharmaMar | <1 mi |
| Highly Selective CDK7 Inhibitor Q901 in Selected Advanced Solid Tumors | Phase 1/2 | Qurient Co., Ltd. | <1 mi |
| Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders | — | Mayo Clinic | <1 mi |
| Proton Radiation for Unresectable, Borderline Resectable, or Medically Inoperable Carcinoma of the Pancreas | Phase 2 | Proton Collaborative Group | <1 mi |
| Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2) | Phase 2/3 | BicycleTx Limited | <1 mi |
| Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells | Phase 2/3 | Celgene | <1 mi |
| Registry to Collect Data on Patients Undergoing Segmental Mandibular Defect Reconstruction Following Oral Squamous Cell Carcinoma Resection and Drugs-induced Osteonecrosis | — | AO Innovation Translation Center | <1 mi |
| Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Study to Investigate the Efficacy and Safety of RP1 in Adult Patients With Organ Transplants and Advanced Skin Malignancies | Phase 1/2 | Replimune Inc. | <1 mi |
| Ex Vivo Expansion (ACT-X) | — | Mayo Clinic | <1 mi |
| Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma. | Phase 1 | Tcelltech Inc. | <1 mi |
| LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | Phase 1/2 | enGene, Inc. | <1 mi |
| BMS-986340 in Combination With Nivolumab, Gemcitabine and Nab-paclitaxel for the Treatment of Metastatic and Recurrent Pancreatic Adenocarcinoma | Phase 2 | Mayo Clinic | <1 mi |
| Evaluation of Tirzepatide as an Adjunct to Buprenorphine for the Treatment of Opioid Use Disorder | Phase 2 | T. John Winhusen, PhD | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| A Study of Treatment for Medulloblastoma Using Sodium Thiosulfate to Reduce Hearing Loss | Phase 3 | Children's Oncology Group | <1 mi |
| Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC | Phase 2 | CG Oncology, Inc. | <1 mi |
| A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) | Phase 3 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| SRS Compared With FSRS for Treatment of Intact Metastatic Brain Disease, FRACTIONATE Trial | Phase 2 | Mayo Clinic | <1 mi |
| Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Neoadjuvant Darovasertib in Primary Uveal Melanoma | Phase 3 | IDEAYA Biosciences | <1 mi |
| A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma | Phase 3 | Kite, A Gilead Company | <1 mi |
| A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients | Phase 3 | Children's Oncology Group | <1 mi |
| A Phase 1 Study of Ruxolitinib, Steroids and Lenalidomide for Relapsed/Refractory Multiple Myeloma (RRMM) Patients | Phase 1 | Oncotherapeutics | <1 mi |
| A Virtual Community Health Educator for Increasing Clinical Trial Referrals Among Cancer Patients and Their Caregivers | N/A | Mayo Clinic | <1 mi |
| Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer | Phase 2 | Ono Pharmaceutical Co. Ltd | <1 mi |
| DOC1021 Dendritic Cell Immunotherapy for Treatment of Newly Diagnosed Adult Glioblastoma (GBM) | Phase 2 | Diakonos Oncology Corporation | <1 mi |
| Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer | — | Mayo Clinic | <1 mi |
| Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma | N/A | Melanoma and Skin Cancer Trials Limited | <1 mi |
| BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Ivosidenib in Participants With Locally Advanced or Metastatic Conventional Chondrosarcoma Untreated or Previously Treated With 1 Systemic Treatment Regimen | Phase 3 | Servier Bio-Innovation LLC | <1 mi |
| A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors | Phase 1/2 | Artios Pharma Ltd | <1 mi |
| A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer | Phase 2 | BioNTech SE | <1 mi |
| Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies | — | Children's Oncology Group | <1 mi |
| Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML) | Phase 3 | PedAL BCU, LLC | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| Non-Invasive Identification of Endometrial Cancer/Endometrial Atypical Hyperplasia With an AI-Based Classifier Applied to Transvaginal Ultrasound in Patients With Post-Menopausal Bleeding | — | Mayo Clinic | <1 mi |
| Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma | N/A | Mayo Clinic | <1 mi |
| In-home Intravesical Chemotherapy for the Treatment of Bladder Cancer, INVITE Trial | Phase 1/2 | Mayo Clinic | <1 mi |
| A Study to Test the Addition of the Drug Cabozantinib to Chemotherapy in Patients With Newly Diagnosed Osteosarcoma | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head) | Phase 3 | Regeneron Pharmaceuticals | <1 mi |
| TEMPUS ARIES: A Biobank Registry Platform Study in Oncology | — | Tempus AI | <1 mi |
| Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study | Phase 1/2 | PedAL BCU, LLC | <1 mi |
| UFPTI 2403-PR12: Real-Time Volumetric Ionizing Radiation Acoustic Imaging for In-vivo Proton Treatment Monitoring in Pencil-Beam Scanning | N/A | University of Florida | <1 mi |
| CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. | Phase 2 | TORL Biotherapeutics, LLC | <1 mi |
| Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer | Phase 3 | Astellas Pharma Global Development, Inc. | <1 mi |
| Biomarkers to Predict Cancer Therapy-related Cardiotoxicity | — | Mayo Clinic | <1 mi |
| Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery | Phase 3 | NRG Oncology | <1 mi |
| Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors | Phase 1/2 | Xilio Development, Inc. | <1 mi |
| Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer | Phase 3 | AbbVie | <1 mi |
| Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma | Phase 1/2 | AstraZeneca | <1 mi |
| A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy | Phase 3 | Lyell Immunopharma, Inc. | <1 mi |
| Study of IBI3020 Treatment in Participants With Late-Stage Solid Tumors | Phase 1 | Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. | <1 mi |
| A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | Phase 2 | Astellas Pharma Global Development, Inc. | <1 mi |
| Allogenic Adipose-Derived Mesenchymal Stem Cells for the Treatment of Recurrent Glioblastoma or Recurrent Astrocytoma in Patients Undergoing Craniotomy | Phase 1 | Mayo Clinic | <1 mi |
| A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents | Phase 3 | AstraZeneca | <1 mi |
| JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC | Phase 3 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up | — | Center for Biomedical Research, LLC | <1 mi |
| A Study of Live Tumor Fragments of Surgical Resections | — | Mayo Clinic | <1 mi |
| SPECT-CT Guided ELEctive Contralateral Neck Treatment for Patients With Lateralized Oropharyngeal Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) | Phase 3 | AbbVie | <1 mi |
| Study of Human Brain-Gut Axis and Gut Microbiome in Patients With Brain Lesions - Repository for Neuroscience Research | — | Mayo Clinic | <1 mi |
| A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Master Protocol to Evaluate DCC-3009 in Gastrointestinal Stromal Tumor (GIST) | Phase 1/2 | Deciphera Pharmaceuticals, LLC | <1 mi |
| Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| Study of Lunresertib Alone or in Combination With RP-3500 or Debio 0123 in Patients With Advanced Solid Tumors | Phase 1 | Debiopharm International SA | <1 mi |
| REtroperitoneal SArcoma Registry: an International Prospective Initiative | — | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | <1 mi |
| Dose Adjusted Chemoradiotherapy in HPV-Associated Oropharynx Cancer of the Elderly | N/A | Omar Mahmoud | <1 mi |
| Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587/KEYNOTE-587) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Feasibility and Effect of Wrapping Nerves With a Multi-Layer Perinatal Tissue Allograft During Prostatectomy | N/A | Mayo Clinic | <1 mi |
| Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML | Phase 3 | Daiichi Sankyo | <1 mi |
| A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma | Phase 2/3 | Global Coalition for Adaptive Research | <1 mi |
| A Study Comparing BMS-986504 in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30) | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Evaluation of a Novel Auto Segmentation Algorithm for Normal Structure Delineation in Radiation Treatment Planning | — | Mayo Clinic | <1 mi |
| Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC) | Phase 3 | Polaris Group | <1 mi |
| Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs) | — | Alexion Pharmaceuticals, Inc. | <1 mi |
| Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) | Phase 1/2 | Juno Therapeutics, a Subsidiary of Celgene | <1 mi |
| Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma | Phase 3 | Children's Oncology Group | <1 mi |
| Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy | Phase 3 | Children's Oncology Group | <1 mi |
| Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors | Phase 3 | Children's Oncology Group | <1 mi |
| Trial of Nadofaragene Firadenovec vs. Observation in Participants With Intermediate Risk Non-Muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | <1 mi |
| Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain | Phase 2 | Dogwood Therapeutics Inc. | <1 mi |
| Comparing Carbon Ion Therapy, Surgery, and Proton Therapy for Management of Pelvic Sarcomas Involving the Bone | — | Mayo Clinic | <1 mi |
| A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations | Phase 2 | Sameek Roychowdhury | <1 mi |
| A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST) | Phase 1 | Kura Oncology, Inc. | <1 mi |
| Pre-myeloid Cancer and Bone Marrow Failure Clinic Study | N/A | Mayo Clinic | <1 mi |
| Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer | N/A | Mayo Clinic | <1 mi |
| Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma | Phase 3 | Genmab | <1 mi |
| Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body | — | Bayer | <1 mi |
| Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer | Phase 1/2 | Mayo Clinic | <1 mi |
| A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT | Phase 2 | Children's Oncology Group | <1 mi |
| Evaluating In Home Cancer Therapy Versus In Clinic Cancer Therapy in Black Men With Locally Advanced, Biochemically Recurrent and Metastatic Prostate Cancer | Phase 2 | Mayo Clinic | <1 mi |
| Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study | — | M.D. Anderson Cancer Center | <1 mi |
| Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies | Phase 1 | Epigenetix, Inc. | <1 mi |
| Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma | Phase 1 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| Radioembolization With Tremelimumab and Durvalumab for Locally Advanced Unresectable or Oligo-Metastatic Intrahepatic Cholangiocarcinoma | Phase 1 | Mayo Clinic | <1 mi |
| Pancreatic Cancer Early Detection Consortium | — | Arbor Research Collaborative for Health | <1 mi |
| Collecting Blood and Stool Samples to Detect Colorectal Cancer or Advanced Neoplasia in Lynch Syndrome Patients | — | Mayo Clinic | <1 mi |
| International Registry for Men With Advanced Prostate Cancer (IRONMAN) | — | Prostate Cancer Clinical Trials Consortium | <1 mi |
| Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease | Phase 2 | AbbVie | <1 mi |
| MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad) | Phase 3 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | <1 mi |
| A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib | Phase 4 | Eli Lilly and Company | <1 mi |
| A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) | — | Center for International Blood and Marrow Transplant Research | <1 mi |
| SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) | Phase 3 | Nuvation Bio Inc. | <1 mi |
| A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4) | Phase 3 | Celgene | <1 mi |
| Identification and Differentiation of Thyroid Nodules by Acoustic Imaging and Viscoelastic Parameters | — | Mayo Clinic | <1 mi |
| A Collaborative Intervention for Improving Cancer Pain Management in Cancer Survivors (ASCENT) | N/A | Mayo Clinic | <1 mi |
| A Study of 177Lu-FAP-2286 in Advanced Solid Tumors | Phase 1/2 | Novartis Pharmaceuticals | <1 mi |
| Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma | Phase 1 | Jiangsu Simcere Pharmaceutical Co., Ltd. | <1 mi |
| A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer | Phase 1/2 | ImmunityBio, Inc. | <1 mi |
| Testing the Use of the Combination of Selumetinib and Olaparib or Selumetinib Alone Targeted Treatment for RAS Pathway Mutant Recurrent or Persistent Ovarian and Endometrial Cancers, A ComboMATCH Treatment Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Registry Study for Radiation Therapy Outcomes | — | Proton Collaborative Group | <1 mi |
| Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD) | N/A | Mayo Clinic | <1 mi |
| Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation | Phase 3 | Amgen | <1 mi |
| Immune Profile of Acute Myeloid Leukemia Patients Receiving Azacitidine Plus Venetoclax Induction Chemotherapy | — | Mayo Clinic | <1 mi |
| An Extension Study for Patients Previously Enrolled in Studies With Pelabresib | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC | Phase 2/3 | Bicara Therapeutics | <1 mi |
| Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients With Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial | Phase 2 | Mayo Clinic | <1 mi |
| IVM With Low Cost Priming, Enhanced Oocyte Recovery, and Delayed Transfer | N/A | Bruce Rose, MD | <1 mi |
| Preoperative Radiosurgery for the Treatment of High Grade Glioma, NeoGlioma Trial | Phase 1 | Mayo Clinic | <1 mi |
| SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma | Phase 3 | Immatics US, Inc. | <1 mi |
| Acalabrutinib With or Without Obinutuzumab in Treating Patients With Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 2 | Mayo Clinic | <1 mi |
| A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV) | Phase 2 | Disc Medicine, Inc | <1 mi |
| Role of Gut Microbiome in Cancer Therapy | — | Mayo Clinic | <1 mi |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma | Phase 1/2 | Perspective Therapeutics | <1 mi |
| A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy | — | Massachusetts General Hospital | <1 mi |
| The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis | N/A | Ad scientiam | <1 mi |
| A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Phase 3 | BeOne Medicines | <1 mi |
| Building Community Living Labs in Black Communities to Advance Prostate Health Equity and Reduce Prostate Cancer Disparities in Black Men | N/A | Mayo Clinic | <1 mi |
| Hugo™ Robotic-Assisted Surgery (RAS) System in Gynecological Subjects (Embrace Gynecology) | N/A | Medtronic - MITG | <1 mi |
| A Study of Rilvegostomig or Durvalumab Plus Chemotherapy for First-Line Treatment of Biliary Tract Cancer (ARTEMIDE-Biliary02) | Phase 3 | AstraZeneca | <1 mi |
| A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies | Phase 1/2 | BeOne Medicines | <1 mi |
| CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL) | Phase 1/2 | Curis, Inc. | <1 mi |
| Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer | Phase 1 | Celyad Oncology SA | <1 mi |
| A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors | Phase 1 | Vividion Therapeutics, Inc. | <1 mi |
| Digoxin Medulloblastoma Study | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Comparison of Proton or Intensity Modulated Radiation Therapy After Surgery for Endometrial or Cervical Cancer | N/A | Mayo Clinic | <1 mi |
| Inotuzumab Ozogamicin in Treating Younger Patients With B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia | Phase 2 | Children's Oncology Group | <1 mi |
| Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration | Phase 2 | Medical College of Wisconsin | <1 mi |
| Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Acute Lymphoblastic Leukemia | Phase 1/2 | AstraZeneca | <1 mi |
| Fabry Disease Registry & Pregnancy Sub-registry | — | Genzyme, a Sanofi Company | <1 mi |
| Umbrella Study for Analysis of Data Related to Patients With Cancer | — | Tempus AI | <1 mi |
| A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes | Phase 1/2 | Chordia Therapeutics, Inc. | <1 mi |
| Study in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02 | Phase 1 | Celyad Oncology SA | <1 mi |
| Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Digital Treatment Platform for the Delivery of Home-Based Sequential Therapy in Patients With Glioma | N/A | Mayo Clinic | <1 mi |
| Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Customized TULSA-PRO Ablation Registry | — | Profound Medical Inc. | <1 mi |
| Retifanlimab with Bevacizumab and Hypofractionated Radiotherapy for the Treatment of Recurrent Glioblastoma | Phase 2 | Academic and Community Cancer Research United | <1 mi |
| Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies | Phase 1 | Mayo Clinic | <1 mi |
| Multi-Cancer Detection Observational Cohort Study | — | Mayo Clinic | <1 mi |
| EF-41/KEYNOTE D58: Phase 3 Study of Optune Concomitant With Temozolomide Plus Pembrolizumab in Newly Diagnosed Glioblastoma | Phase 3 | NovoCure GmbH | <1 mi |
| Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas | Phase 2 | Alliance for Clinical Trials in Oncology | <1 mi |
| MTI-301 for the Treatment of Metastatic or Unresectable and Refractory Solid Cancers | Phase 1 | Mayo Clinic | <1 mi |
| Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma | Phase 1 | Celgene | <1 mi |
| iCCaRE Consortium Pilot Project 1: Feasibility of a Point of Prostate Cancer Diagnosis Intervention for Newly Diagnosed Black Men | — | Mayo Clinic | <1 mi |
| Enfortumab Vedotin for the Treatment of Patients With Metastatic or Unresectable Squamous Cell Carcinoma of the Penis | Phase 2 | Mayo Clinic | <1 mi |
| Treatment of Inflammatory Myelitis and Optic Neuritis With Early vs Rescue Plasma Exchange (TIMELY-PLEX) | Phase 3 | Mayo Clinic | <1 mi |
| Intensity Modulated Proton or X-Ray Therapy After Surgery for Treatment of Head and Neck Cancer, the HEADLIGHT Study | Phase 2 | Mayo Clinic | <1 mi |
| Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) | Phase 3 | Children's Oncology Group | <1 mi |
| A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma | Phase 1 | K36 Therapeutics, Inc. | <1 mi |
| Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | <1 mi |
| Quality of Life After Treatment for Bladder Cancer: The Bladder Cancer Survivorship Study | — | Mayo Clinic | <1 mi |
| A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma | Phase 2/3 | Replimune Inc. | <1 mi |
| A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors | Phase 1 | SparX Biotech(Jiangsu) Co., Ltd. | <1 mi |
| Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL | Phase 2 | AstraZeneca | <1 mi |
| A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML | Phase 1 | Kura Oncology, Inc. | <1 mi |
| A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer | Phase 1 | City of Hope Medical Center | <1 mi |
| Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | Phase 3 | Immunocore Ltd | <1 mi |
| Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer | Phase 2 | Protara Therapeutics | <1 mi |
| Study of DISC-0974 (RALLY-MF) in Participants With Myelofibrosis or Myelodysplastic Syndrome and Anemia | Phase 1/2 | Disc Medicine, Inc | <1 mi |
| Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy | Phase 3 | Clarity Pharmaceuticals Ltd | <1 mi |
| A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) | Phase 1 | Hoffmann-La Roche | <1 mi |
| Risk Adapted De-Intensification of Radio-Chemotherapy for Oropharyngeal Squamous Cell Carcinoma | Phase 2 | University of Florida | <1 mi |
| Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Registry of Patients With Brain Tumors Treated With STaRT (GammaTiles) | — | GT Medical Technologies, Inc. | <1 mi |
| APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies | Early 1 | Ascentage Pharma Group Inc. | <1 mi |
| Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Understanding of Genetics by Men at Risk for Prostate Cancer | N/A | Mayo Clinic | <1 mi |
| The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| INTERogating Cancer for Etiology, Prevention and Therapy Navigation | — | Mayo Clinic | <1 mi |
| Nab-Paclitaxel + Cisplatin + Gemcitabine + TTF in pt. w/ Metastatic PAC | Phase 1/2 | Mayo Clinic | <1 mi |
| Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer | Phase 3 | AstraZeneca | <1 mi |
| Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma | Phase 3 | AbbVie | <1 mi |
| Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients | Early 1 | Mayo Clinic | <1 mi |
| Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy | Phase 2 | Mayo Clinic | <1 mi |
| Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy | Phase 3 | RayzeBio, Inc. | <1 mi |
| Customized 3D Printed Oral Stents During Head and Neck Radiotherapy | Phase 2 | M.D. Anderson Cancer Center | <1 mi |
| De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA | Phase 2 | Mayo Clinic | <1 mi |
| Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas | Phase 1 | Mayo Clinic | <1 mi |
| A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT | Phase 2 | Children's Oncology Group | <1 mi |
| Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Neuroendocrine Tumors | Phase 1/2 | Perspective Therapeutics | <1 mi |
| A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) | Phase 3 | Children's Oncology Group | <1 mi |
| Using Induced-Pluripotent Stem Cells to Model Cancer Therapy-Related Adverse Events | — | Mayo Clinic | <1 mi |
| A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma | Phase 3 | BeiGene | <1 mi |
| Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients | Phase 2 | Vyriad, Inc. | <1 mi |
| A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer | Phase 3 | AstraZeneca | <1 mi |
| A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients | Phase 3 | Merus B.V. | <1 mi |
| A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors | Phase 3 | BeOne Medicines | <1 mi |
| Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation | Phase 1 | Institut de Recherches Internationales Servier | <1 mi |
| Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| 64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer | Phase 3 | Clarity Pharmaceuticals Ltd | <1 mi |
| Collection of Research Data and Samples From Patients Who Experience Immunotherapy Side Effects | — | Alliance for Clinical Trials in Oncology | <1 mi |
| Feasibility of Patient-Centered Home Care (PCHC) to Reduce Disparities in High-Risk Black Men (BM) With Prostate Cancer (CaP) | — | Mayo Clinic | <1 mi |
| A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM | Phase 1 | Boston Scientific Corporation | <1 mi |
| A Study to Compare Iberdomide Maintenance Versus Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplant in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Bristol-Myers Squibb | <1 mi |
| Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma | Phase 3 | European Organisation for Research and Treatment of Cancer - EORTC | <1 mi |
| Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2/3 | Exelixis | <1 mi |
| A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors | Phase 1/2 | AstraZeneca | <1 mi |
| Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer | Phase 2 | Academic and Community Cancer Research United | <1 mi |
| Chemotherapy for the Treatment of Patients With Newly Diagnosed Very Low-Risk and Low Risk Fusion Negative Rhabdomyosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| A Phase I/II Study of AZD4512 Monotherapy or in Combination With Anticancer Agents in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma | Phase 1/2 | AstraZeneca | <1 mi |
| A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer | Phase 2 | Eli Lilly and Company | <1 mi |
| First in Human Study of Ziftomenib in Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | Kura Oncology, Inc. | <1 mi |
| Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Testing the Use of AMG 510 (Sotorasib) and Panitumumab as a Targeted Treatment for KRAS G12C Mutant Solid Tumor Cancers (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients With Operative Metastatic Brain Tumors | Phase 3 | Mayo Clinic | <1 mi |
| A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Decitabine in Combination With Standard of Care Therapy for the Treatment of Surgically Resectable HPV-Negative Head and Neck Cancer | Phase 1 | Mayo Clinic | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| Navicam for Detection of Barrett's Esophagus | N/A | Mayo Clinic | <1 mi |
| Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01) | Phase 1 | Janux Therapeutics | <1 mi |
| Inpatient Use of Personal Continuous Glucose Monitor (CGM) to Improve Diabetes Mellitus Control | N/A | Mayo Clinic | <1 mi |
| A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes | Phase 2 | Zucara Therapeutics Inc. | <1 mi |
| A Study to Test Whether BI 764524 Helps People With an Eye Condition Called Diabetic Retinopathy | Phase 2 | Boehringer Ingelheim | <1 mi |
| Trial to Evaluate the Safety and Effectiveness of Treatment With COMS One Device in Subjects With Diabetic Foot Ulcers | N/A | Piomic Medical | <1 mi |
| Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes | N/A | Endogenex, Inc. | <1 mi |
| Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring | — | Abbott Diabetes Care | <1 mi |
| Fenofibrate for Prevention of DR Worsening | Phase 3 | Jaeb Center for Health Research | <1 mi |
| Nonhealing Diabetic Foot Ulcers Treated With Standard of Care (SOC) Alone or Standard of Care and Amnion-Intermediate-Chorion (AIC) | Phase 4 | Cellution Biologics | <1 mi |
| Amnio-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone | N/A | Capsicure, LLC | <1 mi |
| Remedy to Diabetes Distress (R2D2): A Scalable Screen to Treat Program for School-age Families | N/A | Nemours Children's Clinic | <1 mi |
| Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD) | — | Mayo Clinic | <1 mi |
| A Study to Evaluate the Effect of Obicetrapib/Ezetimibe 10 mg Fixed-Dose Combination or Obicetrapib 10 mg Daily on Top of Guideline-Recommended Lipid-Lowering Therapy in Participants With Type 2 Diabetes and/or Metabolic Syndrome | Phase 3 | NewAmsterdam Pharma | <1 mi |
| Continuous Glucose Monitor for Mayo Clinic Advanced Care at Home Patients | N/A | Mayo Clinic | <1 mi |
| CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance | N/A | Nemours Children's Clinic | <1 mi |
| Proact: A Study of REACT in Subjects With Type 2 Diabetes Mellitus and Chronic Kidney Disease | Phase 3 | Prokidney | <1 mi |
| Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003) | Phase 1 | Merck Sharp & Dohme LLC | <1 mi |
| Breaking Disparities in Access to Advanced Diabetes Technologies in Children With Type 1 Diabetes | — | Nemours Children's Clinic | <1 mi |
| A Study of Dulaglutide (LY2189265) 3.0 mg and 4.5 mg in Pediatric Participants With Type 2 Diabetes Mellitus (AWARD-PEDS PLUS) | Phase 3 | Eli Lilly and Company | <1 mi |
| Registry for Stage 2 Type 1 Diabetes | — | Sanofi | <1 mi |
| A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma | Phase 2 | Children's Oncology Group | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Orally Administered VX-01 | Phase 2 | Vantage Biosciences Ltd | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder | Phase 2 | AbbVie | <1 mi |
| Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | <1 mi |
| A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms | Phase 4 | Axsome Therapeutics, Inc. | <1 mi |
| A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder | Phase 3 | Cybin IRL Limited | <1 mi |
| Study of ABX-002 for the Adjunctive Treatment of Major Depressive Disorder (AMPLIFY) | Phase 2 | Autobahn Therapeutics, Inc. | <1 mi |
| A Study of Ketamine Infusions to Treat Clinically-depressed ICU Patients | Phase 2 | Mayo Clinic | <1 mi |
| Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol | Phase 3 | Axsome Therapeutics, Inc. | <1 mi |
| A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) | Phase 3 | Xenon Pharmaceuticals Inc. | <1 mi |
| A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder | Phase 2 | Sirtsei Pharmaceuticals, Inc. | <1 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder | Phase 3 | Xenon Pharmaceuticals Inc. | <1 mi |
| A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder | Phase 2 | Syndeio Biosciences, Inc | <1 mi |
| Longitudinal Early-onset Alzheimer's Disease Study Protocol | — | Indiana University | <1 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| Dominantly Inherited Alzheimer Network (DIAN) | — | Washington University School of Medicine | <1 mi |
| [18F]PI-2620 Phase 3 Histopathological Study | Phase 3 | Life Molecular Imaging Ltd | <1 mi |
| Preventing Alzheimer's With Cognitive Training | Phase 3 | University of South Florida | <1 mi |
| A Double-blind Dual Study Assessing Safety and Efficacy of Buntanetap in Participants With Early AD | Phase 3 | Annovis Bio Inc. | <1 mi |
| Sex-Specific Effects of Endocrine Disruption on Aging and Alzheimer's Disease | Phase 4 | Mayo Clinic | <1 mi |
| Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease | N/A | MMI (Medical Microinstruments, Inc.) | <1 mi |
| VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2) | Phase 3 | Viking Therapeutics, Inc. | <1 mi |
| Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain After Gastric Bypass | N/A | Boston Scientific Corporation | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Sotagliflozin in Symptomatic Obstructive and Non-obstructive Hypertrophic Cardiomyopathy | Phase 3 | Lexicon Pharmaceuticals | <1 mi |
| The Rhythm Evaluation for AntiCoagulaTion With Continuous Monitoring of Atrial Fibrillation | Phase 3 | Johns Hopkins University | <1 mi |
| Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS | Phase 3 | DalCor Pharmaceuticals | <1 mi |
| Anticoagulation in ICH Survivors for Stroke Prevention and Recovery | Phase 3 | Yale University | <1 mi |
| Coherent Sine Burst Electroporation (CSE) Ablation System US IDE Study for Patients With Atrial Fibrillation | N/A | Arga Medtech SA | <1 mi |
| LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF | Phase 3 | Tenax Therapeutics, Inc. | <1 mi |
| SELUTION 4 De Novo Small Vessel IDE Trial | N/A | M.A. Med Alliance S.A. | <1 mi |
| A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events | N/A | Cleerly, Inc. | <1 mi |
| Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy | Phase 4 | Dennis M. McNamara, MD, MS | <1 mi |
| Virtual Reality for Non-cardiac Chest Pain | N/A | Mayo Clinic | <1 mi |
| The ENCIRCLE Trial | N/A | Edwards Lifesciences | <1 mi |
| Switching From Dual Antiplatelet Therapy to Monotherapy With Potent P2Y12 Inhibitors | Phase 4 | University of Florida | <1 mi |
| PROGRESS: Management of Moderate Aortic Stenosis by Clinical Surveillance or TAVR | N/A | Edwards Lifesciences | <1 mi |
| Comparison of Dual Antiplatelet Therapy De-escalation by Dose Reduction Versus Switching in Patients Undergoing PCI: The Switching Antiplatelet-8 (SWAP-8) Study | Phase 4 | University of Florida | <1 mi |
| MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) | Phase 3 | Intellia Therapeutics | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07328948 in Adults With Heart Failure (BRANCH-HF) | Phase 2 | Pfizer | <1 mi |
| A Precision Medicine Approach to Identify Patients Undergoing Elective PCI at Risk of Peri-PCI Myocardial Infarction | — | University of Florida | <1 mi |
| MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels | N/A | Concept Medical Inc. | <1 mi |
| A Prospective Registry Study to Assess Real-world Patient Characteristics, Treatment Patterns, and Longitudinal Outcomes in Patients Receiving Mavacamten and Other Treatments for Symptomatic Obstructive Hypertrophic Cardiomyopathy (Obstructive-HCM) | — | Bristol-Myers Squibb | <1 mi |
| GORE® CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients With Patent Foramen Ovale (PFO): the REDUCE Post Approval Study | N/A | W.L.Gore & Associates | <1 mi |
| Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement | N/A | University of British Columbia | <1 mi |
| AI Powered Mapping Technology for Identifying Arrhythmias | — | Heart Rhythm Clinical and Research Solutions, LLC | <1 mi |
| Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant | Phase 3 | Eidos Therapeutics, a BridgeBio company | <1 mi |
| CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3) | Phase 3 | Cardiol Therapeutics Inc. | <1 mi |
| Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI | Phase 4 | University of Florida | <1 mi |
| Artificial Intelligence Mapping and Ablation of Non-Pulmonary Vein Electrical Drivers of AF Study | N/A | Vektor Medical | <1 mi |
| A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study) | Phase 2 | Tectonic Therapeutic | <1 mi |
| Dual Antiplatelet Therapy Escalation From Standard-dose Clopidogrel to Low-Dose Prasugrel in Patients With High Bleeding and Ischemic Risk Undergoing PCI: A Prospective, Randomized Pharmacodynamic Study (TAILOR-BLEED-2) | Phase 4 | University of Florida | <1 mi |
| Left vs Left Randomized Clinical Trial | N/A | Baylor College of Medicine | <1 mi |
| Product Surveillance Registry | — | Medtronic | <1 mi |
| Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products | — | Medtronic | <1 mi |
| Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) | Phase 2 | Bristol-Myers Squibb | <1 mi |
| Ataciguat for Slowing the Progression of Moderate Calcific Aortic Valve Stenosis: A Randomized, Placebo Controlled Study | Phase 2/3 | Kardigan, Inc. | <1 mi |
| Effects of Low-dose Ticagrelor vs. Clopidogrel in Stable Patients Undergoing Elective Percutaneous Coronary Intervention | Phase 4 | University of Florida | <1 mi |
| Real-world Experience of Catheter Ablation for the Treatment of Paroxysmal and Persistent Atrial Fibrillation | — | Heart Rhythm Clinical and Research Solutions, LLC | <1 mi |
| Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment | — | Children's Oncology Group | <1 mi |
| PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm | N/A | Kardion Inc | <1 mi |
| The Switching Antiplatelet-9 (SWAP-9) Study | Phase 4 | University of Florida | <1 mi |
| Bridge to Lung Transplant With Trans-septal Extra-corporeal Membrane Oxygenation (ECMO) for Right Heart Failure From Pulmonary Hypertension | Phase 1 | Mayo Clinic | <1 mi |
| Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity | Phase 3 | Amgen | <1 mi |
| Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction | Phase 3 | Cytokinetics | <1 mi |
| The Fourth Left Atrial Appendage Occlusion Study | N/A | Hamilton Health Sciences Corporation | <1 mi |
| TECTONIC CAD IVL IDE Study | N/A | Abbott Medical Devices | <1 mi |
| The CONFORM Pivotal Trial | N/A | Conformal Medical, Inc | <1 mi |
| Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day | — | Heart Rhythm Clinical and Research Solutions, LLC | <1 mi |
| OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events | Phase 3 | Amgen | <1 mi |
| Efficacy of the COronary SInus Reducer in Patients With Refractory Angina II | N/A | Shockwave Medical, Inc. | <1 mi |
| A Study of Assessment on Safety and Effectiveness of BWI Pulsed Field Ablation With OMNYPULSE Catheter for the Treatment of Paroxysmal Atrial Fibrillation (PAF) | N/A | Biosense Webster, Inc. | <1 mi |
| Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. | N/A | Medtronic Cardiovascular | <1 mi |
| A Study to Test if a Fixed-Dose Combination of Fluticasone Propionate/Albuterol Sulfate is Effective in Preventing Asthma Exacerbations | Phase 3 | Teva Branded Pharmaceutical Products R&D LLC | <1 mi |
| Evaluating the Efficacy and Safety of PT027 Compared With PT007 Administered As Needed in Participants 12 to < 18 Years of Age With Asthma | Phase 3 | AstraZeneca | <1 mi |
| Optimizing a Sensor-Enabled mHealth Intervention for Adolescents With Suboptimal Asthma Control | N/A | University of Kansas | <1 mi |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | — | Duke University | <1 mi |
| Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis | Phase 2 | AbbVie | <1 mi |
| Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare | Phase 2/3 | Olatec Therapeutics LLC | <1 mi |
| Exactech Vantage Total Ankle System Post Market Clinical Follow-Up - US Only | — | Exactech | <1 mi |
| A Study to Investigate Efficacy and Safety of AZD1163 in Participants With Rheumatoid Arthritis | Phase 2 | AstraZeneca | <1 mi |
| Knee Injections for Obese Patients With Knee Arthritis | Phase 4 | Mayo Clinic | <1 mi |
| Exactech Shoulder Post Market Clinical Follow-up Study | — | Exactech | <1 mi |
| RA-PRO PRAGMATIC TRIAL | Phase 3 | University of Alabama at Birmingham | <1 mi |
| Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD | Phase 2 | Johns Hopkins University | <1 mi |
| myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home | N/A | Temple University | <1 mi |
| A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease | Phase 2 | AstraZeneca | <1 mi |
| Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3 | N/A | Apreo Health, Inc. | <1 mi |
| Potential Benefits of Parent Child Interaction Therapy (PCIT) | — | University of Florida | <1 mi |
| P3b Short-term Study of CTN in Patients With ADHD and Comorbid Anxiety | Phase 3 | Otsuka Pharmaceutical Development & Commercialization, Inc. | <1 mi |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Voyage) | Phase 3 | Definium Therapeutics US, Inc. | <1 mi |
| Study to Evaluate the Efficacy and Safety of VQW-765 for the On-Demand Treatment of Social Anxiety Disorder | Phase 3 | Vanda Pharmaceuticals | <1 mi |
| Study to Assess Adverse Events and Change in Disease Activity When Oral ABBV-932 is Added to Antidepressant Therapies in Adult Participants With Generalized Anxiety Disorder | Phase 2 | AbbVie | <1 mi |
| Virtual Reality Intervention to Improve Psychological Symptom Burden for Cancer Patients Undergoing Treatment | N/A | Mayo Clinic | <1 mi |
| A Study of NTX-1472 in Social Anxiety Disorder | Phase 2 | Newleos Therapeutics, Inc. | <1 mi |
| Registry of Deep Brain Stimulation With the VERCISE™ System: Vercise DBS Registry | — | Boston Scientific Corporation | <1 mi |
| Globus Pallidus Stimulation to Treat Insomnia | N/A | Mayo Clinic | <1 mi |
| RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus | Phase 1/2 | Cabaletta Bio | <1 mi |
| Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Cutaneous Lupus Erythematosus (CLE) | Phase 2 | Immunovant Sciences GmbH | <1 mi |
| A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE) | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1) | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | AbbVie | <1 mi |
| PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | Phase 2 | PhenoNet, Inc. | <1 mi |
| Safety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers | Phase 1/2 | Ashvattha Therapeutics, Inc. | <1 mi |
| AMT-260 Gene Therapy Study in Adults With Unilateral Refractory Mesial Temporal Lobe Epilepsy | Phase 1/2 | UniQure Biopharma B.V. | <1 mi |
| AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis | Phase 1 | Amylyx Pharmaceuticals Inc. | <1 mi |
| Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis | Phase 3 | Sanofi | <1 mi |
| Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis | Phase 3 | Sanofi | <1 mi |
| TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer | — | Mayo Clinic | <1 mi |
| A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies | Phase 1/2 | 858 Therapeutics, Inc. | <1 mi |
| Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy | Phase 3 | Proton Collaborative Group | <1 mi |
| Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63) | Phase 3 | Gilead Sciences | <1 mi |
| DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients | — | Mayo Clinic | <1 mi |
| Biospecimen and Medical Data Collection and Tumor Biopsy in Creating Research Tissue Registry in Patients With Inflammatory or Invasive Breast Cancer | — | M.D. Anderson Cancer Center | <1 mi |
| A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study | Phase 2 | GlaxoSmithKline | <1 mi |
| 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss | Phase 2 | Mayo Clinic | <1 mi |
| A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) | Phase 3 | Hoffmann-La Roche | <1 mi |
| Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Participants With Metastatic Breast Cancer | Phase 1/2 | Stemline Therapeutics, Inc. | <1 mi |
| Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Integrating Molecular Pathology, Radiology, and Genetics to Improve Breast Cancer Risk | — | Mayo Clinic | <1 mi |
| Adding a Genetic Risk Evaluation to Standard Breast Cancer Risk Assessment for African American and Hispanic Women | — | Mayo Clinic | <1 mi |
| (Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer | Phase 2 | Atossa Therapeutics, Inc. | <1 mi |
| MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles | — | Agendia | <1 mi |
| Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA) | Phase 3 | NRG Oncology | <1 mi |
| Saruparib (AZD5305) Plus Camizestrant Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer | Phase 3 | AstraZeneca | <1 mi |
| Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy | N/A | M.D. Anderson Cancer Center | <1 mi |
| An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) | Phase 3 | AstraZeneca | <1 mi |
| A Study of XMT-1660 in Participants With Solid Tumors | Phase 1 | Mersana Therapeutics | <1 mi |
| Cancer Genetic Testing in Ethnic Populations | N/A | Mayo Clinic | <1 mi |
| A Randomized Controlled Trial (RCT) to Determine the Efficacy of a Multidisciplinary CBT Based Pain Management Program for the Treatment of Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) in Breast Cancer Survivors | N/A | Mayo Clinic | <1 mi |
| A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer | Phase 2 | Puma Biotechnology, Inc. | <1 mi |
| A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence | Phase 3 | Stemline Therapeutics, Inc. | <1 mi |
| Virtual Support Platform (HERCaRE Application) for the Improvement of Survivorship Among Black Breast Cancer Survivors | N/A | Mayo Clinic | <1 mi |
| Postoperative Outcomes and Patient Satisfaction With Mayo Clinic Florida Care Hotel After Mastectomy and Tissue Expander Placement | — | Mayo Clinic | <1 mi |
| Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy | — | Mayo Clinic | <1 mi |
| Low Dose Aspirin for the Prevention of Postpartum Related Breast Cancer | Phase 2 | Mayo Clinic | <1 mi |
| Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration | Phase 1/2 | ORIC Pharmaceuticals | <1 mi |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer | Phase 3 | Olema Pharmaceuticals, Inc. | <1 mi |
| Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation | Phase 3 | Sermonix Pharmaceuticals Inc. | <1 mi |
| Evaluating the Association Between Changes in the Gut Microbiome, Fatigue, and Chemotherapy-Induced Nausea in Early Stage Breast Cancer | — | Mayo Clinic | <1 mi |
| A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA) | Phase 3 | Eli Lilly and Company | <1 mi |
| Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread | Phase 1/2 | Boehringer Ingelheim | <1 mi |
| A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation | Phase 3 | AstraZeneca | <1 mi |
| E-Mindfulness Approaches for Living After Breast Cancer | Phase 3 | NRG Oncology | <1 mi |
| Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Phase 1 Study of CLR 125 in Triple Negative Breast Cancer | Phase 1 | Cellectar Biosciences, Inc. | <1 mi |
| Neurotization of the Nipple Areolar Complex to Restore Sensation for Patients With Breast Cancer Undergoing Nipple Sparing Mastectomy and Reconstruction | Phase 2 | Mayo Clinic | <1 mi |
| Identifying Patterns in the Breath of Individuals With Breast Cancer | — | Breathe BioMedical Inc | <1 mi |
| A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ | Phase 1 | Mayo Clinic | <1 mi |
| Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors | N/A | NRG Oncology | <1 mi |
| Study of PF-07220060 With Letrozole in Adults With HR-positive HER2-negative Breast Cancer Who Have Not Received Anticancer Treatment for Advanced/Metastatic Disease | Phase 3 | Pfizer | <1 mi |
| Immune Response to Anti-HER2 Therapies in Patients With HER2-Positive Stage I-IV Breast Cancer | — | Mayo Clinic | <1 mi |
| Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25 | Phase 3 | NRG Oncology | <1 mi |
| A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors | Phase 1 | Exelixis | <1 mi |
| Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. | Phase 3 | BriaCell Therapeutics Corporation | <1 mi |
| Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| A Multilevel Approach to Connecting Underrepresented Populations to Clinical Trials | — | University of Florida | <1 mi |
| A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer | Phase 1/2 | IDEAYA Biosciences | <1 mi |
| Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy | Phase 1 | Abdera Therapeutics Inc. | <1 mi |
| Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers | Phase 1 | Nuvectis Pharma, Inc. | <1 mi |
| A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03) | Phase 1/2 | Daiichi Sankyo | <1 mi |
| A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | Phase 3 | AstraZeneca | <1 mi |
| Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors | Phase 1 | AstraZeneca | <1 mi |
| Safety and Durability of Sirolimus for Treatment of LAM | — | University of Cincinnati | <1 mi |
| A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | AstraZeneca | <1 mi |
| Study to Evaluate the Safety, Tolerability & Efficacy of TNG462 in Combination in PDAC & NSCLC Patients | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer | N/A | Mayo Clinic | <1 mi |
| Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC | Phase 1 | RayzeBio, Inc. | <1 mi |
| A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations | Phase 1/2 | Daiichi Sankyo | <1 mi |
| A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression | Phase 1/2 | A2 Biotherapeutics Inc. | <1 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1 | Phase 3 | Summit Therapeutics | <1 mi |
| A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation | Phase 1 | AstraZeneca | <1 mi |
| A Multicenter Study in Bronchoscopy Combining Stimulated Raman Histology With Artificial Intelligence for Rapid Lung Cancer Detection - The ON-SITE Study | — | Invenio Imaging Inc. | <1 mi |
| Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing | — | A2 Biotherapeutics Inc. | <1 mi |
| Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | <1 mi |
| A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations | Phase 1/2 | BlossomHill Therapeutics | <1 mi |
| A Study to Compare the Combination of BMS-986504 With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | Phase 3 | NRG Oncology | <1 mi |
| Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers | Phase 1 | Novartis Pharmaceuticals | <1 mi |
| A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | Phase 3 | Mirati Therapeutics Inc. | <1 mi |
| A Platform Study in Non-Small Cell Lung Cancer (NSCLC) | Phase 1/2 | AstraZeneca | <1 mi |
| KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors | Phase 1 | Kura Oncology, Inc. | <1 mi |
| Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma | Phase 1 | Xencor, Inc. | <1 mi |
| MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma | Phase 3 | AstraZeneca | <1 mi |
| Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | Phase 2 | Mirati Therapeutics Inc. | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression | Phase 1/2 | A2 Biotherapeutics Inc. | <1 mi |
| Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion | Phase 1 | Bristol-Myers Squibb | <1 mi |
| A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer | Phase 1/2 | BioNTech SE | <1 mi |
| A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors | Phase 1/2 | Cogent Biosciences, Inc. | <1 mi |
| Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant | Phase 2 | Mayo Clinic | <1 mi |
| Thoracotomy Versus Thoracoscopic Management of Pulmonary Metastases in Patients With Osteosarcoma | Phase 3 | Children's Oncology Group | <1 mi |
| Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | <1 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | Phase 3 | AstraZeneca | <1 mi |
| DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers | Phase 2 | Boehringer Ingelheim | <1 mi |
| A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 3 | AbbVie | <1 mi |
| Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients | Phase 3 | Summit Therapeutics | <1 mi |
| A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of KK2269 in Adult Participants With Solid Tumors | Phase 1 | Kyowa Kirin Co., Ltd. | <1 mi |
| A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | AbbVie | <1 mi |
| Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | Phase 2 | Mirum Pharmaceuticals, Inc. | <1 mi |
| A Longitudinal Observational Study of Patients With Nonalcoholic Steatohepatitis (NASH) and Related Conditions Across the Entire Spectrum of Nonalcoholic Fatty Liver Disease (NAFLD) | — | Target PharmaSolutions, Inc. | <1 mi |
| Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis | Phase 3 | Zydus Therapeutics Inc. | <1 mi |
| A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis) | Phase 3 | 89bio, Inc. | <1 mi |
| A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) | Phase 3 | Eli Lilly and Company | <1 mi |
| Ultrasound With Subharmonic Imaging and Subharmonic Aided Pressure Estimation (SHAPE) to Identify Portal Hypertension | N/A | Mayo Clinic | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH | Phase 3 | 89bio, Inc. | <1 mi |
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma | Phase 2 | Coherus Oncology, Inc. | <1 mi |
| An Open-Label, Multiple-Center, Phase IIa/IIb Clinical Trial to Evaluate the Efficacy, Safety and Tolerability of VG161 as Monotherapy and in Combination With Nivolumab for Treatment of Patients With Hepatocellular Carcinoma or Intrahepatic Cholangiocarcinoma | Phase 2 | Virogin Biotech Canada Ltd | <1 mi |
| Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma | Phase 1 | Shanghai Henlius Biotech | <1 mi |
| The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas | Phase 2 | Mayo Clinic | <1 mi |
| At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer | Phase 2 | Mayo Clinic | <1 mi |
| SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry | — | Massive Bio, Inc. | <1 mi |
| Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma | Phase 3 | AstraZeneca | <1 mi |
| A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | Phase 1/2 | GI Innovation, Inc. | <1 mi |
| Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma | Phase 3 | Children's Oncology Group | <1 mi |
| Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | Phase 1/2 | Mayo Clinic | <1 mi |
| Atezolizumab in Combination With a Multi-Kinase Inhibitor for the Treatment of Unresectable, Locally Advanced, or Metastatic Liver Cancer | Phase 2 | Academic and Community Cancer Research United | <1 mi |
| A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma | Phase 1 | Alnylam Pharmaceuticals | <1 mi |
| Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform | — | Mayo Clinic | <1 mi |
| Comparison of In-Home Versus In-Clinic Administration of Subcutaneous Nivolumab Through Cancer CARE (Connected Access and Remote Expertise) Beyond Walls (CCBW) Program | Phase 2 | Mayo Clinic | <1 mi |
| A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-011 in Patients With Advanced Solid Tumor | Phase 1 | Abbisko Therapeutics Co, Ltd | <1 mi |
| Optimizing Y90 Therapy for Radiation Lobectomy | — | Northwestern University | <1 mi |
| A Phase 1, First in Human Study of TORL-4-500 in Patients With Advanced Cancer | Phase 1 | TORL Biotherapeutics, LLC | <1 mi |
| Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors | Phase 1 | Exelixis | <1 mi |
| Intravital Microscopy in Human Solid Tumors | N/A | Mayo Clinic | <1 mi |
| AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2 | Phase 3 | AstraZeneca | <1 mi |
| Ocular Assessments in Patients Treated With Tivdak® in Recurrent or Metastatic Cervical Cancer | Phase 4 | Pfizer | <1 mi |
| A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD | Phase 2 | Verona Pharma plc | <1 mi |
| TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers | Phase 1 | Tizona Therapeutics, Inc | <1 mi |
| A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression | N/A | LivaNova | <1 mi |
| A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy | Phase 3 | AstraZeneca | <1 mi |
| Multicenter Study of Lumateperone for the Treatment of Bipolar Depression in Pediatric Patients | Phase 3 | Intra-Cellular Therapies, Inc. | <1 mi |
| Study to Assess the Effects of Oral NMRA-335140 Versus Placebo in Participants With Major Depressive Disorder | Phase 3 | Neumora Therapeutics, Inc. | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AEs) With Cariprazine in the Treatment of Depressive Episodes in Pediatric Participants Participants (10 to 17 Years of Age) With Bipolar I Disorder. | Phase 3 | AbbVie | <1 mi |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Agitation Associated With Alzheimer's Dementia | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-2) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study to Assess the Efficacy and Safety of ML-007C-MA for the Treatment of Alzheimer's Disease Psychosis | Phase 2 | MapLight Therapeutics | <1 mi |
| A Study to Evaluate Solrikitug in Participants With COPD (ZION) | Phase 2 | Uniquity One (UNI) | <1 mi |
| A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease | Phase 3 | AstraZeneca | <1 mi |
| A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006) | Phase 3 | AstraZeneca | <1 mi |
| LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) | Phase 3 | Inventiva Pharma | <1 mi |
| Assessment of CCM in HF With Higher Ejection Fraction | N/A | Impulse Dynamics | <1 mi |
| Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adults With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids | Phase 2 | AstraZeneca | <1 mi |
| Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma | Phase 4 | Sanofi | <1 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | <1 mi |
| A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH | Phase 3 | Akero Therapeutics, Inc | <1 mi |
| A Study to Learn About the Investigational Medicine Called PF-06821497 (Mevrometostat) in Men With mCRPC Who Were Previously Treated With Abiraterone Acetate for Prostate Cancer (MEVPRO-1). | Phase 3 | Pfizer | <1 mi |
| Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer | Phase 3 | NRG Oncology | <1 mi |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases | Phase 2 | SWOG Cancer Research Network | <1 mi |
| Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis | Phase 2/3 | CSL Behring | <1 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines | Phase 3 | Takeda | <1 mi |
| A Study of Dotinurad Versus Allopurinol in Participants With Gout | Phase 3 | Crystalys Therapeutics | <1 mi |
| A Master Protocol Study (LY900028) of Multiple Intervention-Specific-Appendices (ISAs) in Participants With Chronic Pain | Phase 2 | Eli Lilly and Company | <1 mi |
| Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS | N/A | Philip Morris Products S.A. | <1 mi |
| A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer | Phase 1/2 | Pfizer | <1 mi |
| A Study to Evaluate the Efficacy and Safety of MK-1167 in Participants With Alzheimer's Disease Dementia (MK-1167-008) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| Investigation of the Effects of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of Opemalirsen (AZD2373) | Phase 1 | AstraZeneca | <1 mi |
| Silmitasertib (CX-4945) in Combination With Chemotherapy for Relapsed Refractory Solid Tumors | Phase 1/2 | Milton S. Hershey Medical Center | <1 mi |
| A Phase 3B Study to Evaluate Bone Mineral Density With Long-Term Use of Relugolix Combination Tablet in Women With Uterine Fibroids or Endometriosis | Phase 3 | Sumitomo Pharma Switzerland GmbH | <1 mi |
| Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| A Study of Tagraxofusp in Combination With Venetoclax and Azacitidine in Adults With Untreated CD123+ Acute Myeloid Leukemia Who Cannot Undergo Intensive Chemotherapy | Phase 2 | Stemline Therapeutics, Inc. | <1 mi |
| Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma | Phase 2 | Giselle Sholler | <1 mi |
| TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer | Phase 2 | American Society of Clinical Oncology | <1 mi |
| A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors) | Phase 1 | Boehringer Ingelheim | <1 mi |
| Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL | Phase 2 | Allogene Therapeutics | <1 mi |
| Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer | Phase 3 | Incyte Corporation | <1 mi |
| Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute) | Phase 3 | Amgen | <1 mi |
| A Phase 1/2 Study of BHV-1510 (Previously PBI-410) in Advanced Solid Tumors | Phase 1/2 | Biohaven Therapeutics Ltd. | <1 mi |
| DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) | Phase 3 | Day One Biopharmaceuticals, Inc. | <1 mi |
| Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma | Phase 2 | Giselle Sholler | <1 mi |
| Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | Phase 3 | AstraZeneca | <1 mi |
| Beat Childhood Cancer Specimen Banking and Data Registry | — | Giselle Sholler | <1 mi |
| DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma | Phase 2 | Giselle Sholler | <1 mi |
| Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Serious Gaming for Chemotherapy-induced Nausea and Vomiting | N/A | University of Central Florida | <1 mi |
| A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma | Phase 2 | Hoffmann-La Roche | <1 mi |
| Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents | Phase 2 | Joshua Zeidner | <1 mi |
| Pediatric Precision Laboratory Advanced Neuroblastoma Therapy | Phase 2 | Giselle Sholler | <1 mi |
| Efficacy and Safety of GL0034 in Overweight or Obese Adults With Type II Diabetes Mellitus | Phase 2 | Sun Pharmaceutical Industries Limited | <1 mi |
| Study to Evaluate if Exposure to Drug is Impacted in Participants With Renal Insufficiency | Phase 1 | Sun Pharmaceutical Industries Limited | <1 mi |
| FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS) | Phase 2 | Sanofi | <1 mi |
| "A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" | Phase 3 | Cybin IRL Limited | <1 mi |
| A Study to Evaluate the Effectiveness of DT-101 in Patients With Depression | Phase 2 | Draig Therapeutics Ltd | <1 mi |
| A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| Development of a Database to Investigate Digital and Blood-Based Biomarkers and Their Relationship to Tau and Amyloid PET Imaging in Older Participants Who Are Cognitively Normal (CN), Have Mild Cognitive Impairment (MCI), or Have Mild-to-Moderate AD Dementia | — | GAP Innovations, PBC | <1 mi |
| ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease | N/A | InSightec | <1 mi |
| ACP-204 in Adults With Alzheimer's Disease Psychosis | Phase 2/3 | ACADIA Pharmaceuticals Inc. | <1 mi |
| A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1) | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type | Phase 3 | Suven Life Sciences Limited | <1 mi |
| Allopregnanolone Regenerative Therapeutic for Mild Alzheimer's Disease | Phase 2 | University of Arizona | <1 mi |
| Screening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies | Phase 3 | Hoffmann-La Roche | <1 mi |
| Feasibility and Efficacy Study of the CardioPulmonary Management (CPM) System in Patients With Chronic Heart Failure | N/A | Analog Device, Inc. | <1 mi |
| National Collaborative to Improve Care of Children With Complex Congenital Heart Disease | — | Children's Hospital Medical Center, Cincinnati | <1 mi |
| The EMPOWER Trial - The Carillon Mitral Contour System® in Treating Heart Failure With at Least Mild FMR | N/A | Cardiac Dimensions, Inc. | <1 mi |
| Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment | Phase 3 | AstraZeneca | <1 mi |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma | Phase 2 | Incyte Corporation | <1 mi |
| Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry | — | Duke University | <1 mi |
| A Study to Investigate the Treatment Effect of Subcutaneous Injections of Pentosan Polysulfate Sodium Compared With Placebo in Adult Participants With Knee Osteoarthritis Pain. | Phase 3 | Paradigm Biopharmaceuticals Ltd. | <1 mi |
| Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype | Phase 3 | Sanofi | <1 mi |
| A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD | Phase 2 | Upstream Bio Inc. | <1 mi |
| Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| Lenrispodun as Adjunctive Therapy in the Treatment of Patients With Motor Fluctuations Due to Parkinson's Disease | Phase 2 | Intra-Cellular Therapies, Inc. | <1 mi |
| Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease | — | AbbVie | <1 mi |
| A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease | Phase 4 | Impax Laboratories, LLC | <1 mi |
| Together After Cancer | N/A | University of South Florida | <1 mi |
| Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC | Phase 3 | Nuvalent Inc. | <1 mi |
| The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | Phase 1/2 | PMV Pharmaceuticals, Inc | <1 mi |
| Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Johnson & Johnson Enterprise Innovation Inc. | <1 mi |
| A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | <1 mi |
| Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier | — | Veracyte, Inc. | <1 mi |
| A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer | Phase 1/2 | Iovance Biotherapeutics, Inc. | <1 mi |
| Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors | Phase 1 | SystImmune Inc. | <1 mi |
| A Study of Lepodisiran (LY3819469) in Participants With Normal, Mild, Moderate, or Severe Liver Function | Phase 1 | Eli Lilly and Company | <1 mi |
| A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Phase 2 | Gilead Sciences | <1 mi |
| RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD) | Phase 2 | Altimmune, Inc. | <1 mi |
| Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer | Phase 3 | Genmab | <1 mi |
| Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01) | Phase 3 | Daiichi Sankyo | <1 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) Monotherapy Versus Treatment of Physician's Choice as Second-line Treatment for Participants With Recurrent or Metastatic Cervical Cancer (MK-2870-020/TroFuse-020/Gog-3101/ENGOT-cx20) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer | Phase 3 | AstraZeneca | <1 mi |
| Selinexor in Maintenance Therapy After Systemic Therapy for Participants With p53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma | Phase 3 | Karyopharm Therapeutics Inc | <1 mi |
| A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in Patients With Refractory Advanced/Metastatic Colorectal Cancer | Phase 2 | Criterium, Inc. | <1 mi |
| Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer | Phase 3 | Verastem, Inc. | <1 mi |
| A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | <1 mi |
| A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations | Phase 3 | AstraZeneca | <1 mi |
| Study of Erdafitinib Intravesical Delivery System for Localized Bladder Cancer | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| A Clinical Study of MK-2214 in People With Early Alzheimer's Disease (MK-2214-004) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| A Clinical Study of Tulisokibart (MK-7240) to Treat Rheumatoid Arthritis (RA) (MK-7240-014) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | Phase 2 | Eikon Therapeutics | <1 mi |
| A Study of Brenipatide in Adult Participants With Major Depressive Disorder | Phase 3 | Eli Lilly and Company | <1 mi |
| A Research Study Comparing Different Doses of CDR132L With Placebo on the Structure and Function of the Heart in People With Heart Failure With Preserved Ejection Fraction and Left Ventricular Hypertrophy | Phase 2 | Novo Nordisk A/S | <1 mi |
| A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight | Phase 3 | Novo Nordisk A/S | <1 mi |
| A Study to Learn More About How Well Sevabertinib (BAY 2927088) Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | Phase 3 | Bayer | <1 mi |
| Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease | Phase 2/3 | NRG Oncology | <1 mi |
| A Study of Sigvotatug Vedotin in Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Observational Basket Trial to Collect Tissue to Develop and Train a Live Tumor Diagnostic Platform | — | Elephas | <1 mi |
| A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors | Phase 1/2 | OncoC4, Inc. | <1 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Oral Icalcaprant in Adult Participants With Bipolar I or II Disorder | Phase 2 | AbbVie | <1 mi |
| Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants | N/A | Nationwide Children's Hospital | <1 mi |
| TIDES 2.0: Prevalence and Longitudinal Course of Depression, Anxiety, and Behavior Problems in Children With Cystic Fibrosis Under 12 Years of Age | — | State University of New York at Buffalo | <1 mi |
| Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS | Phase 3 | AstraZeneca | <1 mi |
| Testing the Addition of the Drug Relugolix to the Usual Radiation Therapy for Advanced-Stage Prostate Cancer, The NRG Promethean Study | Phase 2 | NRG Oncology | <1 mi |
| First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer | Phase 1 | Relay Therapeutics, Inc. | <1 mi |
| Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer | Phase 3 | NRG Oncology | <1 mi |
| A Study of DB-1310 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Caris Biorepository Research Protocol | — | Caris Science, Inc. | <1 mi |
| Phase 3 Trial of eRapa in Patients With Familial Adenomatous Polyposis | Phase 3 | Rapamycin Holdings Inc. | <1 mi |
| A Study to Investigate the Efficacy, Safety and Tolerability of Remibrutinib Versus Placebo in Adult Patients With Generalized Myasthenia Gravis | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis | Phase 2 | AbbVie | <1 mi |
| ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors | Phase 3 | OncoC4, Inc. | <1 mi |
| A Phase 1 of CTX-8371 in Patients With Advanced Malignancies | Phase 1 | Compass Therapeutics | <1 mi |
| Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer | Phase 3 | Bayer | <1 mi |
| SMR Stemless Reverse Vs SMR Reverse Shoulder System | N/A | Limacorporate S.p.a | <1 mi |
| To Evaluate the Efficacy of CVN424 in Parkinson's Disease Participants With Motor Complications | Phase 3 | Cerevance | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Intravenous (IV) Prasinezumab in Participants With Early-Stage Parkinson's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Phase 2 Study and Open-Label Extension of NEU-411 in Companion Diagnostic-Positive Participants With Early Parkinson's Disease | Phase 2 | Neuron23 Inc. | <1 mi |
| Tracking Results of Ablations to Combat AF Registry Generation 2 | — | AtriCure, Inc. | <1 mi |
| Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion | Phase 1 | IDEAYA Biosciences | <1 mi |
| A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Phase 1 | BeiGene | <1 mi |
| A Study to Test KISIMA-02 Vaccine-based Immunotherapy and Ezabenlimab in People With Pancreatic Cancer | Phase 1 | Boehringer Ingelheim | <1 mi |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of Relatlimab Plus Nivolumab in Pediatric and Young Adults With Hodgkin and Non-Hodgkin Lymphoma | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| A Study Called FINE-REAL to Learn More About the Use of the Drug Finerenone in a Routine Medical Care Setting | — | Bayer | <1 mi |
| Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | Phase 3 | Novo Nordisk A/S | <1 mi |
| Healthy Eating and Active Lifestyle (HEAL): Breast Cancer Program Outcomes | — | AdventHealth | <1 mi |
| A Study of Alpelisib and Fulvestrant to Treat Endometrial Cancer | Phase 2 | GOG Foundation | <1 mi |
| A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC | Phase 2 | Amgen | <1 mi |
| Exercise to Boost Response to Checkpoint Blockade Immunotherapy | N/A | AdventHealth Translational Research Institute | <1 mi |
| ASCEND CSP IDE Study | N/A | Abbott Medical Devices | <1 mi |
| Phase 1/2a Clinical Trial of PR001 (LY3884961) in Patients With Parkinson's Disease With at Least One GBA1 Mutation (PROPEL) | Phase 1/2 | Prevail Therapeutics | <1 mi |
| Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy | Phase 2 | OncoVerity, Inc. | <1 mi |
| A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation | Phase 3 | European Myeloma Network B.V. | <1 mi |
| BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| Carboplatin or Olaparib for BRcA Deficient Prostate Cancer | Phase 2 | VA Office of Research and Development | <1 mi |
| Neoadjuvant Darolutamide and Relugolix Combination Preceding Radical Prostatectomy for Prostate Cancer | Phase 1 | AdventHealth | <1 mi |
| Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial | Phase 2/3 | National Cancer Institute (NCI) | <1 mi |
| Neuroblastoma Maintenance Therapy Trial | Phase 2 | Giselle Sholler | <1 mi |
| Evaluation of RAS Inhibitor Treatment in Participants With Advanced or Metastatic Solid Tumors Harboring RAS Mutations | Phase 1 | Adlai Nortye Biopharma Co., Ltd. | <1 mi |
| A Prospective Study of a Lifestyle Medicine Survivorship Program for Patients With Gynecologic Cancer | N/A | AdventHealth | <1 mi |
| Evaluate REC-4881 in Participants With Familial Adenomatous Polyposis (FAP) | Phase 1/2 | Recursion Pharmaceuticals Inc. | <1 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Ipilimumab or Cabozantinib in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208) | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| A Study to Learn About the Study Medicine PF-08052667 in People With Bladder Cancer | Phase 1 | Pfizer | <1 mi |
| A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| A Study Assessing Adverse Events and Disease Activity When Comparing Intravenously (IV) Infused ABBV-400 to Trifluridine and Tipiracil (LONSURF) Oral Tablets Plus IV Infused Bevacizumab in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer | Phase 3 | AbbVie | <1 mi |
| A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Avistone Biotechnology Co., Ltd. | <1 mi |
| A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer. | Phase 2 | Iovance Biotherapeutics, Inc. | <1 mi |
| A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors | Phase 1 | NextCure, Inc. | <1 mi |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) | Phase 1 | Caribou Biosciences, Inc. | <1 mi |
| A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Study of Ifinatamab Deruxtecan (DS-7300a, I-DXd) in Participants With Advanced Solid Malignant Tumors | Phase 1/2 | Daiichi Sankyo | <1 mi |
| A Study of XB371 Administered in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | <1 mi |
| NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer | Phase 1 | Akamis Bio | <1 mi |
| A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer | Phase 1/2 | Theravectys S.A. | <1 mi |
| Initial Safety of SFM Plus OTOLoc for Creating Side-to-side or End-to-side Colorectal Anastomoses | N/A | GI Windows, Inc. | <1 mi |
| A Study of JNJ-89862175 for Treatment of Advanced Solid Tumors | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors | Phase 1/2 | Merus B.V. | <1 mi |
| A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known to Express the Tumor Marker CA19-9 | Phase 1/2 | BioNTech SE | <1 mi |
| P-CD19CD20-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With B Cell Malignancies | Phase 1 | Poseida Therapeutics, Inc. | <1 mi |
| CLN-617 Alone and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors | Phase 1 | Cullinan Therapeutics Inc. | <1 mi |
| A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors | Phase 1/2 | Takeda | <1 mi |
| Phase 3 Trial Evaluating the Safety & Efficacy of IMNN-001 Administered in Combination w/ Standard NACT & Adjuvant Chemotherapy in Newly Diagnosed Patients w/ Advanced EOC, Fallopian Tube or Primary Peritoneal Cancer | Phase 3 | Imunon | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815 | Phase 1 | Jazz Pharmaceuticals | <1 mi |
| A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract | Phase 3 | Eli Lilly and Company | <1 mi |
| TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Phase 1/2 | Tanja Andrea Gruber | <1 mi |
| Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy | — | Viome | <1 mi |
| Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer | Phase 3 | Jazz Pharmaceuticals | <1 mi |
| JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors | Phase 1 | Jazz Pharmaceuticals | <1 mi |
| Eflornithine (DFMO) and Etoposide for Relapsed/Refractory Neuroblastoma | Phase 2 | Giselle Sholler | <1 mi |
| A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation. | Phase 1 | PMV Pharmaceuticals, Inc | <1 mi |
| Pan Tumor Rollover Study | Phase 2 | Bristol-Myers Squibb | <1 mi |
| First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | Phase 1/2 | Corbus Pharmaceuticals Inc. | <1 mi |
| A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Phase 1 | Hoffmann-La Roche | <1 mi |
| Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma | Phase 2 | St. Jude Children's Research Hospital | <1 mi |
| AI for Onsite Cytology Evaluation in Endoscopic Ultrasound | — | Orlando Health, Inc. | <1 mi |
| A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma | Phase 3 | AVEO Pharmaceuticals, Inc. | <1 mi |
| ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies | Phase 1 | Acepodia Biotech, Inc. | <1 mi |
| Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076) | Phase 3 | Genelux Corporation | <1 mi |
| Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma | Phase 1/2 | Genfit | <1 mi |
| Artificial Intelligence in Endoscopic Ultrasound | — | Orlando Health, Inc. | <1 mi |
| A Study of SNDX-5613 in Combination With Intensive Chemotherapy in Participants With Acute Myeloid Leukemias | Phase 1 | Syndax Pharmaceuticals | <1 mi |
| Testing an Enhanced Digital Delivery Model for Inherited Cancer Genetic Testing in Young Adults With Cancer | N/A | Alliance for Clinical Trials in Oncology | <1 mi |
| FORAGER-1: A Study of LOXO-435 (LY3866288) in Participants With Cancer With a Change in a Gene Called FGFR3 | Phase 1 | Eli Lilly and Company | <1 mi |
| Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colorectal Cancer | N/A | AdventHealth Translational Research Institute | <1 mi |
| Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer | — | University of Central Florida | <1 mi |
| Investigations of Reproductive Cancers in Women | — | PinkDx, Inc. | <1 mi |
| A Phase I Study to Evaluate the Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors | Phase 1 | MediLink Therapeutics (Suzhou) Co., Ltd. | <1 mi |
| A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | <1 mi |
| Endoscopic Submucosal Dissection (ESD) | — | AdventHealth | <1 mi |
| Study of CHS-114 in Participants With Advanced Solid Tumors | Phase 1 | Coherus Oncology, Inc. | <1 mi |
| Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | Phase 3 | Iovance Biotherapeutics, Inc. | <1 mi |
| Alpha Radiation Emitters Device for the Treatment of Pancreatic Cancer With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer | N/A | Alpha Tau Medical LTD. | <1 mi |
| A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) | Phase 3 | Merus B.V. | <1 mi |
| A Phase 2 Study of Avutometinib (VS-6766) Plus Defactinib | Phase 2 | University of Oklahoma | <1 mi |
| A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | AbbVie | <1 mi |
| High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers | Phase 2 | VA Office of Research and Development | <1 mi |
| Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer | N/A | AdventHealth Translational Research Institute | <1 mi |
| EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope | N/A | Orlando Health, Inc. | <1 mi |
| PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence | Phase 2 | AdventHealth | <1 mi |
| CR-001 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Crescent Biopharma, Inc. | <1 mi |
| A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer | Phase 1 | Genentech, Inc. | <1 mi |
| A Phase 1/2 Study to Investigate CRB-701 in Solid Tumors | Phase 1/2 | Corbus Pharmaceuticals Inc. | <1 mi |
| Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections | — | Orlando Health, Inc. | <1 mi |
| Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors | Phase 1/2 | ModernaTX, Inc. | <1 mi |
| Capability Assessment for Diet and Activity (CADA) Model for Diabetes | — | University of Central Florida | <1 mi |
| Closed Loop and Education for Hypoglycemia Awareness Restoration | N/A | Milton S. Hershey Medical Center | <1 mi |
| Dynamic in Vivo PET Imaging and ex Vivo Biopsies From Skeletal Muscle and Adipose Tissue to Investigate the Effects of Exercise on Insulin Resistance and Mitochondrial Energetics in Type 2 Diabetes | N/A | AdventHealth Translational Research Institute | <1 mi |
| The Role of Type 2 Diabetes on Skeletal Muscle Atrophy and Recovery Following Bed Rest in Older Adults | N/A | AdventHealth Translational Research Institute | <1 mi |
| Transdisciplinary Care for Young Adults With Type 1 Diabetes | N/A | Nemours Children's Clinic | <1 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms: Metabolic Outcomes Using Novel CGM Metrics | — | Milton S. Hershey Medical Center | <1 mi |
| Diabetes RElated to Acute Pancreatitis and Its Mechanisms | — | Milton S. Hershey Medical Center | <1 mi |
| Accessing Care, Clinical Trials and Screening for Underserved Children and Adults With Type 1 Diabetes (ACCESS-T1D) | — | AdventHealth Translational Research Institute | <1 mi |
| Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial | N/A | Sonavex, Inc. | <1 mi |
| Targeting Network Dysfunction in Apathy of Late-life Depression Using Digital Therapeutics | N/A | AdventHealth | <1 mi |
| ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response | Phase 2 | ACADIA Pharmaceuticals Inc. | <1 mi |
| The Lake Nona Life Project | — | University of Central Florida | <1 mi |
| University of Central Florida Music Study | N/A | University of Central Florida | <1 mi |
| Clinical Study of SNK01 in Participants With Moderate Alzheimer's Disease | Phase 1/2 | NKGen Biotech, Inc. | <1 mi |
| University of Central Florida CereBank | — | University of Central Florida | <1 mi |
| A Study to See How Metabolism is Influenced by Weight Loss Due to Intervention With Cagrilintide and Semaglutide Compared to Diet | Phase 1 | Novo Nordisk A/S | <1 mi |
| A Dose Escalation Study of AV-380 in Cancer Patients With Cachexia | Phase 1 | AVEO Pharmaceuticals, Inc. | <1 mi |
| Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure | N/A | BrioHealth Solutions, Inc. | <1 mi |
| A Study Assessing Long-Term Safety and Effectiveness in Treatment Management of Atrial Fibrillation With VARIPULSE Catheter System | N/A | Biosense Webster, Inc. | <1 mi |
| REdo tranScatheter Aortic Valve Replacement for Transcatheter aOrtic Valve failuRE | — | Medtronic Cardiovascular | <1 mi |
| Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair | N/A | NeoChord | <1 mi |
| Sotagliflozin to Slow Kidney Function Decline in Persons With Type 1 Diabetes and Diabetic Kidney Disease | Phase 3 | Alessandro Doria | <1 mi |
| BoxX-NoAF Clinical Trial | N/A | AtriCure, Inc. | <1 mi |
| Extension Study of Sotatercept in People With Pulmonary Hypertension (MK-7962-023) | Phase 2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study About How Blood Cell Growth Patterns Relate to Heart Health After Treatment for Hodgkin Lymphoma | — | Children's Oncology Group | <1 mi |
| Innate Immunity in Allergic Asthma | — | University of Central Florida | <1 mi |
| Individualizing Treatment for Asthma in Primary Care (Full Study) | Phase 4 | DARTNet Institute | <1 mi |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Sjogren's Disease | Phase 1 | Cullinan Therapeutics Inc. | <1 mi |
| Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2) | Phase 3 | GlaxoSmithKline | <1 mi |
| An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema | N/A | Pulmonx Corporation | <1 mi |
| A Phase 3 Trial of MM120 for Generalized Anxiety Disorder (Panorama) | Phase 3 | Definium Therapeutics US, Inc. | <1 mi |
| A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Systemic Lupus Erythematosus | Phase 1 | Cullinan Therapeutics Inc. | <1 mi |
| Rheumatology Diet Study | — | University of Central Florida | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | Phase 3 | Novartis Pharmaceuticals | <1 mi |
| Increasing Germline Genetic Testing for Patients With Cancer | N/A | Josh Peterson | <1 mi |
| Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer | Phase 2 | Jonsson Comprehensive Cancer Center | <1 mi |
| Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer | Phase 2 | Oana Danciu | <1 mi |
| Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast Cancer | Phase 1 | Olema Pharmaceuticals, Inc. | <1 mi |
| Tumor-Derived FGF19 | — | University of Central Florida | <1 mi |
| A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| UCF MammoChat: Image Repository | — | University of Central Florida | <1 mi |
| A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer | Phase 1 | Stemline Therapeutics, Inc. | <1 mi |
| A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors | Phase 1 | IDEAYA Biosciences | <1 mi |
| Building on Trust: Navigating Preventive Lung, Breast, and Prostate Cancer Screenings at Community Resource Spots | — | AdventHealth | <1 mi |
| A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors | Phase 1/2 | Bayer | <1 mi |
| MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors | Phase 1/2 | Tasca Therapeutics | <1 mi |
| A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors | Phase 1 | Phrontline Biopharma | <1 mi |
| A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas | Phase 1 | Dren Bio | <1 mi |
| A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors | Phase 1 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Real World Registry for Use of the Ion Endoluminal System | — | Intuitive Surgical | <1 mi |
| Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | Phase 1/2 | Eli Lilly and Company | <1 mi |
| Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment | Phase 3 | AstraZeneca | <1 mi |
| Safety and Efficacy of OBX-115 in Advanced Solid Tumors | Phase 1/2 | Obsidian Therapeutics, Inc. | <1 mi |
| AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001) | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | Phase 1 | Alterome Therapeutics, Inc. | <1 mi |
| A Study of LY4175408 in Participants With Advanced Cancer | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | <1 mi |
| A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | Phase 1/2 | Terremoto Biosciences Inc. | <1 mi |
| A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors | Phase 2 | Jazz Pharmaceuticals | <1 mi |
| Acute Exercise and Endogenous Glucose Production in Type 2 Diabetes: Implications for Glycemic Control and Treatment of Hepatic Steatosis | N/A | AdventHealth Translational Research Institute | <1 mi |
| AdventHealth Research Institute Non-Alcoholic Fatty Liver Disease Biobank and Registry (AVAIL) | — | AdventHealth Translational Research Institute | <1 mi |
| A Study to Investigate Pharmacokinetics (PK) and Safety of a Single Dose of Mavorixafor in Participants With Hepatic Impairment (HI) Compared to Matched Healthy Volunteers With Normal Hepatic Function | Phase 1 | X4 Pharmaceuticals | <1 mi |
| Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function | Phase 1 | Aligos Therapeutics | <1 mi |
| Natural History of Wilson Disease | — | Yale University | <1 mi |
| A Study to Test How BI 1584862 is Taken up in the Blood of People With and Without Liver Problems | Phase 1 | Boehringer Ingelheim | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Different Levels of Liver Damage and in Participants With Healthy Livers. | Phase 1 | Eli Lilly and Company | <1 mi |
| A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD) | Phase 2 | Deciphera Pharmaceuticals, LLC | <1 mi |
| A Study Evaluating Atezolizumab, With or Without Bevacizumab, in Participants With Unresectable Hepatocellular Carcinoma and Child-pugh B7 and B8 Cirrhosis | Phase 2 | Genentech, Inc. | <1 mi |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes | Phase 3 | Novo Nordisk A/S | <1 mi |
| Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depressive Disorder | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Phase 3 | Karuna Therapeutics, Inc., a Bristol Myers Squibb company | <1 mi |
| A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) | Phase 2 | Upstream Bio Inc. | <1 mi |
| A Randomized, Double-Blind, Placebo-Controlled Trial on Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Combination in Participants 12 Years and Older With Asthma | Phase 3 | Teva Branded Pharmaceutical Products R&D, Inc. | <1 mi |
| Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery | Phase 2 | ECOG-ACRIN Cancer Research Group | <1 mi |
| A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Comparing Radiation Therapy to Usual Care for Patients With High-Risk Bone Asymptomatic Metastases, PREEMPT Trial | Phase 3 | NRG Oncology | <1 mi |
| Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial | Phase 3 | NRG Oncology | <1 mi |
| Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | N/A | NRG Oncology | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Study Participants With Moderately to Severely Active Systemic Lupus Erythematosus | Phase 3 | UCB Biopharma SRL | <1 mi |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain | Phase 3 | NRG Oncology | <1 mi |
| Testing if High Dose Radiation Only to the Sites of Brain Cancer Compared to Whole Brain Radiation That Avoids the Hippocampus is Better at Preventing Loss of Memory and Thinking Ability | Phase 3 | NRG Oncology | <1 mi |
| S1827 (MAVERICK) Testing Whether the Use of Brain Scans Alone Instead of Brain Scans Plus Preventive Brain Radiation Affects Lifespan in Patients With Small Cell Lung Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors | Phase 2 | SWOG Cancer Research Network | <1 mi |
| IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma | Phase 2/3 | IDEAYA Biosciences | <1 mi |
| Evaluate the Safety, Tolerability, Pharmacodynamics and Efficacy of CNP-106 in Subjects With Myasthenia Gravis | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| Phase 1/2 Study of Linvoseltamab in Adult Patients With Relapsed or Refractory Multiple Myeloma | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome | Phase 1 | BlossomHill Therapeutics | <1 mi |
| Study of INCA036978 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| CLN-049 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Phase 1 | Cullinan Therapeutics Inc. | <1 mi |
| NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors | N/A | University of South Florida | <1 mi |
| Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Prospective Study to Assess a Diagnostic Aid for Cancer | — | Harbinger Health | <1 mi |
| Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia | N/A | Massachusetts General Hospital | <1 mi |
| Phase 2 Open Label Randomized Study of Pirtobrutinib and Brexucabtagene Autoleucel in R/R MCL | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | AstraZeneca | <1 mi |
| A Clinical Study to Assess the Efficacy and Safety of Alpha DaRT224 for the Treatment of Patients With Recurrent Cutaneous Squamous Cell Carcinoma | N/A | Alpha Tau Medical LTD. | <1 mi |
| Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML | Phase 3 | Kura Oncology, Inc. | <1 mi |
| A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1) | Phase 1/2 | Sumitomo Pharma America, Inc. | <1 mi |
| A Study of Elritercept to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions | Phase 3 | Takeda | <1 mi |
| Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC | Phase 3 | RenovoRx | <1 mi |
| Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer | Phase 3 | Curium US LLC | <1 mi |
| WATER IV Prostate Cancer | N/A | PROCEPT BioRobotics | <1 mi |
| Longitudinal Bladder Cancer Study for Tumour Recurrence | — | Pacific Edge Limited | <1 mi |
| A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases | Phase 2 | Pierre Fabre Medicament | <1 mi |
| A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma | Phase 3 | Aura Biosciences | <1 mi |
| A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases | Phase 3 | Rakuten Medical, Inc. | <1 mi |
| A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) | Phase 1 | AstraZeneca | <1 mi |
| uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto | — | UroGen Pharma Ltd. | <1 mi |
| Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry | — | Immune Oncology Research Institute | <1 mi |
| CNP-103 in Adolescent and Adult Subjects Ages 12-35 With Recently Diagnosed (Within 6 Months) Stage 3 Type 1 Diabetes (T1D) | Phase 1/2 | COUR Pharmaceutical Development Company, Inc. | <1 mi |
| Evaluation of Efficacy and Safety of Milsaperidone as Adjunctive Therapy in Patients With Major Depressive Disorder | Phase 3 | Vanda Pharmaceuticals | <1 mi |
| Study of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder | Phase 3 | Intra-Cellular Therapies, Inc. | <1 mi |
| A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor | Phase 4 | Neurocrine Biosciences | <1 mi |
| Cocooned Moms Study | N/A | InovCares Connected Comprehensive Healthcare Corporation | <1 mi |
| NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| A Study to Assess the Efficacy, Safety and Tolerability of VLS-01 Buccal Film, Compared to Placebo in Patients With Treatment Resistant Depression (ELUMINA) | Phase 2 | atai Therapeutics, Inc. | <1 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease | Phase 2 | Celgene | <1 mi |
| Clinical Evaluation of the AccuCinch® Ventricular Restoration System in Patients Who Present With Symptomatic Heart Failure With Reduced Ejection Fraction (HFrEF): The CORCINCH-HF Study | N/A | Ancora Heart, Inc. | <1 mi |
| A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic Asthma | Phase 2 | Kymera Therapeutics, Inc. | <1 mi |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1) | Phase 3 | Generate Biomedicines | <1 mi |
| Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients | Phase 2 | Arthrosi Therapeutics | <1 mi |
| Safety and Effectiveness of the HIT Reverse HRS | N/A | Hip Innovation Technology | <1 mi |
| Clinical Trial on Agitation in Alzheimer's Dementia | Phase 2 | IGC Pharma, LLC | <1 mi |
| A Phase 2a Multicenter Clinical Trial of TB006 in Participants With Parkinson's Disease | Phase 2 | TrueBinding, Inc. | <1 mi |
| A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease | Phase 3 | BlueRock Therapeutics | <1 mi |
| A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) | Phase 4 | GlaxoSmithKline | <1 mi |
| A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1) | Phase 1/2 | Nkarta, Inc. | <1 mi |
| A Research Study to Evaluate the Effects of a New Oral Medicine Called Cenerimod in Adults With Systemic Lupus Erythematosus | Phase 3 | Viatris Innovation GmbH | <1 mi |
| A Study of LY3541860 in Adult Participants With Relapsing Multiple Sclerosis | Phase 2 | Eli Lilly and Company | <1 mi |
| Study of COYA 302 for the Treatment of ALS | Phase 2 | Coya Therapeutics | <1 mi |
| A Study of LY4257496 in Participants With Cancer (OMNIRAY) | Phase 1 | Eli Lilly and Company | <1 mi |
| A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer | Phase 2 | Processa Pharmaceuticals | <1 mi |
| A Registry for People With T-cell Lymphoma | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer | Phase 3 | SWOG Cancer Research Network | <1 mi |
| A Study of LY4337713 in Participants With FAP-Positive Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects | Phase 3 | Greenwich LifeSciences, Inc. | <1 mi |
| Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets | Phase 3 | InSightec | <1 mi |
| A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis | Phase 3 | Ipsen | <1 mi |
| FXR Effect on Severe Alcohol-Associated Hepatitis (FRESH) Study | Phase 2 | Intercept Pharmaceuticals | <1 mi |
| Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis | Phase 3 | Gilead Sciences | <1 mi |
| Study of RP2 in Combination With Second-line Therapy in Patients With Locally Advanced or Metastatic HCC | Phase 2 | Replimune Inc. | <1 mi |
| A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma | Phase 2 | K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc | <1 mi |
| Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread | Phase 2 | Gilead Sciences | <1 mi |
| AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma | Phase 1 | Carna Biosciences, Inc. | <1 mi |
| A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA) | Phase 4 | Eli Lilly and Company | <1 mi |
| Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer | Phase 3 | Daiichi Sankyo | <1 mi |
| ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| EXActDNA-003 / NSABP B-64: Study of Molecular Residual Disease Detection in Breast Cancer (MRD) | — | Exact Sciences Corporation | <1 mi |
| Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac Toxicity | Phase 3 | SWOG Cancer Research Network | <1 mi |
| Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection | — | Alliance for Clinical Trials in Oncology | <1 mi |
| Creation of an Infrastructure to Support Delivery of mHealth Interventions for Cancer Patients | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention | Phase 4 | Duke University | <1 mi |
| A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types | Phase 1/2 | Eisai Inc. | <1 mi |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug | Phase 3 | MoonLake Immunotherapeutics AG | <1 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of SPY072 in Rheumatic Disease | Phase 2 | Spyre Therapeutics, Inc. | <1 mi |
| Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response | Phase 3 | MoonLake Immunotherapeutics AG | <1 mi |
| A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma | Phase 2 | Eli Lilly and Company | <1 mi |
| Study of ALTO-300 in MDD | Phase 2 | Alto Neuroscience | <1 mi |
| A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| A Study of Buntanetap in Participants With PD | Phase 2/3 | Annovis Bio Inc. | <1 mi |
| Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | <1 mi |
| A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes | Phase 3 | Sanofi | <1 mi |
| Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements | Phase 1/2 | Turning Point Therapeutics, Inc. | <1 mi |
| National Cancer Institute "Cancer Moonshot Biobank" | — | National Cancer Institute (NCI) | <1 mi |
| ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer | Phase 3 | ImmunityBio, Inc. | <1 mi |
| A Study of Alisertib in Patients With Extensive Stage Small Cell Lung Cancer | Phase 2 | Puma Biotechnology, Inc. | <1 mi |
| A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors | Phase 1 | Daiichi Sankyo | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure | N/A | Procyrion | <1 mi |
| Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | Phase 2/3 | BioNTech SE | <1 mi |
| A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer | Phase 2 | Cybrexa Therapeutics | <1 mi |
| A Study to Assess Adverse Events, How the Drug Moves Through the Body and Effectiveness of Intravenous Infusions of ABBV-319 in Adult Participants With Systemic Lupus Erythematosus (SLE) and Sjogren's Disease (SjD) | Phase 1 | AbbVie | <1 mi |
| Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis | Phase 2 | NMD Pharma A/S | <1 mi |
| A Phase 1b/2 Study of IM-101 in Adult Participants With Generalized Myasthenia Gravis and Ocular Myasthenia Gravis | Phase 1/2 | ImmunAbs Inc. | <1 mi |
| PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort | — | Michael J. Fox Foundation for Parkinson's Research | <1 mi |
| TRIcvalve biCAVal Valve System for Severe Tricuspid Regurgitation (TRICAV-I) | N/A | P+F Products + Features USA Inc. | <1 mi |
| The REBALANCE Study - a Prospective, Multicenter, Randomized, Pivotal Study of the May Health System | N/A | May Health | <1 mi |
| A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease | Phase 3 | Hoffmann-La Roche | <1 mi |
| A Randomized Comparison of Personalized Therapy Mgmt Based On Coronary Atherosclerotic Plaque Vs. Usual Care for Symptomatic Patients With Suspicion of CAD | N/A | Cleerly, Inc. | <1 mi |
| Investigating an mRNA CAR T-cell Therapy, Known as Descartes-08, as a Potential Approach to Treat Myasthenia Gravis | Phase 3 | Cartesian Therapeutics | <1 mi |
| NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | <1 mi |
| First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors | Phase 1/2 | Eli Lilly and Company | <1 mi |
| Observational Study Protocol: LIVER-R | — | AstraZeneca | <1 mi |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study With an Open-Label Extension Evaluating the Efficacy and Safety of VENT-03 in Adult Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Lupus Erythematosus | Phase 2 | Ventus Therapeutics U.S., Inc. | <1 mi |
| Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics | — | Wake Forest University Health Sciences | <1 mi |
| Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis | Phase 3 | Immunovant Sciences GmbH | <1 mi |
| A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation | Phase 1/2 | Syndax Pharmaceuticals | <1 mi |
| QTX3034 in Patients With KRAS G12D Mutation | Phase 1 | Quanta Therapeutics | <1 mi |
| Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer | Phase 2 | NRG Oncology | <1 mi |
| Study of AVZO-021 in Patients With Advanced Solid Tumors | Phase 1/2 | Avenzo Therapeutics, Inc. | <1 mi |
| Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors | Phase 1 | Revolution Medicines, Inc. | <1 mi |
| Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors | Phase 1/2 | BioNTech SE | <1 mi |
| A Long-term Extension Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) | Phase 3 | Amgen | <1 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer | Phase 3 | NRG Oncology | <1 mi |
| Lay-Delivered Behavioral Activation in Senior Centers | N/A | University of Washington | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) | Phase 2 | Innate Pharma | <1 mi |
| Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors | Phase 1/2 | Immunocore Ltd | <1 mi |
| Combining Radiation Therapy With Immunotherapy for the Treatment of Metastatic Squamous Cell Carcinoma of the Head and Neck | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS | Phase 1 | Auron Therapeutics, Inc. | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB198 as Monotherapy and in Combination in Participants With Advanced Hematologic Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| Physical Activity and Nutrition to Halt Elevated Risk in the Pancreas Interception Center | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Pembrolizumab and Sunitinib Malate in Treating Participants With Refractory Metastatic or Unresectable Thymic Cancer | Phase 2 | Dwight Owen | <1 mi |
| Dose Escalation/ Expansion Study of CA-4948 as Monotherapy in Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS) | Phase 1/2 | Curis, Inc. | <1 mi |
| FID-007 and Cetuximab in Treating Patients With Advanced Head and Neck Squamous Cell Carcinoma | Phase 2 | Fulgent Pharma LLC. | <1 mi |
| Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study Investigating Intravesical HDAC Inhibition to Improve Response to Immuno-Oncology Agents | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study to Evaluate the Efficacy and Safety of GDC-8264 in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI) and Major Adverse Kidney Events (MAKE) | Phase 2 | Genentech, Inc. | <1 mi |
| DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer | Phase 1 | Legend Biotech USA Inc | <1 mi |
| Study of DF6215 in Patients with Advanced Solid Tumors | Phase 1 | Dragonfly Therapeutics | <1 mi |
| Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer | Phase 3 | Eleison Pharmaceuticals LLC. | <1 mi |
| Therapy Adapted for High Risk and Low Risk HIV-Associated Anal Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials | Phase 3 | Celgene | <1 mi |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma | Phase 2 | Genmab | <1 mi |
| Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source | Phase 1/2 | CivaTech Oncology | <1 mi |
| Study of REM-422 in Patients With AML or Higher Risk MDS | Phase 1 | Remix Therapeutics | <1 mi |
| Safety of MT-401-OTS in Patients With Relapsed AML or MDS | Phase 1 | Marker Therapeutics, Inc. | <1 mi |
| Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells | Phase 1 | Celyad Oncology SA | <1 mi |
| A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma | Phase 2 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| ColoCare Study - Colorectal Cancer Cohort | — | University of Utah | <1 mi |
| Utero-ovarian Transposition in Patients With Pelvic Malignancies Undergoing Whole Pelvic Radiotherapy | N/A | University of South Florida | <1 mi |
| Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients | Phase 3 | Philogen S.p.A. | <1 mi |
| Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors | Phase 1 | Xencor, Inc. | <1 mi |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Patients With Bladder Cancer (MK-2870-027) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS) | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies | Phase 1 | Orca Biosystems, Inc. | <1 mi |
| Single-Arm Comprehensive Ablative Bridging Irradiation I Prior to CD19 CAR-T In High-Risk R/R LBCL | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer | Phase 1 | Astellas Pharma Global Development, Inc. | <1 mi |
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC | Phase 2 | Massachusetts General Hospital | <1 mi |
| Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120) | Phase 2 | Icahn School of Medicine at Mount Sinai | <1 mi |
| A Prospective, US-based Study Assessing Mogamulizumab-associated Rash in Patients Diagnosed With Mycosis Fungoides or Sezary Syndrome and Treated With Standard of Care Mogamulizumab | — | City of Hope Medical Center | <1 mi |
| Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL | Phase 3 | Soligenix | <1 mi |
| Study of Canakinumab in Patients With Myelofibrosis | Phase 2 | John Mascarenhas | <1 mi |
| BMT-CARE: Psychosocial Intervention for Transplant Caregivers | N/A | Massachusetts General Hospital | <1 mi |
| Neratinib In Combination With Chemotherapy/Trastuzumab/Pembrolizumab In HER2 Gastroesophageal Cancer | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Using Aspirin to Improve Immunological Features of Ovarian Tumors | Early 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| ProSalud in Latinos Living in Rural/Agricultural Communities Within Moffitt's Catchment Area | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome | Phase 2 | Orca Biosystems, Inc. | <1 mi |
| Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors | Phase 1 | Nested Therapeutics, Inc | <1 mi |
| Clinical Trial of CD40L-augmented TIL for Patients With Advanced Melanoma | Phase 1/2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Imugene Limited | <1 mi |
| A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma | Phase 1 | Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | <1 mi |
| PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores | Phase 2/3 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Safety and Preliminary Efficacy of OBT076 in Recurrent/Metastatic CD205+ Solid Tumors | Phase 1 | Oxford BioTherapeutics Ltd | <1 mi |
| Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS) | Phase 2 | Fred Hutchinson Cancer Center | <1 mi |
| Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT | Phase 3 | Priothera SAS | <1 mi |
| BCL2i CLAG-M in R/R Acute Myeloid Leukemia | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms | Phase 1 | Janssen Research & Development, LLC | <1 mi |
| Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Itacitinib Pre-modulation in DLBCL Receiving CAR T Cell Therapy | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Axitinib + Ipilimumab in Advanced Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study of NALIRIFOX in Advanced Unresectable Small Bowel Tumors | Phase 2 | Tiago Biachi de Castria | <1 mi |
| A Phase I, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Cellular Kinetics, Immunogenicity, Pharmacodynamics, and Preliminary Efficacy of AZD0120 in Participants With Multiple Myeloma (DURGA-2) | Phase 1 | AstraZeneca | <1 mi |
| Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB) | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study of AZD0754 in Participants With Metastatic Prostate Cancer | Phase 1/2 | AstraZeneca | <1 mi |
| Study of Afatinib in Advanced Cutaneous Squamous Cell Carcinoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Hybrid Effectiveness-Implementation Trial to Integrate Precision Skin Cancer Risk Feedback in FQHCs | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC | Phase 2 | ImmVira Pharma Co. Ltd | <1 mi |
| Discontinuation of Hypomethylating Agent and Venetoclax in Patients With AML MRD | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery | Phase 2 | Oncoinvent Solutions AS | <1 mi |
| Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours | Phase 1/2 | Bold Therapeutics, Inc. | <1 mi |
| Remote Resistance Exercise Powering Survivors - Gastrointestinal Oncology | Phase 1/2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study of KTE-X19 in Minimal Residual Disease (MRD) Positive B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Multicenter HomeVENT: Home Values and Experiences Navigation Track | N/A | Johns Hopkins University | <1 mi |
| A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML) | Phase 1/2 | Debiopharm International SA | <1 mi |
| A Study of Calderasib (MK-1084) in KRAS Mutant Advanced Solid Tumors (MK-1084-001) | Phase 1 | Merck Sharp & Dohme LLC | <1 mi |
| Outreach Core Activities | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDS | Phase 1/2 | BlueSphere Bio, Inc | <1 mi |
| A Phase 2 Study of WU-CART-007, an Anti-CD7 Allogeneic CAR-T Cell Therapy in T-Cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma (T-RRex) | Phase 2 | Wugen, Inc. | <1 mi |
| Multi-Institutional Registry for Malignant Peripheral Nerve Sheath Tumors | — | Washington University School of Medicine | <1 mi |
| Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1 | Phase 1 | SystImmune Inc. | <1 mi |
| CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms | Phase 2 | University of Michigan Rogel Cancer Center | <1 mi |
| Elranatamab Post Cilta-cel in Patients With Clinical High Risk Relapsed Myeloma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | MOMA Therapeutics | <1 mi |
| Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of XB628 in Participants With Recurrent Advanced or Metastatic Solid Tumors | Phase 1 | Exelixis | <1 mi |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma | Phase 1 | Hoffmann-La Roche | <1 mi |
| Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Generating Novel Therapeutic Strategies Based on Evolutionary Tumor Board | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A First-in-Human Study of FID-022 in Solid Tumor Patients | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| TREAT-BE Study (Treatment With Resection and Endoscopic Ablation Techniques for Barrett's Esophagus) | — | University of Colorado, Denver | <1 mi |
| Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer. | Phase 3 | SOFIE | <1 mi |
| A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | Phase 1/2 | Ossium Health, Inc. | <1 mi |
| Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations | — | Blueprint Medicines Corporation | <1 mi |
| A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML | Phase 1 | Stelexis BioSciences | <1 mi |
| Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S) | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Trial of Durvalumab (MEDI4736) Plus Monalizumab in Non-Muscle-Invasive Bladder Cancer | Phase 2 | John Sfakianos | <1 mi |
| A Trial to Find Out How Safe REGN7075 is and How Well it Works in Combination With Cemiplimab for Adult Participants With Advanced Cancers | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| MB-105 in Patients With CD5 Positive T-cell Lymphoma | Phase 2 | March Biosciences Inc | <1 mi |
| A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML) | Phase 1 | Solu Therapeutics, Inc | <1 mi |
| Phase 2a Study of High-Dose Testosterone Followed by Radioligand Therapy in mCRPC | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel | Phase 2 | Janssen Research & Development, LLC | <1 mi |
| Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement | Phase 2 | Taiho Oncology, Inc. | <1 mi |
| Colonoscopy vs Stool Testing for Older Adults With Colon Polyps | N/A | Dartmouth-Hitchcock Medical Center | <1 mi |
| Pacritinib vs. Hydroxyurea in Advanced Proliferative Chronic Myelomonocytic Leukemia | Phase 2 | Theradex | <1 mi |
| IVIG for Infection Prevention After CAR-T-Cell Therapy | Phase 2 | Fred Hutchinson Cancer Center | <1 mi |
| A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis. | Phase 1/2 | Alexion Pharmaceuticals, Inc. | <1 mi |
| Study of the Combination Dostarlimab With Niraparib In Patients With Penile Carcinoma | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC) | Phase 1 | TuHURA Biosciences, Inc. | <1 mi |
| CPX-351 in Combination With Gemtuzumab Ozogamicin in Newly Diagnosed AML | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) | N/A | University of South Florida | <1 mi |
| A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel | Phase 4 | Janssen Research & Development, LLC | <1 mi |
| Phase 1/2 Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors | Phase 1/2 | Pyxis Oncology, Inc | <1 mi |
| American Hepato-Pancreato-Biliary Association (AHPBA) Pancreatic Irreversible Electroporation (IRE) Registry | — | University of Louisville | <1 mi |
| Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma | Phase 1 | Modulation Therapeutics, Inc. | <1 mi |
| A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects | Phase 1 | C4 Therapeutics, Inc. | <1 mi |
| A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate Cancer | Phase 2 | Astellas Pharma Global Development, Inc. | <1 mi |
| International Penile Advanced Cancer Trial (International Rare Cancers Initiative Study) | Phase 3 | Institute of Cancer Research, United Kingdom | <1 mi |
| A Study of BGB-11417 in Participants With Myeloid Malignancies | Phase 1/2 | BeiGene | <1 mi |
| AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia | Phase 1/2 | AstraZeneca | <1 mi |
| Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma | Early 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors | Phase 1 | Hanmi Pharmaceutical Company Limited | <1 mi |
| Enasidenib (AG-221) Maintenance Post Allogeneic HCT in Patients With IDH2 Mutation | Phase 2 | City of Hope Medical Center | <1 mi |
| A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias | Phase 1 | Crossbow Therapeutics, Inc. | <1 mi |
| A Study of Amivantamab Monotherapy and in Addition to Standard-of-Care Chemotherapy in Participants With Advanced or Metastatic Colorectal Cancer | Phase 1/2 | Janssen Research & Development, LLC | <1 mi |
| Avapritinib With Decitabine in Patients With SM-AHN | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | Phase 1/2 | Milton S. Hershey Medical Center | <1 mi |
| Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Support Through Remote Observation and Nutrition Guidance Program for Individuals With Gastroesophageal Cancer | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Post-Market Study of the Signia Circular Stapler With Tri-Staple Technology in Left-sided Colon, Sigmoid, and Rectal Resections | N/A | Medtronic - MITG | <1 mi |
| Exercise Prehabilitation for Locoregional Esophageal Cancer | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of AZD0486 in Subjects With B-Cell Non-Hodgkin Lymphoma | Phase 1 | AstraZeneca | <1 mi |
| A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases | Phase 1 | Arcellx, Inc. | <1 mi |
| A Phase II Study of ACR-368 and Low Dose Gemcitabine in R/M HNSCC | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Phase 1 Study of ACE-232 to Treat Patients With Metastatic Castration-Resistant Prostate Cancer | Phase 1 | Acerand Therapeutics (Hong Kong) Limited | <1 mi |
| Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma | Early 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Predictors of Health-Related QOL in Adults With CLL or Small Lymphocytic Lymphoma | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC) | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | Phase 1/2 | Dren Bio | <1 mi |
| Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer 2 | — | University of Washington | <1 mi |
| A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis | Phase 2/3 | Janssen Research & Development, LLC | <1 mi |
| A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib | Phase 1/2 | AbbVie | <1 mi |
| GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes | N/A | Medtronic Diabetes | <1 mi |
| Twiist Postmarket Surveillance Study for Type 1 Diabetes | — | Deka Research and Development | <1 mi |
| DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes | Phase 4 | Ohio State University | <1 mi |
| Study of Enhanced Programming Stimulation with the Enterra® Therapy System | N/A | Enterra Medical, Inc. | <1 mi |
| A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults | Phase 3 | Eli Lilly and Company | <1 mi |
| Expanding the Support of Family Caregivers of Diverse Patients With Cancer and Diabetes | N/A | UNC Lineberger Comprehensive Cancer Center | <1 mi |
| T1D Pregnancy & Me | — | Jaeb Center for Health Research | <1 mi |
| Pharmacist-led Continuous Glucose Monitoring | — | University of South Florida | <1 mi |
| A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes | N/A | First Institute of All Medicines | <1 mi |
| Treatment ResistAnt Depression Subcallosal CingulatE Network DBS (TRANSCEND) | N/A | Abbott Medical Devices | <1 mi |
| ACT Together: Implementing a Web-Based Program With Brief Coaching for Parents of Children With Disabilities in Pediatric Outpatient Clinics | N/A | University of South Florida | <1 mi |
| Palliative Care Education in Assisted Living for Dementia Care Providers (PCEAL-DCP) | N/A | University of South Florida | <1 mi |
| Clinical Course Of Disease In Participants With FA-CM | — | Lexeo Therapeutics | <1 mi |
| International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry | — | SCAD Alliance | <1 mi |
| POLARx Post Approval Study (POLARx PAS) | N/A | Boston Scientific Corporation | <1 mi |
| Low Dose ColchicinE in pAtients With Peripheral Artery DiseasE to Address Residual Vascular Risk | Phase 3 | Population Health Research Institute | <1 mi |
| MagicTouch for Treatment of In-Stent Restenosis in Coronary Artery Lesions | N/A | Concept Medical Inc. | <1 mi |
| PULSED AF Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | <1 mi |
| Abatacept in Immune Checkpoint Inhibitor Myocarditis | Phase 3 | Massachusetts General Hospital | <1 mi |
| His-Bundle Corrective Pacing in Heart Failure | N/A | University of Rochester | <1 mi |
| Ultrafiltration Versus IV Diuretics in Worsening Heart Failure | N/A | Nuwellis, Inc. | <1 mi |
| Breaking Fasts Ahead of Cardiac Caths | N/A | University of South Florida | <1 mi |
| Physio-Anatomy Clinical Data Collection Study | — | Gentuity, LLC | <1 mi |
| Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study | Phase 2 | University of South Florida | <1 mi |
| Encore PFO Closure Device - The PerFOrm Trial | N/A | Encore Medical Inc. | <1 mi |
| Observational Study Designed to Detect Decompensation of Congestive Heart Failure (dCHF) Using a Non-Invasive Wearable Device | — | CHFDX,Inc. | <1 mi |
| Feasibility of a Smartphone Application for Asthma Self-management | N/A | University of South Florida | <1 mi |
| Optimal Anesthetic for Corticosteroid Injections for Knee Osteoarthritis | Phase 1 | Foundation for Orthopaedic Research and Education | <1 mi |
| A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension | — | Canary Medical | <1 mi |
| ARVIS TKA vs Conventional TKA | N/A | Foundation for Orthopaedic Research and Education | <1 mi |
| Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty) | — | Zimmer Biomet | <1 mi |
| Sustained Acoustic Medicine for Osteoarthritis Pain | Phase 1 | ZetrOZ, Inc. | <1 mi |
| The KinematX Midcarpal Total Wrist Arthroplasty Registry | — | Extremity Medical | <1 mi |
| Evaluate the Safety and Effectiveness of the Polymotion Hip Resurfacing (PHR) System Compared to Total Hip Arthroplasty | N/A | JointMedica Inc. | <1 mi |
| A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarkers in Study Participants With Moderate to Severe Plaque Psoriasis | Phase 3 | UCB Biopharma SRL | <1 mi |
| Woodcasting Versus Thermoplast Splint in CMC Arthroplasty | N/A | Foundation for Orthopaedic Research and Education | <1 mi |
| Telemedicine-Based Virtual Reality Clinic for the Treatment of Phobias | N/A | University of South Florida | <1 mi |
| Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder (PALISADE-4) | Phase 3 | VistaGen Therapeutics, Inc. | <1 mi |
| A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| A Study of Obexelimab in Patients With Systemic Lupus Erythematosus | Phase 2 | Zenas BioPharma (USA), LLC | <1 mi |
| A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus | Phase 1 | Bristol-Myers Squibb | <1 mi |
| A Study to Investigate the Safety, Tolerability, and Efficacy of AZD0120 in Adults With Refractory SLE | Phase 1/2 | AstraZeneca | <1 mi |
| A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity | Phase 2 | Celgene | <1 mi |
| A Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis | Phase 1 | Hoffmann-La Roche | <1 mi |
| Study to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis | Phase 3 | Celgene | <1 mi |
| Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab | Phase 3 | TG Therapeutics, Inc. | <1 mi |
| Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /Trastuzumab in Patients w/ Metastatic HER2+ Breast Cancer | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases | Phase 1/2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT) | — | RPCR, Inc. | <1 mi |
| Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study of CX-5461 in Patients With Solid Tumours and BRCA1/2, PALB2 or Homologous Recombination Deficiency (HRD) Mutation | Phase 1 | Senhwa Biosciences, Inc. | <1 mi |
| Phase 1/1b/2 Study of Oral PMD-026 in Patients With Metastatic Breast Cancer | Phase 1/2 | Phoenix Molecular Designs | <1 mi |
| DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment | Phase 2 | QuantumLeap Healthcare Collaborative | <1 mi |
| A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors | Phase 2 | Seagen, a wholly owned subsidiary of Pfizer | <1 mi |
| Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases | Phase 1/2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study of Screening Brain MRIs in Stage IV Breast Cancer | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy | Early 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A First in Human Dose Escalation of Dendritic Cell Vaccine (DCV) | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| The MIND-BC Study: MIND Diet for Breast Cancer Cognition | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer | Phase 3 | Hoffmann-La Roche | <1 mi |
| The PREDICT Registry: | — | PreludeDx | <1 mi |
| DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer | Phase 2 | QuantumLeap Healthcare Collaborative | <1 mi |
| PRE-I-SPY Phase I/Ib Oncology Platform Program | Phase 1 | QuantumLeap Healthcare Collaborative | <1 mi |
| A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer | Phase 1/2 | Genentech, Inc. | <1 mi |
| Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer | Phase 2 | Roswell Park Cancer Institute | <1 mi |
| Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer | Phase 1/2 | Ellipses Pharma | <1 mi |
| Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis | — | University of Hawaii | <1 mi |
| Immunologic Targeting of ESR1 Receptor for Hormone Receptor Expressing Metastatic Breast Cancer | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Phase II Study of Systemic Screening in Pathologic Node Positive Breast Cancer | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast Cancer | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease | Phase 1/2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer | Phase 1 | Regor Pharmaceuticals Inc. | <1 mi |
| MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors | Phase 1 | Memgen, Inc. | <1 mi |
| Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial | Phase 3 | National Cancer Institute (NCI) | <1 mi |
| Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors | Phase 1 | Bicara Therapeutics | <1 mi |
| Testing Tumor Tissue and Blood to Help Select Personalized Treatments for Patients With Suspected Lung Cancers | — | Lung Cancer Mutation Consortium | <1 mi |
| BBO-11818 in Adult Subjects With KRAS Mutant Cancer | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC | Phase 3 | NovoCure GmbH | <1 mi |
| Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC) | Phase 1 | Amgen | <1 mi |
| Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment | Phase 2 | BioNTech SE | <1 mi |
| A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | Phase 1 | ALX Oncology Inc. | <1 mi |
| Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial) | Phase 2/3 | SWOG Cancer Research Network | <1 mi |
| Adjuvant Pembrolizumab vs Observation Following Curative Resection for Stage I Non-small Cell Lung Cancer (NSCLC) With Primary Tumors Between 1-4 cm | Phase 2 | Greg Durm, MD | <1 mi |
| Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of REGN5093 in Adult Patients With Mesenchymal Epithelial Transition Factor (MET)-Altered Advanced Non-Small Cell Lung Cancer | Phase 1/2 | Regeneron Pharmaceuticals | <1 mi |
| Telephone-based Physical Activity Coaching or Self Monitored Physical Activity to Improve Physical Function in Older Adults Who Are Undergoing Surgery for Lung Cancer and Their Caregivers | N/A | City of Hope Medical Center | <1 mi |
| Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial) | Phase 2 | SWOG Cancer Research Network | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07799544 as Monotherapy or in Combination in People With Advanced Solid Tumors | Phase 1 | Pfizer | <1 mi |
| Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Using Biomarkers for Diagnosis, Risk Stratification of Post -Treatment Recurrence and Long-Term Surveillance of Lung Cancer | — | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| High-Fermented Food Intervention Among Locally Advanced Rectal Cancer Patients (The FEED Trial) | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors | Phase 2 | Apollomics Inc. | <1 mi |
| A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Genentech, Inc. | <1 mi |
| Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS | Phase 1/2 | Revolution Medicines, Inc. | <1 mi |
| A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation | Phase 1/2 | Arvinas Inc. | <1 mi |
| RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses | Phase 2 | Reunion Neuroscience Inc | <1 mi |
| Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311) | Phase 1 | Amgen | <1 mi |
| Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors | Phase 1 | TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) | <1 mi |
| Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | Phase 1/2 | Simcha IL-18, Inc. | <1 mi |
| A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC | Phase 2 | Teligene US | <1 mi |
| Impact of Behavior Modification Interventions and Lung Cancer Screening on Smoking Cessation in People Living With HIV: A Feasibility Study | N/A | AIDS Malignancy Consortium | <1 mi |
| A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease | Phase 1 | GlaxoSmithKline | <1 mi |
| Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs | — | European Foundation for Study of Chronic Liver Failure | <1 mi |
| A Prospective, Single-Center Investigation of the da Vinci SP® Surgical System in Hepatopancreaticobiliary and Foregut Operations for Benign and Malignant Disease | N/A | AdventHealth | <1 mi |
| A Study of TTI-101 as Monotherapy and in Combination in Participants With Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma | Phase 1/2 | Tvardi Therapeutics, Incorporated | <1 mi |
| Multilevel Action Toward Colorectal Cancer and Hepatitis C Education and Screening | N/A | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | Phase 2 | H. Lee Moffitt Cancer Center and Research Institute | <1 mi |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Colorectal Cancer w/Liver Dominant Disease | Phase 2 | Delcath Systems Inc. | <1 mi |
| Multi-analyte Blood Test Clinical Trial | — | Helio Genomics | <1 mi |
| Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen | Phase 3 | Crinetics Pharmaceuticals Inc. | <1 mi |
| Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease | Phase 2 | Delcath Systems Inc. | <1 mi |
| Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI | N/A | VA Office of Research and Development | <1 mi |
| EASi-KIDNEY™ (The Studies of Heart & Kidney Protection With BI 690517 in Combination With Empagliflozin) | Phase 3 | Boehringer Ingelheim | <1 mi |
| A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases | Phase 2 | Amgen | <1 mi |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma | Phase 2 | Sanofi | <1 mi |
| Long-term Safety and Efficacy Evaluation of Lunsekimig (SAR443765) in Adult Participants With Asthma. | Phase 2 | Sanofi | <1 mi |
| A Study to Evaluate Solriktug in Adult Participants With Asthma | Phase 2 | Uniquity One (UNI) | <1 mi |
| A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis | Phase 2 | SynAct Pharma Aps | <1 mi |
| A Study to Evaluate ENERGI-F703 GEL in Diabetic Foot Ulcer | Phase 3 | Energenesis Biomedical Co., Ltd. | <1 mi |
| A Clinical Trial of Four Medicines (Elranatamab Plus Carfilzomib and Dexamethasone or Maplirpacept) in People With Relapsed Refractory Multiple Myeloma | Phase 1 | Pfizer | <1 mi |
| MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) | Phase 3 | Pfizer | <1 mi |
| Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response | Phase 3 | Canadian Cancer Trials Group | <1 mi |
| Testing the Use of Neratinib or the Combination of Neratinib and Palbociclib Targeted Treatment for HER2+ Solid Tumors (A ComboMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Venetoclax for the Treatment of Patients With Relapsed Hairy Cell Leukemia | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Comparing Sentinel Lymph Node (SLN) Biopsy With Standard Neck Dissection for Patients With Early-Stage Oral Cavity Cancer | Phase 2/3 | NRG Oncology | <1 mi |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study | Phase 3 | NRG Oncology | <1 mi |
| Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Heated Intraperitoneal Chemotherapy Followed by Niraparib for Ovarian, Primary Peritoneal and Fallopian Tube Cancer | Phase 3 | GOG Foundation | <1 mi |
| Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy | Phase 1/2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments | Phase 3 | Pfizer | <1 mi |
| Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma | Phase 2 | University of Miami | <1 mi |
| Testing the Addition of an Anti-cancer Drug, SNDX-5613, to the Standard Chemotherapy Treatment (Daunorubicin and Cytarabine) for Newly Diagnosed Patients With Acute Myeloid Leukemia That Has Changes in NPM1 or MLL/KMT2A Gene | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Impact of Sentinel Lymph Node Mapping on Patient Reported Lower Extremity Limb Dysfunction in Stage I Endometrial Cancer | Phase 3 | NRG Oncology | <1 mi |
| A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | Phase 2/3 | Daiichi Sankyo | <1 mi |
| Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM) | Phase 4 | Pfizer | <1 mi |
| A Study to Learn About the Effects of the Combination of Elranatamab (PF-06863135) and Iberdomide in Patients With Relapsed or Refractory Multiple Myeloma (MagnetisMM-30) | Phase 1 | Pfizer | <1 mi |
| CAMP RWE Trial: Amnion Grafts for Healing Hard-to-Heal Ulcers in RW Populations | N/A | Capsicure, LLC | <1 mi |
| Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT) | N/A | Florida International University | <1 mi |
| Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial | Phase 3 | NRG Oncology | <1 mi |
| Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | <1 mi |
| Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2 | Phase 4 | University of Miami | <1 mi |
| Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1 | Phase 4 | University of Miami | <1 mi |
| Ablative Stereotactic MR-Guided Adaptive Reirradiation | N/A | Baptist Health South Florida | <1 mi |
| 53-Week Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 With Mild to Severe Tibio-Femoral Osteoarthritis of the Knee | Phase 2 | OrthoTrophix, Inc | <1 mi |
| A Study Comparing Abemaciclib Plus Temozolomide to Temozolomide Monotherapy in Children and Young Adults With High-grade Glioma Following Radiotherapy | Phase 2 | Eli Lilly and Company | <1 mi |
| First in Human Study of IMGN151 in Recurrent Gynaecological Cancers | Phase 1 | AbbVie | <1 mi |
| Community Health Workers Reduce Social Barriers That Affect the Health of Patients With High Blood Pressure and Diabetes. | N/A | Morehouse School of Medicine | <1 mi |
| A Study to Assess the Safety and Efficacy of Oral LPCN 1154A in Women With Severe PPD | Phase 3 | Lipocine Inc. | <1 mi |
| WIBOFA - Validation of SCT02 With ECG-App for Detection of AF | N/A | Withings | <1 mi |
| Study to Evaluate the Efficacy, Safety, and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Phase 3 | Immunic AG | <1 mi |
| Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis | Phase 3 | Immunic AG | <1 mi |
| A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) | Phase 2 | Adrienne G. Waks | <1 mi |
| Lung EpiCheck Biomarkers Development Study | — | Nucleix Ltd. | <1 mi |
| A Trial Evaluating BJT-778 vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection | Phase 2/3 | Bluejay Therapeutics, Inc. | <1 mi |
| A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor | Phase 1/2 | Eisai Inc. | <1 mi |
| Radioembolization Trial Utilizing Eye90 Microspheres™ for the Treatment of Hepatocellular Carcinoma (HCC) | N/A | ABK Biomedical | <1 mi |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma | Phase 1/2 | Hoffmann-La Roche | <1 mi |
| (Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma | Phase 2 | IDEAYA Biosciences | <1 mi |
| A Diagnostic Study of CD38-Targeted ImmunoPET of Myeloma | Phase 2 | Hoag Memorial Hospital Presbyterian | <1 mi |
| Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma | Phase 1 | Institut de Recherches Internationales Servier | <1 mi |
| ORCHID: An Online Intervention for Persons With HIV (Miami) | N/A | University of Miami | <1 mi |
| Comparing Natriuretic Effects of ER Torsemide to IR Torsemide in Patients With Heart Failure | Phase 4 | Sarfez Pharmaceuticals, Inc. | <1 mi |
| Characteristics and Disease Progression of Mixed Connective Tissue Disease and Systemic Lupus Erythematosus | — | University of Miami | <1 mi |
| Prospective Evaluation of Targeted Axillary Dissection (TAD) | N/A | University of Miami | <1 mi |
| A Study of DF6002 Alone and in Combination With Nivolumab | Phase 1 | Dragonfly Therapeutics | <1 mi |
| AZD3470 as Monotherapy and in Combination With Anticancer Agents in Participants With Relapsed/Refractory Haematologic Malignancies. | Phase 1/2 | AstraZeneca | <1 mi |
| A Dose Finding Study of Debio 4228 in Participants With Advanced Prostate Cancer | Phase 2 | Debiopharm International SA | <1 mi |
| Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women | N/A | M.D. Anderson Cancer Center | <1 mi |
| Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | Phase 1 | Florida International University | <1 mi |
| Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | Phase 1 | Oryzon Genomics S.A. | <1 mi |
| FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Fusion Pharmaceuticals Inc. | <1 mi |
| The Miami "EMPIRE" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation | Phase 2 | Benjamin Spieler | <1 mi |
| A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors | Phase 1 | Arcus Biosciences, Inc. | <1 mi |
| RRx-001 for Reducing Oral Mucositis in Patients Receiving Chemotherapy and Radiation for Head and Neck Cancer | Phase 2 | EpicentRx, Inc. | <1 mi |
| Adjuvant Quisinostat in High-Risk Uveal Melanoma | Phase 2 | University of Miami | <1 mi |
| ERd Combination Treatment in Newly Diagnosed Multiple Myeloma | Phase 2 | University of Miami | <1 mi |
| Enfortumab Vedotin and Pembrolizumab in People With Bladder Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compared to Standard of Care for Maintenance Treatment of Participants With Recurrent Platinum-sensitive Ovarian Cancer After Second-line (2L) Platinum-based Doublet Chemotherapy | Phase 3 | Genmab | <1 mi |
| A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms | Phase 1 | Incyte Corporation | <1 mi |
| Lifestyle Intervention of Food and Exercise for Lymphoma Survivors | N/A | University of Miami | <1 mi |
| Chimeric Antigen Receptor T Cell Therapy Redirected to CD4 (CD4CAR)as a Second Line Treatment for Chronic Myelomonocytic Leukemia, CMML. | Phase 1 | Huda Salman | <1 mi |
| Non-invasive Glioma Characterization Through Molecular Imaging | N/A | University of Miami | <1 mi |
| Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior Immunotherapy | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Spectroscopic MRI, Proton Therapy, and Avastin for Recurrent Glioblastoma | N/A | University of Miami | <1 mi |
| KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis | Phase 2/3 | Kyverna Therapeutics | <1 mi |
| A Study of BV-AVD in People With Bulky Hodgkin Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy | Phase 2/3 | Bristol-Myers Squibb | <1 mi |
| A Study on Using Cell-Free Tumor DNA (ctDNA) Testing to Decide When to StartRoutine Treatment in People With Human Papilloma Virus (HPV)- Associated Oropharynx Cancer (OPC) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis | — | argenx | <1 mi |
| DB107-Retroviral Replicating Vector (RRV) Combined With DB107-Flucytosine (FC) in Patients With Recurrent Glioblastoma or Anaplastic Astrocytoma | Phase 2 | Ashish Shah | <1 mi |
| CAR-T Cell Therapy, Mosunetuzumab and Polatuzumab for Treatment of Refractory/Relapsed Aggressive Non-Hodgkin's Lymphoma (NHL). | Phase 2 | Lazaros Lekakis | <1 mi |
| Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment | Phase 2 | RTOG Foundation, Inc. | <1 mi |
| Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma | Phase 2 | Benjamin T Diamond, MD | <1 mi |
| Immune Reconstitution in Stem Cell Transplant Recipients | — | University of Miami | <1 mi |
| A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors | Phase 1/2 | Immatics US, Inc. | <1 mi |
| SMART TNT for the Conservative Management of Locally Advanced Rectal Cancer | Phase 1 | University of Miami | <1 mi |
| Cabozantinib for Patients With Recurrent or Progressive Meningioma | Phase 2 | Baptist Health South Florida | <1 mi |
| Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer | N/A | Baptist Health South Florida | <1 mi |
| ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod | Phase 2 | argenx | <1 mi |
| A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma | Phase 4 | Eli Lilly and Company | <1 mi |
| Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial | Phase 2 | City of Hope Medical Center | <1 mi |
| Trial of Exercise and Lifestyle for Women With Ovarian and Endometrial Cancer | N/A | Yale University | <1 mi |
| A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG) | Phase 3 | Vor Biopharma | <1 mi |
| A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression | Phase 2 | Incyte Corporation | <1 mi |
| Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML | Phase 2/3 | Moleculin Biotech, Inc. | <1 mi |
| A First-in-human (FIH), Phase I Study of PTX-912 in Patients with Locally Advanced/Metastatic Solid Tumors | Phase 1 | Proviva Therapeutics, Inc. | <1 mi |
| 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery | Phase 1 | Baptist Health South Florida | <1 mi |
| Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | Phase 2 | Izidore Lossos, MD | <1 mi |
| Genomic Profiling in Cancer Patients | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma | Phase 1 | Caribou Biosciences, Inc. | <1 mi |
| Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery | Phase 1 | Baptist Health South Florida | <1 mi |
| A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | <1 mi |
| Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Ruxolitinib With Radiation and Temozolomide Compared to Radiation and Temozolomide for Newly Diagnosed Glioblastoma | Phase 2 | Baptist Health South Florida | <1 mi |
| Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies | Phase 1 | Therapeutic Advances in Childhood Leukemia Consortium | <1 mi |
| Trial of Ixazomib for Kaposi Sarcoma | Phase 2 | AIDS Malignancy Consortium | <1 mi |
| A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma | Phase 1/2 | BeOne Medicines | <1 mi |
| Evaluation of Grief Therapy Approaches for Bereaved Parents | N/A | University of Miami | <1 mi |
| Multidisciplinary Intervention for Adults With Chronic Graft-versus-host Disease | N/A | Massachusetts General Hospital | <1 mi |
| The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL | Phase 2 | Pediatric Transplantation & Cellular Therapy Consortium | <1 mi |
| Hairy Cell Leukemia Patient Data Registry | — | Ohio State University Comprehensive Cancer Center | <1 mi |
| Metastatic Leiomyosarcoma Biomarker Protocol | — | University of Michigan Rogel Cancer Center | <1 mi |
| Tumor-agnostic Precision Immuno-oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study | Phase 2 | Hoffmann-La Roche | <1 mi |
| Sacral Neuromodulation for Male Overactive Bladder (MOAB) | N/A | Axonics, Inc. | <1 mi |
| Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma | Phase 2 | Northwestern University | <1 mi |
| HPV DNA-Guided Radiotherapy De-intensification of Head and Neck Squamous Cell Carcinoma | Phase 2 | University of Virginia | <1 mi |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | <1 mi |
| ctDNA-Guided Sunitinib And Regorafenib Therapy for GIST | Phase 2 | University of Miami | <1 mi |
| Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps | N/A | NRG Oncology | <1 mi |
| ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Phase 2 | Nationwide Children's Hospital | <1 mi |
| Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Loxo Oncology, Inc. | <1 mi |
| Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery | Phase 2 | Thomas Jefferson University | <1 mi |
| Improving Understanding of Glioblastoma Through Preservation of Biologically Active Brain Tissue | — | Baptist Health South Florida | <1 mi |
| CD4CAR for CD4+ Leukemia and Lymphoma | Phase 1 | Huda Salman | <1 mi |
| A Study of Daratumumab | Phase 3 | Janssen Research & Development, LLC | <1 mi |
| Effect of A Multimodal Exercise Intervention on Chemotherapy Uptake in Newly Diagnosed Pediatric and AYA Sarcoma Patients | N/A | University of Miami | <1 mi |
| Collecting Blood and Tissue Sample Donations for Research for HIV/AIDS-Related Cancers | — | AIDS Malignancy Consortium | <1 mi |
| INBRX-106 in Combination With Pembrolizumab in First-line PD-L1 CPS≥20 HNSCC | Phase 2/3 | Inhibrx Biosciences, Inc | <1 mi |
| A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With Advanced, Previously Treated Colorectal Cancer | Phase 4 | Takeda | <1 mi |
| Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection | Phase 1/2 | Blue Earth Therapeutics Ltd | <1 mi |
| Testing Low-Dose Common Chemotherapy (Liposomal Doxorubicin) in Combination With an Anti-Cancer Drug, Peposertib, in Advanced Sarcoma | Phase 1 | National Cancer Institute (NCI) | <1 mi |
| Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study | Phase 2 | Uma Borate | <1 mi |
| ACT001 for the Treatment of Diffuse Intrinsic Pontine Gliomas and H3K27-altered High Grade Gliomas | Phase 2 | Nationwide Children's Hospital | <1 mi |
| Open-Label Study of Pocenbrodib Alone and in Combination With Abiraterone Acetate, Olaparib, or 177Lu-PSMA-617 | Phase 1/2 | Pathos AI, Inc. | <1 mi |
| Metabolic Impact and Compliance of Controlled, Varying, Mediterranean Diets in Pre-Surgical Prostate Cancer Populations (PROVISIONS) | N/A | University of Miami | <1 mi |
| A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001) | Phase 1 | K36 Therapeutics, Inc. | <1 mi |
| Intracavitary Carrier-embedded Cs131 Brachytherapy for Recurrent Brain Metastases: a Randomized Phase II Study | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Exercise and Nutrition for Older Cancer Survivors and Their Support Person: The Vitality Study | N/A | Dana-Farber Cancer Institute | <1 mi |
| Pembrolizumab, Olaparib, and Temozolomide for People With Glioma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) | Phase 1 | AbbVie | <1 mi |
| Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors | Phase 1/2 | Laminar Pharmaceuticals | <1 mi |
| Prehabilitation Protocol for Head and Neck Cancer Patients | N/A | University of Miami | <1 mi |
| Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT) | Phase 1/2 | University of Florida | <1 mi |
| MEKTOVI® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | Phase 2 | Nationwide Children's Hospital | <1 mi |
| A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations | Phase 2 | Fore Biotherapeutics | <1 mi |
| NSAID Use After Robotic Partial Nephrectomy | Phase 2 | University of Miami | <1 mi |
| Venetoclax and Bomedemstat in Patients With Relapsed/Refractory Acute Myeloid Leukemia | Phase 1 | Terrence J Bradley, MD | <1 mi |
| A Phase 1 Study With LYT-200 in Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML), or With Relapsed/Refractory, High-risk Myelodysplastic Syndrome (MDS) | Phase 1 | PureTech | <1 mi |
| Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care | N/A | University of Miami | <1 mi |
| A Study to Provide Continued Access to and Assess Long-Term Safety of the Study Drug(s) | Phase 3 | Daiichi Sankyo | <1 mi |
| BrECADD Therapy in Stage 2 B-IV Hodgkin Lymphoma | Phase 2 | University of Miami | <1 mi |
| Loncastuximab Tesirine in Combination With Rituximab in Patients With Relapsed or Refractory Follicular Lymphoma | Phase 2 | Juan P. Alderuccio, MD | <1 mi |
| A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation | Phase 2 | Center for International Blood and Marrow Transplant Research | <1 mi |
| Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial) | Phase 2 | National Cancer Institute (NCI) | <1 mi |
| Teclistamab in Combination With Daratumumab for High-Risk Smoldering Myeloma: A Clinical and Correlative Phase 2 Immuno-Oncology Study (the REVIVE Study) | Phase 2 | Carl Ola Landgren, MD, PhD | <1 mi |
| IMMUNOPLANT for Newly Diagnosed Multiple Myeloma | Phase 2 | Dickran Kazandjian, MD | <1 mi |
| Safety and Efficacy Study of PRV111 and PRV211 in Subjects With Oral Squamous Cell Carcinoma | Phase 2/3 | Privo Technologies | <1 mi |
| A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia | Phase 2 | MeiraGTx, LLC | <1 mi |
| DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma | Phase 1/2 | University of California, San Francisco | <1 mi |
| Study of Induction PD-1 Blockade in Subjects With Locally Advanced Mismatch Repair Deficient Solid Tumors | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global) | Phase 3 | Telix Pharmaceuticals (Innovations) Pty Limited | <1 mi |
| Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma | Phase 1/2 | Alvaro Alencar, MD | <1 mi |
| First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma | Phase 1/2 | Adcendo ApS | <1 mi |
| PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer | Phase 2 | University of Miami | <1 mi |
| xDRIVE for Florida-based Cancer Patients | N/A | First Ascent Biomedical Inc. | <1 mi |
| Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG) | Phase 1/2 | InSightec | <1 mi |
| Preservation of Swallowing in Respected Oral Cavity Squamous Cell Carcinoma: Examining Radiation Volume Effects (PRESERVE): A Randomized Trial | Phase 2 | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | <1 mi |
| Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial | Phase 3 | M.D. Anderson Cancer Center | <1 mi |
| Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy | Phase 2 | NATCO Pharma Ltd. | <1 mi |
| A Study to Investigate the Safety and Efficacy of KQB548 in Participants With Advanced Solid Malignancies | Phase 1 | Kumquat Biosciences Inc. | <1 mi |
| A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 | Phase 2/3 | BioNTech SE | <1 mi |
| Study of R289 in Patients With Lower-risk Myelodysplastic Syndromes (LR MDS) | Phase 1/2 | Rigel Pharmaceuticals | <1 mi |
| STARLITE for Unresectable High-Grade Gliomas | Phase 1 | University of Miami | <1 mi |
| Two Biologically and Clinically Distinct Entities: Progressive Versus Stable Multiple Myeloma (MM) Precursor Conditions | — | University of Miami | <1 mi |
| Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER | Phase 2 | Canadian Cancer Trials Group | <1 mi |
| Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer | Phase 3 | Alliance for Clinical Trials in Oncology | <1 mi |
| Olutasidenib, Venetoclax, and Azacitidine in IDH1 Mutated Newly Diagnosed Acute Myeloid Leukemia Patients Eligible for Intensive Induction Chemotherapy | Phase 2 | Justin Watts, MD | <1 mi |
| PrOton Pulsed reduCed dOse Rate Radiotherapy for Recurrent CNS maligNancies Trial | N/A | Baptist Health South Florida | <1 mi |
| A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma | Early 1 | AIDS Malignancy Consortium | <1 mi |
| Fostering Oral Chemotherapy Understanding and Safety (FOCUS) Study | N/A | University of Miami | <1 mi |
| A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | Phase 2/3 | Taiho Oncology, Inc. | <1 mi |
| Study of Ruxolitinib in Relapsed or Refractory T or NK Cell Lymphoma | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic | — | Baptist Health South Florida | <1 mi |
| A Study of NVL-330 in Patients With Advanced or Metastatic HER2-altered NSCLC (HEROEX-1) | Phase 1 | Nuvalent Inc. | <1 mi |
| Linvoseltamab in Addition to Lenalidomide (L2) During Maintenance Therapy of NDMM to Deepen Responses or Redrive MRD Negativity After Relapse | Phase 2 | Dickran Kazandjian, MD | <1 mi |
| A Study of Meaning-Centered Psychotherapy for Caregivers to People With Cancer | N/A | Icahn School of Medicine at Mount Sinai | <1 mi |
| The University of Miami Adapt (UAdapt) Trial | Phase 2 | University of Miami | <1 mi |
| DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers | Phase 1 | Boehringer Ingelheim | <1 mi |
| Zanubrutinib With Pemetrexed to Treat Relapsed/Refractory Primary and Secondary Central Nervous System (CNS) Lymphomas | Phase 2 | Baptist Health South Florida | <1 mi |
| Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone Lymphoma | — | International Extranodal Lymphoma Study Group (IELSG) | <1 mi |
| DALY II USA/ MB-CART2019.1 for DLBCL | Phase 2 | Miltenyi Biomedicine GmbH | <1 mi |
| A Study Comparing Personalized Radiation Therapy With Standard Radiation Therapy in People With HPV-Positive Throat Cancer | Phase 3 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Feasibility Safety Study of Benign Centrally-Located Intracranial Tumors in Pediatric and Young Adult Subjects | N/A | InSightec | <1 mi |
| Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Phase 1/2 | Aptose Biosciences Inc. | <1 mi |
| Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma | Phase 1 | Aaron Wolfson | <1 mi |
| Suprachoroidal Administration in Subjects With Metastases to the Choroid | Phase 2 | Aura Biosciences | <1 mi |
| A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies | Phase 1/2 | Deciphera Pharmaceuticals, LLC | <1 mi |
| A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer. | Phase 2 | AbbVie | <1 mi |
| Treatment of Relapsed/Refractory Intracranial Glioma in Patients Under 22 Years of Age | Phase 1/2 | University of Miami | <1 mi |
| Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone Lymphoma | Phase 2 | University of Miami | <1 mi |
| Screening Strategies Among High-risk Populations for Anal Cancer | N/A | Lisa Flowers | <1 mi |
| APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML | Phase 1 | Aptevo Therapeutics | <1 mi |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma | Phase 1 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma | Phase 2 | Jennifer Crombie, MD | <1 mi |
| Collection and Measurement of Biomarkers in Prostate Cancer Radiotherapy Patients | — | University of Miami | <1 mi |
| A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) | Phase 1 | ADC Therapeutics S.A. | <1 mi |
| A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors | Phase 1/2 | Eikon Therapeutics | <1 mi |
| Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects | Phase 1/2 | VBI Vaccines Inc. | <1 mi |
| First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors | Phase 1 | IDRx Inc. - A GSK Company | <1 mi |
| First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors | Phase 1 | CDR-Life AG | <1 mi |
| A Study of Neladalkib (NVL-655) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | Phase 1/2 | Nuvalent Inc. | <1 mi |
| Effect of Azeliragon Combined With Stereotactic Radiation Therapy in Patients With Brain Metastases | Phase 1/2 | Baptist Health South Florida | <1 mi |
| Study Evaluating Safety, Tolerability, and Metabolism of Niraparib | Phase 4 | University of Miami | <1 mi |
| SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET) | Phase 1 | Peter Hosein, MD | <1 mi |
| PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma | Phase 2 | Nationwide Children's Hospital | <1 mi |
| Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant | Phase 1 | Huda Salman | <1 mi |
| Brentuximab Vedotin in Early Stage Hodgkin Lymphoma | Phase 3 | University College, London | <1 mi |
| Self-collection for HPV Testing to Improve Cervical Cancer Prevention (SHIP) Trial (LMI-001-A-S01) | N/A | National Cancer Institute (NCI) | <1 mi |
| Characterization of 18F-Fluciclovine PET Amino Acid Radiotracer in Resected Brain Metastasis | Phase 2 | Baptist Health South Florida | <1 mi |
| ECHO Diabetes FQHC | — | University of Florida | <1 mi |
| Matrion Decellularized Placental Membrane Versus Conventional Wound Management in Subjects With Diabetic Foot Ulcers | N/A | LifeNet Health | <1 mi |
| Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes | Phase 1/2 | Creative Medical Technology Holdings Inc | <1 mi |
| Long Term Follow up of Recipients of Functional Islet Allografts | — | Rodolfo Alejandro | <1 mi |
| Study of GS-4571 in Healthy Participants, Nondiabetic Obese Participants, and Nonobese Participants With Type 2 Diabetes Mellitus (T2DM) | Phase 1 | Gilead Sciences | <1 mi |
| A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes | Phase 1/2 | City of Hope Medical Center | <1 mi |
| Pancreatic Islet Transplantation Into the Anterior Chamber of the Eye | Phase 1/2 | Midhat H. Abdulreda | <1 mi |
| Different Doses of Naronapride Vs. Placebo in Gastroparesis | Phase 2 | Dr. Falk Pharma GmbH | <1 mi |
| A Study of GNTI-122 in Adults Recently Diagnosed With T1D | Phase 1 | GentiBio, Inc | <1 mi |
| Type 1 Diabetes Recurrence in Pancreas Transplants | — | University of Miami | <1 mi |
| A Study to Evaluate the Efficacy, Safety, and Tolerability of ASC30 Tablets in Participants With Type 2 Diabetes Mellitus | Phase 2 | Ascletis Pharma (China) Co., Limited | <1 mi |
| Derm-Maxx in Patients With Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone | N/A | Capsicure, LLC | <1 mi |
| Long Term Surveillance of Islet Transplant Recipients Following Complete Graft Loss | — | Rodolfo Alejandro | <1 mi |
| RESET System Pivotal Trial (Rev F) | N/A | Morphic Medical Inc. | <1 mi |
| A Study of Retatrutide (LY3437943) in Participants Without Type 2 Diabetes Who Have Obesity or Overweight | Phase 3 | Eli Lilly and Company | <1 mi |
| A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes | Phase 3 | Eli Lilly and Company | <1 mi |
| Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease | Phase 2 | Regeneron Pharmaceuticals | <1 mi |
| CGM for the Early Detection and Management of Hyperglycemia in Pregnancy | N/A | Jaeb Center for Health Research | <1 mi |
| A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM | Phase 1/2 | Alnylam Pharmaceuticals | <1 mi |
| A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes | Phase 3 | Vertex Pharmaceuticals Incorporated | <1 mi |
| Studying the Presence of CFRD Complications With Thoughtful Recruitment (SPeCTRuM) | — | Jaeb Center for Health Research | <1 mi |
| SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes | Phase 2 | SAb Biotherapeutics, Inc. | <1 mi |
| Trial Against INtractable Type 2 Diabetes (CAPTAIN-T2D) | Phase 2 | Sparrow Pharmaceuticals | <1 mi |
| Rising Tide - Amniotic Tissue(s) Treatments for Chronic Diabetic Foot Ulcers | N/A | Tides Medical | <1 mi |
| Effect of Amnio-Maxx on the Healing Rate of Chronic Diabetic Foot Ulcers. | Phase 4 | Royal Biologics | <1 mi |
| CAlcium and VAsopressin Following Injury Early Resuscitation (CAVALIER) Trial | Phase 2 | Jason Sperry | <1 mi |
| A Clinical Investigation to Follow the Progress of Exuding Chronic Wounds Using Mepilex® Up as the Primary Dressing. | N/A | Molnlycke Health Care AB | <1 mi |
| Prevention of de Novo Allosensitization in Islet Transplant Recipients Following Complete Graft Loss | N/A | Rodolfo Alejandro | <1 mi |
| A Clinical Trial of MK-1403 in Participants With Type 2 Diabetes Mellitus (MK-1403-006) | Phase 1 | Merck Sharp & Dohme LLC | <1 mi |
| A Remotely Delivered Tai Chi/Qigong Intervention for Older People Living With HIV | N/A | Florida International University | <1 mi |
| Neural and Psychiatric Consequences of Cannabis Use in Adolescents | N/A | University of Miami | <1 mi |
| Study of ABX-002 for the Adjunctive Treatment of Depressive Episodes Associated With Bipolar Disorder in Adults | Phase 2 | Autobahn Therapeutics, Inc. | <1 mi |
| The Neural Underpinnings of Depression and Cannabis Use in Young People Living With HIV | N/A | University of Miami | <1 mi |
| Alzheimer's Disease Treatment With Combination of 40Hz Light and Cognitive Therapy | — | Alzheimer's Light LLC | <1 mi |
| Late Onset Alzheimer's Disease | — | Columbia University | <1 mi |
| A Trial to Evaluate the Safety and Efficacy of Benfotiamine in Patients With Early Alzheimer's Disease (BenfoTeam) | Phase 2 | Alzheimer's Disease Cooperative Study (ADCS) | <1 mi |
| Combating Alzheimer's Through Sleep and Exercise | N/A | University of Miami | <1 mi |
| Human Mesenchymal Stem Cells (hMSC) in Behavioral Problems Due to Alzheimer's Disease. | Phase 2 | Bernard (Barry) Baumel | <1 mi |
| Open-label Extension Study in Participants With Early Alzheimer's Disease | Phase 2 | GlaxoSmithKline | <1 mi |
| Personalized Obstructive Sleep Apnea Treatment and Effects on Alzheimer's Disease Biomarkers and Cognition Among Blacks | N/A | University of Miami | <1 mi |
| Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D | Phase 1 | Alveus Therapeutics, Inc. | <1 mi |
| A Study of LY4086940 in Healthy Participants and Participants With Overweight or Obesity, With or Without Type 2 Diabetes | Phase 1 | Eli Lilly and Company | <1 mi |
| Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) and Diet in Inflammatory Bowel Disease (IBD) Patients | Phase 4 | University of Miami | <1 mi |
| RESCUE: Discontinuation of GLP-1 | — | Boston Scientific Corporation | <1 mi |
| Proof-of-Concept Study Evaluating Total Body Weight, Physical Function & Safety of Enobosarm in Patients Treated With GLP-1 Receptor Agonist, for Weight Loss | Phase 2 | Veru Inc. | <1 mi |
| Understanding Decentralized Trial Engagement and Clinical Impediments Through Digital Efforts (UDECIDE) Among Unrepresented Groups With Poor Cardiovascular and Cardiometabolic Health | N/A | University of Miami | <1 mi |
| AngelMed Guardian® System PMA Post Approval Study | — | Angel Medical Systems | <1 mi |
| Single or Repeated Intravenous Administration of umbiliCAl Cord Mesenchymal sTrOmal Cells in Ischemic Cardiomyopathy | Phase 2 | Roberto Bolli | <1 mi |
| PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III | N/A | Endotronix, Inc. | <1 mi |
| Prevail Global Study | N/A | Medtronic Vascular | <1 mi |
| Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass | Phase 3 | Octapharma | <1 mi |
| SuperSaturated Oxygen Comprehensive Observational Registry | — | TherOx | <1 mi |
| Minima Stent System Post- Approval Study (PAS) | — | Renata Medical | <1 mi |
| Repeat Ablation of Persistent Atrial Fibrillation, Including Mitral Isthmus Catheter Ablation, With the FARAPULSE Pulsed Field Ablation System | N/A | Boston Scientific Corporation | <1 mi |
| Use of Point-of-Care Ultrasound (POCUS) to Reduce Hospital Length of Stay in Patients With Heart Failure ( POCUSHF ) | N/A | Florida International University | <1 mi |
| PREEMIE: Study for Treatment of PDA in Premature Infants | N/A | Merit Medical Systems, Inc. | <1 mi |
| A Multicenter Trial Assessing the Impact of Lipoprotein(a) Lowering With Pelacarsen (TQJ230) on the Progression of Calcific Aortic Valve Stenosis | Phase 2 | Novartis Pharmaceuticals | <1 mi |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes | Phase 4 | VA Office of Research and Development | <1 mi |
| A Basket Study of Vosoritide in Children With Turner Syndrome, Short Stature Homeobox-Containing Gene Deficiency, and Noonan Syndrome With Inadequate Growth During or After Human Growth Hormone Treatment | Phase 2 | BioMarin Pharmaceutical | <1 mi |
| Pediatric Influence of Cooling Duration on Efficacy in Cardiac Arrest Patients (P-ICECAP) | N/A | University of Michigan | <1 mi |
| A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | Phase 3 | GlaxoSmithKline | <1 mi |
| A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Different Devices in Participants Aged 4 to Less Than 12 Years Old With Asthma | Phase 1 | AstraZeneca | <1 mi |
| Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma | Phase 2 | Windward Bio | <1 mi |
| A Multicentre, Randomised, Double-blind, Parallel Group, Placebo-controlled, Time-to-first Asthma Exacerbation Phase III Efficacy and Safety Study of Benralizumab in Paediatric Patients With Severe Eosinophilic Asthma (DOMINICA) | Phase 3 | AstraZeneca | <1 mi |
| Efficacy and Safety of Subcutaneous Dupilumab in Participants With Asthma/Asthmatic Wheeze Aged 2 to <6 Years (LIBERTY ASTHMA TREKIDS) | Phase 3 | Sanofi | <1 mi |
| Rademikibart Add-on Treatment of an Acute Asthma Exacerbation (Seabreeze STAT Asthma) | Phase 2 | Connect Biopharm LLC | <1 mi |
| A Study to Investigate the Clinical Effect and the Safety of PRX-115 Infused Intravenously at Different Dosing Regimens, With and Without Methotrexate, Versus Placebo in Adults Gout Patients (RELEASE) | Phase 2 | Protalix | <1 mi |
| Magnesium-L-Threonate for Sleep Quality Post-Arthroplasty | Phase 4 | University of Miami | <1 mi |
| R-2487 in Patients With Rheumatoid Arthritis | Phase 1 | Rise Therapeutics LLC | <1 mi |
| ZYNRELEF for Pain Management in Total Knee Arthroplasty | Phase 4 | Baptist Health South Florida | <1 mi |
| A Study of LY4213663 in Healthy Participants and Participants With Rheumatoid Arthritis | Phase 1 | Eli Lilly and Company | <1 mi |
| General vs Spinal in Total Joint Arthroplasty (TJA) | N/A | University of Miami | <1 mi |
| Inhaled Corticosteroids (ICS) on Pulmonary Endothelial Function in COPD | Phase 2 | University of Miami | <1 mi |
| A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. | Phase 4 | Sanofi | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease | Phase 2/3 | Pfizer | <1 mi |
| Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1) | Phase 3 | GlaxoSmithKline | <1 mi |
| Physiologic Effects of Nasal High Flow on Exercise Tolerance in COPD | N/A | University of Miami | <1 mi |
| Rademikibart Add-on Treatment of an Acute COPD Exacerbation (Seabreeze STAT COPD) | Phase 2 | Connect Biopharm LLC | <1 mi |
| A Study Comparing Music Therapy and Cognitive Behavioral Therapy for Anxiety in Cancer Survivors | Phase 4 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Radiotherapy Patient Education With Virtual Reality | N/A | University of Miami | <1 mi |
| Improving Minority Health Through Biofeedback and Stress Reduction | N/A | Amelia Saul, PhD, CTRS, BCB | <1 mi |
| Cultural Adaptation of a SSI for Youth Anxiety | N/A | University of Miami | <1 mi |
| Community Park-Based Programs for Health Promotion: The Fit2Lead Prospective Cohort Study | — | Duke University | <1 mi |
| Mental Health in Primary Care | N/A | University of Miami | <1 mi |
| Community Park-Based Programs for Health Promotion: Fit2Play Prospective Cohort Study | — | Duke University | <1 mi |
| Parkinson's Foundation Surveys | — | Parkinson's Foundation | <1 mi |
| Use of CereGate Therapy for Freezing of Gait in PD | N/A | CereGate Inc. | <1 mi |
| Parkinson's Foundation PD GENEration Genetic Registry | — | Parkinson's Foundation | <1 mi |
| A Post-Approval Registry for Exablate 4000 Type 1.0 and Type 1.1 for Unilateral Thalamotomy for the Treatment of Medication-Refractory Tremor Dominant Idiopathic Parkinson's Disease | — | InSightec | <1 mi |
| A Research Trial to Assess if Cenerimod is Efficacious and Safe to Treat Active Lupus Nephritis on Top of Regular Treatment | Phase 3 | Viatris Innovation GmbH | <1 mi |
| A 2-Part Study to Learn Whether Litifilimab (BIIB059) Injections Can Improve Symptoms of Adult Participants Who Have Active Cutaneous Lupus Erythematosus | Phase 2/3 | Biogen | <1 mi |
| VIBRANT: VIB4920 for Active Lupus Nephritis | Phase 2 | National Institute of Allergy and Infectious Diseases (NIAID) | <1 mi |
| A Phase III Study to Investigate the Efficacy and Safety of Anifrolumab in Adults With Chronic and/or Subacute Cutaneous Lupus Erythematosus | Phase 3 | AstraZeneca | <1 mi |
| Lupus Landmark Study: A Prospective Registry and Biorepository | — | Lupus Research Alliance | <1 mi |
| Longitudinal Cognitive Assessment by BoCA | — | Alzheimer's Light LLC | <1 mi |
| TSC Biosample Repository and Natural History Database | — | National Tuberous Sclerosis Association | <1 mi |
| A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) | — | TG Therapeutics, Inc. | <1 mi |
| Clinical Applications of Advanced Ophthalmic Imaging | N/A | University of Miami | <1 mi |
| Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer | N/A | University of Miami | <1 mi |
| A Trial Comparing Screening Mammography With and Without Assistance From Artificial Intelligence for Breast Cancer Detection and Recall Rates in Adult Patients | Phase 4 | Jonsson Comprehensive Cancer Center | <1 mi |
| Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study | Phase 3 | American Society of Clinical Oncology | <1 mi |
| Sequencing Antibody Drug Conjugates in ER+/HER2 LOW/ULTRA LOW MBC | Phase 2 | Reshma L. Mahtani, D.O. | <1 mi |
| Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer | N/A | University of Miami | <1 mi |
| ATEMPT 2.0: Adjuvant T-DM1 vs TH | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| Precise Oncology Interventions in Nutrition and Training (OnPoint) | N/A | University of Miami | <1 mi |
| SABER Study for Selected Early Stage Breast Cancer | N/A | University of Miami | <1 mi |
| With Love, Grandma ("Con Cariño, Abuelita") Pilot Study | N/A | University of Miami Sylvester Comprehensive Cancer Center | <1 mi |
| A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer | Phase 2 | Dana-Farber Cancer Institute | <1 mi |
| Women Informed to Screen Depending on Measures of Risk (Wisdom Study) | N/A | University of California, San Francisco | <1 mi |
| Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer | Phase 1/2 | SynDevRx, Inc. | <1 mi |
| First in Human Study of TUB-030 in Patients With Advanced Solid Tumors | Phase 1/2 | Tubulis GmbH | <1 mi |
| A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of Breast Cancer Risk Factors and Outcomes of People in Florida | — | Memorial Sloan Kettering Cancer Center | <1 mi |
| Breast Re-irradiation After Second Ipsilateral Lumpectomy | N/A | Youssef Zeidan | <1 mi |
| Application of Chinese Herbal Complementary and Alternative Medicine (CAM) to Improve Human Health and to Further Botanical and Horticultural Sciences | N/A | University of Miami | <1 mi |
| DATO-BASE: DATOpotamab-deruxtecan for Breast Cancer Brain metAstaSEs | Phase 2 | Sarah Sammons, MD | <1 mi |
| Empathic Communication Skills (ECS) Training | N/A | Memorial Sloan Kettering Cancer Center | <1 mi |
| Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC) | Phase 3 | Shanghai Junshi Bioscience Co., Ltd. | <1 mi |
| ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung Cancer | Phase 2 | University of Miami | <1 mi |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers | Phase 1 | Iambic Therapeutics, Inc | <1 mi |
| A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors | Phase 1/2 | Marengo Therapeutics, Inc. | <1 mi |
| Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy | N/A | VA Office of Research and Development | <1 mi |
| A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | Phase 1 | Aktis Oncology, Inc. | <1 mi |
| PromotinG Lung Cancer screenIng Awareness and Implementation in Hispanics/Latinx Head and Neck canceR Survivors | N/A | University of Miami | <1 mi |
| BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS) | Phase 2 | SCRI Development Innovations, LLC | <1 mi |
| Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer | Phase 1/2 | Aulos Bioscience, Inc. | <1 mi |
| cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease | — | Adela, Inc | <1 mi |
| A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002) | Phase 1/2 | Merck Sharp & Dohme LLC | <1 mi |
| A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | Phase 3 | Merck Sharp & Dohme LLC | <1 mi |
| Investigating the Effectiveness of Stereotactic Body Radiotherapy (SBRT) in Addition to Standard of Care Treatment for Cancer That Has Spread Beyond the Original Site of Disease | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Eli Lilly and Company | <1 mi |
| Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer | Phase 3 | Gilead Sciences | <1 mi |
| Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | Phase 2 | Genelux Corporation | <1 mi |
| A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations. | Phase 1 | Pfizer | <1 mi |
| A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation | Phase 1 | Clasp Therapeutics, Inc. | <1 mi |
| ARGONAUT: Stool and Blood Sample Bank for Cancer Patients | — | Persephone Biosciences | <1 mi |
| A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors | Phase 1/2 | Bristol-Myers Squibb | <1 mi |
| Analysis of RATS, VATS and Open Lung Resections After Neoadjuvant Chemo-immunotherapy in Patients Performed in Five Referred Centers | — | Scientific Institute San Raffaele | <1 mi |
| A Study of VET3-TGI in Patients With Solid Tumors | Phase 1 | KaliVir Immunotherapeutics | <1 mi |
| A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | Phase 3 | Bristol-Myers Squibb | <1 mi |
| A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment | — | Ipsen | <1 mi |
| A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) | Phase 1 | Regeneron Pharmaceuticals | <1 mi |
| Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis) | Phase 3 | Takeda | <1 mi |
| A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH) | Phase 2 | Boehringer Ingelheim | <1 mi |
| A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH | Phase 3 | GlaxoSmithKline | <1 mi |
| Evaluation of Non-Invasive Tests for Metabolic Liver Disease | — | Foundation for the National Institutes of Health | <1 mi |
| A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME) | Phase 2 | Aligos Therapeutics | <1 mi |
| Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Phase 3 | Disc Medicine, Inc | <1 mi |
| Veteran-Centered Care for Advanced Liver Disease (Vet-CALD) | N/A | VA Office of Research and Development | <1 mi |
| A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH | Phase 3 | GlaxoSmithKline | <1 mi |
| Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States | Phase 2 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | <1 mi |
| Technology Enabled Strategies to Promote Treatment Adherence in Liver Transplant | N/A | University of Pennsylvania | <1 mi |
| Longitudinal Study of the Porphyrias | — | Icahn School of Medicine at Mount Sinai | <1 mi |
| Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein | Phase 3 | Takeda | <1 mi |
| A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Memorial Sloan Kettering Cancer Center | <1 mi |
| Targeted Navigation in Hepatocellular Carcinoma (HCC) | N/A | University of Miami | <1 mi |
| Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma | Phase 2 | University of Miami | <1 mi |
| Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma | Phase 2 | University of Miami | <1 mi |
| CapTemY90 for Grade 2/3 NET Liver Metastases | Phase 2 | Abramson Cancer Center at Penn Medicine | <1 mi |
| A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | <1 mi |
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | <1 mi |
| PSMA PET for the Staging and Management of Hepatocellular Carcinoma | — | VA Office of Research and Development | <1 mi |
| Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors | Phase 1/2 | ModeX Therapeutics, An OPKO Health Company | <1 mi |
| RSSearch Patient Registry-Long Term Study of Use of SRS/SBRT | — | The Radiosurgery Society | <1 mi |
| A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy | Phase 3 | Pierre Fabre Medicament | <1 mi |
| Real-world Evaluation of the HistoSonics Edison System for Treatment of Liver Tumors Across Multidisciplinary Users (BOOMBOX: Master Study) | — | HistoSonics, Inc. | <1 mi |
| A Study of Raludotatug Deruxtecan (R-DXd) in People With Gastrointestinal Cancers (MK-5909-005) | Phase 2 | Merck Sharp & Dohme LLC | 4 mi |
| Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients | Phase 2 | National Cancer Institute (NCI) | 4 mi |
| Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer | Phase 3 | National Cancer Institute (NCI) | 4 mi |
| A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) | Phase 3 | Merck Sharp & Dohme LLC | 4 mi |
| Groningen International Study on Sentinel Nodes in Vulvar Cancer-III | Phase 2 | University Medical Center Groningen | 4 mi |
| A Study of CUSP06 in Patients With Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors | Phase 1 | OnCusp Therapeutics, Inc. | 4 mi |
| A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemia | Phase 2 | Janssen Research & Development, LLC | 4 mi |
| Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer | Phase 2 | Faeth Therapeutics | 4 mi |
| A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103) | Phase 3 | Merck Sharp & Dohme LLC | 4 mi |
| Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer | Phase 2 | Aadi Bioscience, Inc. | 4 mi |
| mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma | Phase 3 | Alliance for Clinical Trials in Oncology | 4 mi |
| A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies | Phase 2 | Curis, Inc. | 4 mi |
| A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22) | Phase 3 | Merck Sharp & Dohme LLC | 4 mi |
| Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial | Phase 2 | National Cancer Institute (NCI) | 4 mi |
| Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer | Phase 3 | Daiichi Sankyo | 4 mi |
| Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment | Phase 2 | SWOG Cancer Research Network | 4 mi |
| A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer | Phase 1/2 | Alliance Foundation Trials, LLC. | 4 mi |
| A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A) | Phase 1/2 | Merck Sharp & Dohme LLC | 4 mi |
| A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer | Phase 3 | Seagen, a wholly owned subsidiary of Pfizer | 4 mi |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | Phase 1 | Nurix Therapeutics, Inc. | 4 mi |
| A TRIAL TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND EFFICACY OF SHR-A1904 IN SUBJECTS WITH ADVANCED SOLID TUMORS | Phase 1/2 | Jiangsu HengRui Medicine Co., Ltd. | 4 mi |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) | Phase 2 | Merck Sharp & Dohme LLC | 4 mi |
| Study to Evaluate Adverse Events and Change in Disease Activity in Adult Participants With B-Cell Malignancies Receiving Oral ABBV-525 Tablets | Phase 1 | AbbVie | 4 mi |
| A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma | Phase 2 | Acrivon Therapeutics | 4 mi |
| Study of Patritumab Deruxtecan in Participants With Gastrointestinal Cancers (MK-1022-011) (HERTHENA-PanTumor02) | Phase 1/2 | Merck Sharp & Dohme LLC | 4 mi |
| Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma | Phase 3 | TransThera Sciences (Nanjing), Inc. | 4 mi |
| Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment | Phase 3 | National Cancer Institute (NCI) | 4 mi |
| A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) | Phase 3 | Merck Sharp & Dohme LLC | 4 mi |
| Trial to Assess Chelation Therapy in Critical Limb Ischemia | Phase 3 | Mt. Sinai Medical Center, Miami | 4 mi |
| Safely Optimizing Body Weight With TCMCB07 in Patients With Newly Diagnosed Metastatic Colorectal Cancer Undergoing Chemotherapy | Phase 2 | Endevica Bio | 4 mi |
| Edwards PASCAL Transcatheter Valve Repair System Pivotal Clinical Trial | N/A | Edwards Lifesciences | 4 mi |
| S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer | N/A | SWOG Cancer Research Network | 4 mi |
| Study of INCB123667 in Subjects With Advanced Solid Tumors | Phase 1 | Incyte Corporation | 4 mi |
| CtDNA Based MRD Testing for NAC Monitoring in TNBC | — | Personalis Inc. | 4 mi |
| AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc | N/A | Columbia University | 4 mi |
| A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004) | Phase 3 | Merck Sharp & Dohme LLC | 4 mi |
| A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | Phase 3 | Merck Sharp & Dohme LLC | 4 mi |
| Study of Novel Immunomodulators as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Hepatobiliary Cancer | Phase 2 | AstraZeneca | 4 mi |
| An Adaptive Phase 2a/2b Study of LY3871801 in Adult Participants With Rheumatoid Arthritis | Phase 2 | Eli Lilly and Company | 5 mi |
| Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening | — | Freenome Holdings Inc. | 5 mi |
| Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation | Phase 2 | Regeneron Pharmaceuticals | 5 mi |
| A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease | Phase 2 | Novartis Pharmaceuticals | 5 mi |
| A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease | Phase 1 | Verve Therapeutics, Inc. | 5 mi |
| Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma | Phase 4 | Regeneron Pharmaceuticals | 5 mi |
| A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee | Phase 2 | Pacira Pharmaceuticals, Inc | 5 mi |
| A Study to Evaluate the Safety and Effectiveness of JUVÉDERM Products in Adult Participants for the Change of Their Overall Facial Appearance | Phase 4 | AbbVie | 6 mi |
| FAMILY Sleep Program | N/A | University of Miami | 6 mi |
| Dyadic Sleep Study | N/A | University of Miami | 6 mi |
| A Study of Zidesamtinib (NVL-520) in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | Phase 1/2 | Nuvalent Inc. | 6 mi |
| PanTheR Registry Trial | — | RenovoRx | 6 mi |
| A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma | Phase 3 | Hoffmann-La Roche | 6 mi |
| Families With Pride ("Familias Con Orgullo"). | N/A | University of Miami | 6 mi |
| Geolocation Positional System (GPS) Experience | N/A | University of Miami | 6 mi |
| Study of JK07 in Patients With Chronic Heart Failure | Phase 2 | Salubris Biotherapeutics Inc | 6 mi |
| Unified Protocol: Community Connections | N/A | University of Miami | 6 mi |
| Periodization and Parkinson's Disease | N/A | University of Miami | 6 mi |
| Low Versus High Load Training and Parkinson's Disease | N/A | University of Miami | 6 mi |
| BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 | SillaJen, Inc. | 6 mi |
| Alpha-1 Research Registry | — | Alpha-1 Foundation | 6 mi |
| A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01 | Phase 1 | Alzheimer's Disease Expert Lab (ADEL), Inc. | 6 mi |
| Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) | Phase 3 | Neurocrine Biosciences | 6 mi |
| A Study to Determine if BHV-8000 is Effective, Safe and Tolerable as a Treatment for Adults Living With Early Parkinson's Disease | Phase 2/3 | Biohaven Therapeutics Ltd. | 6 mi |
| A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease | Phase 1 | Eli Lilly and Company | 6 mi |
| A Study of LY4006895 in Healthy Participants With Early Symptomatic Alzheimer's Disease (AD) | Phase 1 | Eli Lilly and Company | 6 mi |
| Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. | Phase 3 | Novartis Pharmaceuticals | 6 mi |
| A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis | Phase 3 | Zenas BioPharma (USA), LLC | 6 mi |
| Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis | Phase 3 | Sandoz | 6 mi |
| A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) | Phase 2 | Hoffmann-La Roche | 6 mi |
| A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis | Phase 3 | Zenas BioPharma (USA), LLC | 6 mi |
| A Study to Learn if Bimekizumab Given in Different Ways is Safe and Moves Similarly Throughout the Body Over Time in Adults | Phase 1 | UCB Biopharma SRL | 7 mi |
| A Study to Assess the Concentration of Bimekizumab in Mature Breast Milk From Mothers Receiving Treatment With Bimzelx® (Bimekizumab) | Phase 1 | UCB Biopharma SRL | 7 mi |
| Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis | Phase 3 | Sun Pharmaceutical Industries Limited | 9 mi |
| A Phase 3 Single-arm Study of UGN-104 for the Treatment of Low-grade Upper Tract Urothelial Cancer | Phase 3 | UroGen Pharma Ltd. | 9 mi |
| A Clinical Study of Intismeran Autogene (V940) and BCG in People With Bladder Cancer (V940-011/INTerpath-011) | Phase 2 | Merck Sharp & Dohme LLC | 9 mi |
| (Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis | Phase 2 | Cogent Biosciences, Inc. | 9 mi |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) | Phase 2/3 | Merck Sharp & Dohme LLC | 9 mi |
| A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG. | Phase 3 | Novartis Pharmaceuticals | 9 mi |
| Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer | Phase 3 | Summit Therapeutics | 9 mi |
| A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010) | Phase 3 | Merck Sharp & Dohme LLC | 9 mi |
| A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Phase 2 | Kyntra Bio | 9 mi |
| TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer | N/A | Urological Research Network, LLC | 9 mi |
| Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | Phase 2/3 | Eikon Therapeutics | 9 mi |
| A CCTA Imaging Trial to Evaluate the Effect of Obicetrapib/Ezetimibe on Coronary Plaque | Phase 3 | NewAmsterdam Pharma | 9 mi |
| AMBER-HFpEF: Assessment of CK-4021586 in a Multi-Center, Blinded Evaluation of Safety and Tolerability Results in HFpEF | Phase 2 | Cytokinetics | 9 mi |
| A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines | Phase 3 | Takeda | 9 mi |
| A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease | Phase 1 | GlaxoSmithKline | 9 mi |
| Intranasal Insulin and Glutathione as an Add-On Therapy in Parkinson's Disease | Phase 2 | Gateway Institute for Brain Research | 9 mi |
| A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) | Phase 3 | Merck Sharp & Dohme LLC | 9 mi |
| A Pivotal Phase II Clinical Trial of Utidelone Injection Plus Capecitabine in HER2-negative Breast Cancer Patients With Brain Metastases | Phase 2 | Biostar Pharma, Inc. | 9 mi |
| A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | Phase 3 | Hoffmann-La Roche | 9 mi |
| A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202) | Phase 3 | Bristol-Myers Squibb | 9 mi |
| REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis | Phase 3 | Regeneron Pharmaceuticals | 9 mi |
| A Trial to Evaluate Efficacy and Safety of Maridebart Cafraglutide in Adults Living With Elevated Liver Fat and Obesity or Overweight | Phase 2 | Amgen | 9 mi |
| Non-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis | Phase 3 | Sanofi | 9 mi |
| A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011) | Phase 3 | Merck Sharp & Dohme LLC | 9 mi |
| Shield Post-Approval Study Protocol | — | Guardant Health, Inc. | 9 mi |
| I-124 PET/CT Imaging and Dosimetry for RAI-Naïve or Refractory Thyroid Cancer | — | Miami Cancer Research Center, Inc. | 9 mi |
| Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T | Phase 2 | Dendreon | 10 mi |
| A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) | Phase 3 | Xenon Pharmaceuticals Inc. | 10 mi |
| Guselkumab vs Golimumab in PsA TNF Inadequate Responder Patients | Phase 3 | University of Pennsylvania | 10 mi |
| A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease | Phase 2 | GlaxoSmithKline | 11 mi |
| TRITON-CM: A Study to Evaluate Nucresiran in Patients With Transthyretin Amyloidosis With Cardiomyopathy | Phase 3 | Alnylam Pharmaceuticals | 11 mi |
| NOX1416 in Treatment of Chronic Non-Healing Diabetic Foot Ulcers | Phase 1 | NOxy Health Products, LLC | 11 mi |
| eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation | Phase 3 | GlaxoSmithKline | 11 mi |
| A Non-Randomized Open Label Clinical Trial Evaluating DermaBind TL | Phase 4 | HealthTech Wound Care | 11 mi |
| A Study to Evaluate LY3537021 for the Treatment of Nausea and Vomiting Caused by Chemotherapy in Adults With Cancer | Phase 2 | Eli Lilly and Company | 13 mi |
| Cryaoablation Assisted Partial Nephrectomy a Non Ischemic Approach | N/A | Urological Research Network, LLC | 13 mi |
| MRI/Ultrasound Fusion Guided Prostate Cryotherapy | — | Urological Research Network, LLC | 13 mi |
| MRI/Ultrasound Fusion Guided Laser Ablation of Prostate Cancer | — | Urological Research Network, LLC | 13 mi |
| The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer | Phase 3 | Quercis Pharma AG | 13 mi |
| A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH) | Phase 2 | Eccogene | 13 mi |
| A Phase 1, Randomized, Double-blind, Placebo-controlled Study Evaluating AMG 691 in Healthy Participants and Participants With Mild-to-Moderate Asthma | Phase 1 | Amgen | 13 mi |
| BTL-699-2 and HPM-6000UF Devices for the Improvement of Depressive Symptoms and Sexual Function Among Perimenopausal and Postmenopausal Women | N/A | BTL Industries Ltd. | 13 mi |
| Prospective Analysis of EnVisio Spatial Intelligence for Soft Tissue Localization and Guided Surgical Excision | — | Elucent Medical | 13 mi |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes | Phase 3 | vTv Therapeutics | 13 mi |
| A Study to Evaluate Sleep Electroencephalogram (EEG) Features (Brain Activity While Sleeping) in Participants With Major Depressive Disorder (MDD) | — | Janssen Research & Development, LLC | 13 mi |
| A Study of LY3457263 Compared With Placebo in Participants With Type 2 Diabetes on a Stable Dose of Semaglutide or Tirzepatide | Phase 2 | Eli Lilly and Company | 14 mi |
| Evaluating the Use of Photodynamic Therapy to Treat Facial Cutaneous Squamous Cell Carcinoma in Situ (SCCis) | Phase 2 | The Center for Clinical and Cosmetic Research | 14 mi |
| A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease | Phase 3 | Bristol-Myers Squibb | 14 mi |
| AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases. | Phase 2 | Artiva Biotherapeutics, Inc. | 14 mi |
| Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients | Phase 3 | Alliance for Clinical Trials in Oncology | 15 mi |
| Phase 3 Study of Anifrolumab in Adult Patients With Active Proliferative Lupus Nephritis | Phase 3 | AstraZeneca | 15 mi |
| To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma | Phase 2 | Stamford Pharmaceuticals, Inc. | 16 mi |
| A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations | Phase 1 | Atavistik Bio, Inc | 16 mi |
| Study of Oral MRT-2359 in Selected Cancer Patients | Phase 1/2 | Monte Rosa Therapeutics, Inc | 16 mi |
| Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid Tumors | Phase 1 | Lantern Pharma Inc. | 16 mi |
| A Clinical Study of YL205 in Patients With Advanced Solid Tumors | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | 16 mi |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of GSK5733584 for Injection in Participants With Advanced Solid Tumors | Phase 1 | GlaxoSmithKline | 16 mi |
| A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors | Phase 1 | Genentech, Inc. | 16 mi |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Parabilis Medicines, Inc. | 16 mi |
| IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers | Phase 1/2 | Indapta Therapeutics, INC. | 16 mi |
| JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation | Phase 1/2 | Jacobio Pharmaceuticals Co., Ltd. | 16 mi |
| To Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of DAY301 in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Day One Biopharmaceuticals, Inc. | 16 mi |
| A Phase 1 Study of BHV-1530 in Advanced Solid Tumors | Phase 1 | Biohaven Therapeutics Ltd. | 16 mi |
| Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma | Phase 2 | SCRI Development Innovations, LLC | 16 mi |
| A Study of ASP3082 in Adults With Advanced Solid Tumors | Phase 1 | Astellas Pharma Inc | 16 mi |
| An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | Teva Branded Pharmaceutical Products R&D, Inc. | 16 mi |
| SAD Study in Patients With Parkinson's Disease and Motor Fluctuations | Phase 1 | Serina Therapeutics | 16 mi |
| Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors | Phase 1 | MOMA Therapeutics | 16 mi |
| A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer | Phase 1 | Edgewood Oncology Inc. | 16 mi |
| Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer | Phase 1/2 | Incyclix Bio | 16 mi |
| A Study of PARP1 Selective Inhibitor, EIK1004 (IMP1707) in Participants With Advanced Solid Tumors. | Phase 1/2 | Eikon Therapeutics | 16 mi |
| S095035 as a Single Agent and in Combination in Adult Participants With Advanced or Metastatic Solid Tumors With Deletion of MTAP | Phase 1/2 | Servier Bio-Innovation LLC | 16 mi |
| BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors | Phase 1 | BeiGene | 16 mi |
| A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors | Phase 1/2 | Frontier Medicines Corporation | 16 mi |
| A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors | Phase 1 | BeiGene | 16 mi |
| A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy | Phase 1/2 | 7 Hills Pharma, LLC | 16 mi |
| A Study to Compare the Blood Levels and Safety of Tazemetostat in Participants With Advanced Cancer and Moderate/Severe Liver Impairment to Participants With Advanced Cancer and Normal Liver Function | Phase 1 | Epizyme, Inc. | 16 mi |
| Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus Erythematosus | Phase 2 | Sanofi | 16 mi |
| A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients | Phase 3 | Colorado Prevention Center | 16 mi |
| A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa | — | argenx | 16 mi |
| Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | Phase 3 | Novo Nordisk A/S | 16 mi |
| Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors | Phase 1 | OncoC4, Inc. | 16 mi |
| A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors | Phase 2 | Daiichi Sankyo | 16 mi |
| A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM) | Phase 3 | GlaxoSmithKline | 17 mi |
| A Clinical Investigation Evaluating Wound Closure with OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's | N/A | Compedica Inc | 17 mi |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | Phase 1/2 | Astellas Pharma Global Development, Inc. | 17 mi |
| Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC | Phase 1/2 | Xencor, Inc. | 17 mi |
| A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010). | Phase 3 | Merck Sharp & Dohme LLC | 17 mi |
| To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCL | Phase 3 | Acrotech Biopharma Inc. | 17 mi |
| A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL) | Phase 3 | BeOne Medicines | 17 mi |
| A Study to Compare Different Doses of RO7795081 With a Placebo or Semaglutide in People With Type 2 Diabetes | Phase 2 | Hoffmann-La Roche | 17 mi |
| A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01) | Phase 2/3 | Bristol-Myers Squibb | 17 mi |
| Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | Phase 2/3 | Bristol-Myers Squibb | 17 mi |
| Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor) | Phase 1/2 | EMD Serono Research & Development Institute, Inc. | 17 mi |
| VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma | Phase 1/2 | VM Oncology, LLC | 17 mi |
| Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2/3 | AbbVie | 17 mi |
| A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease | Phase 2 | Novo Nordisk A/S | 17 mi |
| Phase III Long-term Extension Trial to Assess Safety and Efficacy of CYB003 in MDD (EXTEND) | Phase 3 | Cybin IRL Limited | 17 mi |
| RESPONDER-HF Trial | N/A | Corvia Medical | 17 mi |
| A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma | Phase 2 | Janssen Research & Development, LLC | 17 mi |
| Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL) | Phase 1/2 | SWOG Cancer Research Network | 17 mi |
| A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation | Phase 1 | TScan Therapeutics, Inc. | 17 mi |
| Collection of Samples USOPTIVAL Study | — | Universal Diagnostics | 17 mi |
| DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma | Phase 2 | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 17 mi |
| A Study of LY3938577 in Participants With Type 2 Diabetes Previously Treated With Basal Insulin | Phase 2 | Eli Lilly and Company | 17 mi |
| A Multicenter, Prospective, Controlled Clinical Trial Evaluating the Efficacy of a Single Layer Placental-based Allograft and Standard of Care in the Management of Nonhealing Diabetic Foot Ulcers | Phase 4 | Applied Biologics, LLC | 17 mi |
| Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE. | Phase 2 | LB Pharmaceuticals Inc. | 17 mi |
| Valve Hemodynamic Optimization Based on Doppler-Echocardiography vs Catheterization Measurements Following ViV TAVR | N/A | Institut universitaire de cardiologie et de pneumologie de Québec, University Laval | 17 mi |
| ATrial Tachycardia PAcing Therapy in Congenital Heart | — | Ian Law | 17 mi |
| A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction | Phase 3 | Bayer | 17 mi |
| Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy | — | Tenaya Therapeutics | 17 mi |
| A Study to Learn About The COVID-19 (Study) Vaccine (Called COMIRNATY) in People That Are Less Than 21 Years Old. | Phase 4 | Pfizer | 17 mi |
| Fontan Udenafil Exercise Longitudinal Assessment Trial - 2 | Phase 3 | Mezzion Pharma Co. Ltd | 17 mi |
| Coronary Microvascular Disease (CMD) Registry | — | Medstar Health Research Institute | 17 mi |
| A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab | Phase 3 | AbbVie | 17 mi |
| A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucocorticoids and ≥2 Immunosuppressants | — | Bristol-Myers Squibb | 17 mi |
| Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases | Phase 1/2 | Colette Shen | 17 mi |
| Phase IIIb Study of Ribociclib + ET in Early Breast Cancer | Phase 3 | Novartis Pharmaceuticals | 17 mi |
| ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation | — | Guardant Health, Inc. | 17 mi |
| An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors | Phase 1 | BeOne Medicines | 17 mi |
| Exploring the Potential of Robotic Telesurgery in Remote Settings | N/A | AdventHealth | 17 mi |
| A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors | Phase 1 | BeiGene | 17 mi |
| A Phase 1 Study of CPO301 in Adult Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | 17 mi |
| A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2 | Phase 1 | Mersana Therapeutics | 17 mi |
| A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer | Phase 3 | Shanghai Henlius Biotech | 18 mi |
| Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) | Phase 3 | Revolution Medicines, Inc. | 18 mi |
| A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma | Phase 3 | GlaxoSmithKline | 18 mi |
| Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma | Phase 2/3 | Daiichi Sankyo | 18 mi |
| Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma | Phase 3 | Regeneron Pharmaceuticals | 18 mi |
| A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) | Phase 3 | Celgene | 18 mi |
| A Study to Compare the Efficacy and Safety of BMS-986489 (BMS-986012+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). | Phase 3 | Bristol-Myers Squibb | 18 mi |
| CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | Phase 1/2 | Children's Oncology Group | 18 mi |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | 18 mi |
| Study of Lurbinectedin Monotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Ewing Sarcoma | Phase 1/2 | Jazz Pharmaceuticals | 18 mi |
| Feasibility and Acceptability of Internet-based Parent-child Interaction Therapy (I-PCIT) in Pediatric Cancer | N/A | Johns Hopkins All Children's Hospital | 18 mi |
| Tumor Infiltrating Lymphocyte Therapy for Pediatric High Risk Solid Tumors | Phase 1 | H. Lee Moffitt Cancer Center and Research Institute | 18 mi |
| Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants | Phase 1 | Iovance Biotherapeutics, Inc. | 18 mi |
| Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma | Phase 1/2 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 18 mi |
| A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma | Phase 3 | Grifols Therapeutics LLC | 18 mi |
| A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS Tumors | Phase 1/2 | Hoffmann-La Roche | 18 mi |
| A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of TERN-701 in Participants With Chronic Myeloid Leukemia (CARDINAL) | Phase 1/2 | Terns, Inc. | 18 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants 12 Years of Age or Older With Locally Advanced or Metastatic Solid Tumors That Harbor MET Amplification Receiving Intravenously Infused Telisotuzumab Adizutecan | Phase 2 | AbbVie | 18 mi |
| Study of STP938 in Advanced Solid Tumours | Phase 1 | Step Pharma, SAS | 18 mi |
| Outcomes in Pediatric and Young Adult B-Cell Malignancies After Commercially Available Immunotherapy | — | Stanford University | 18 mi |
| International Pediatric Adrenocortical Tumor Registry | — | St. Jude Children's Research Hospital | 18 mi |
| Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01) | Phase 1/2 | Merck Sharp & Dohme LLC | 18 mi |
| Targeted Immunotherapy After Myeloablative TBI-Based Conditioning & AlloHCT in CAYA with High Risk T-Cell ALL & Lymphoma | Phase 1 | New York Medical College | 18 mi |
| DISCOVERY of Risk Factors for Type 2 Diabetes in Youth | — | George Washington University | 18 mi |
| Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD) | N/A | Duke University | 18 mi |
| Implementation pRogram to Improve Screening and Management for CKD in Diabetes (IRIS-CKD) (Program 2) | N/A | Duke University | 18 mi |
| Quality of Pediatric Resuscitation in a Multicenter Collaborative | — | Children's Hospital of Philadelphia | 18 mi |
| Slow Heart Registry of Fetal Immune-mediated High Degree Heart Block | — | The Hospital for Sick Children | 18 mi |
| A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections | Phase 3 | X4 Pharmaceuticals | 18 mi |
| Efficacy, Safety, and Pharmacokinetics of Vericiguat in Pediatric Participants With Heart Failure Due to Left Ventricular Systolic Dysfunction (MK-1242-036) | Phase 2/3 | Merck Sharp & Dohme LLC | 18 mi |
| Azithromycin for Critical Asthma - Pediatrics | Phase 2/3 | Johns Hopkins All Children's Hospital | 18 mi |
| Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) | Phase 3 | Merck Sharp & Dohme LLC | 18 mi |
| A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016) | Phase 3 | Merck Sharp & Dohme LLC | 18 mi |
| Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | Phase 1/2 | Genmab | 18 mi |
| A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | Phase 1/2 | Hoffmann-La Roche | 18 mi |
| A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors | Phase 1 | Eli Lilly and Company | 18 mi |
| A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer | Phase 3 | AstraZeneca | 18 mi |
| A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation | Phase 3 | Novo Nordisk A/S | 20 mi |
| A Clinical Trial to Assess the Efficacy, Safety, and Tolerability of a Repeat Dose of Fasedienol Nasal Spray for the Acute Treatment of Anxiety in Adults With Social Anxiety Disorder | Phase 2 | VistaGen Therapeutics, Inc. | 20 mi |
| A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer | Phase 3 | AstraZeneca | 20 mi |
| DESTINY-PANTUMOUR04 | — | AstraZeneca | 21 mi |
| A Study to Evaluate the Efficacy and Safety of Deucravacitinib in Adults With Active Sjögren's Syndrome | Phase 3 | Bristol-Myers Squibb | 21 mi |
| Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension). | Phase 3 | Novartis Pharmaceuticals | 21 mi |
| STOP AF First Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | 21 mi |
| Efficacy of a Breathwork Practice (SKY) on Well-Being of Individuals With Parkinson's Disease (iPD) and Care Partners | N/A | Nova Southeastern University | 21 mi |
| ARTIST: Aortic Regurgitation Trial Investigating Surgery Versus Trilogy™ | N/A | JenaValve Technology, Inc. | 21 mi |
| Study of GS-0151 in Participants With Rheumatoid Arthritis | Phase 1 | Gilead Sciences | 21 mi |
| A Phase 1/2a Study of DB-2304 in Healthy Adults and SLE Participants | Phase 1/2 | DualityBio Inc. | 21 mi |
| Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer | Phase 3 | Daiichi Sankyo | 22 mi |
| Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial | Phase 3 | NRG Oncology | 22 mi |
| A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease | Phase 4 | Janssen Research & Development, LLC | 22 mi |
| A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation | Phase 2 | VA Office of Research and Development | 22 mi |
| Replacing Invasive Cystoscopy With Urine Testing for Non-muscle Invasive Bladder Cancer Surveillance | Phase 2 | White River Junction Veterans Affairs Medical Center | 22 mi |
| A Study of Pasritamig Versus Placebo in Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC) | Phase 3 | Janssen Research & Development, LLC | 22 mi |
| Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer | Phase 2/3 | VA Office of Research and Development | 22 mi |
| A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE) | Phase 3 | Zai Lab (Shanghai) Co., Ltd. | 24 mi |
| A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011) | Phase 3 | Merck Sharp & Dohme LLC | 24 mi |
| KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) | Phase 2 | Merck Sharp & Dohme LLC | 24 mi |
| GEMINI-NSCLC: NSCLC Biomarker Study | — | Tempus AI | 24 mi |
| A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F) | Phase 1/2 | Merck Sharp & Dohme LLC | 24 mi |
| Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer | Phase 3 | BioNTech SE | 24 mi |
| Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma | Phase 3 | ECOG-ACRIN Cancer Research Group | 25 mi |
| Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene) | Phase 1 | Boehringer Ingelheim | 25 mi |
| Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer | Phase 3 | GlaxoSmithKline | 25 mi |
| Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays | N/A | Alliance for Clinical Trials in Oncology | 25 mi |
| Met Non Small Cell Cancer Registry (MOMENT) | — | EMD Serono Research & Development Institute, Inc. | 25 mi |
| Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers | Phase 2 | SWOG Cancer Research Network | 25 mi |
| AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Cancer | Phase 3 | AstraZeneca | 25 mi |
| Molecular Genetics Studies of Cancer Patients and Their Relatives | — | City of Hope Medical Center | 25 mi |
| Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial | Phase 3 | ECOG-ACRIN Cancer Research Group | 25 mi |
| Evaluating the Impact of Social and Genetic Factors on Outcomes in Adolescent and Young Adult Cancer Survivors | — | ECOG-ACRIN Cancer Research Group | 25 mi |
| Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study | Phase 3 | National Cancer Institute (NCI) | 25 mi |
| Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations | Phase 2 | Alliance for Clinical Trials in Oncology | 25 mi |
| Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia | Phase 2 | National Cancer Institute (NCI) | 25 mi |
| Testing Whether the Addition of Carboplatin Chemotherapy to Cabazitaxel Chemotherapy Will Improve Outcomes Compared to Cabazitaxel Alone in People With Castrate-Resistant Prostate Cancer That Has Spread Beyond the Prostate to Other Parts of the Body | Phase 3 | SWOG Cancer Research Network | 25 mi |
| Evaluating Whether an Educational Website Called Current Together After Cancer (CTAC) Improves Follow-up Care for Colorectal Cancer Survivors | Phase 3 | SWOG Cancer Research Network | 25 mi |
| Investigating Cardiac Health of Adults With Trauma | N/A | Nova Southeastern University | 25 mi |
| The Student Wellness and Emotional Growth Resiliency (SWAG-R) Program | N/A | Nova Southeastern University | 25 mi |
| Mobile Health for Adherence in Breast Cancer Patients | N/A | ECOG-ACRIN Cancer Research Group | 25 mi |
| Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change | Phase 2 | National Cancer Institute (NCI) | 25 mi |
| Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer | Phase 3 | National Cancer Institute (NCI) | 25 mi |
| Study of PF-07248144 in Advanced or Metastatic Solid Tumors | Phase 1 | Pfizer | 25 mi |
| Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis | Phase 2 | Novartis Pharmaceuticals | 26 mi |
| A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone Lymphoma | Phase 3 | Regeneron Pharmaceuticals | 26 mi |
| HMPL-A580 in Participants With Advanced or Metastatic Solid Tumor | Phase 1/2 | Hutchmed | 26 mi |
| Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 2 | Karyopharm Therapeutics Inc | 26 mi |
| First-in-human Study of DB-1305/BNT325 for Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 26 mi |
| Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies | Phase 1 | InnoCare Pharma Inc. | 26 mi |
| Study of ORIC-944 in Patients With Metastatic Prostate Cancer | Phase 1 | ORIC Pharmaceuticals | 26 mi |
| ZEN003694 and Enzalutamide Versus Enzalutamide Monotherapy in Metastatic Castration-Resistant Prostate Cancer | Phase 2 | Zenith Epigenetics | 26 mi |
| A Phase Ⅰ/Ⅱa Study of HMPL-A251 in Participants With Advanced or Metastatic HER2-expressing Solid Tumors | Phase 1/2 | Hutchmed | 26 mi |
| Depemokimab Asthma Imaging and Bronchoscopy Sub-Study | Phase 3 | GlaxoSmithKline | 26 mi |
| Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases. | Phase 1 | IRIS Research and Development, LLC | 26 mi |
| Tibulizumab Systemic Sclerosis Understanding and Response Evaluation (TibuSURE) | Phase 2 | Zura Bio Inc | 26 mi |
| Phase 3 Study of Gedatolisib as First-Line Treatment for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer (VIKTORIA-2) | Phase 3 | Celcuity Inc | 26 mi |
| A Study of IBI363 in Subjects with Advanced Solid Malignancies | Phase 2 | Innovent Biologics (Suzhou) Co. Ltd. | 26 mi |
| This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1. | Phase 3 | Pfizer | 26 mi |
| A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer | Phase 1 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 26 mi |
| IBI363 vs Docetaxel in Patients With Advanced Squamous Lung Cancer After Standard Treatments Have Failed | Phase 3 | Fortvita Biologics (USA)Inc. | 26 mi |
| Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors | Phase 1 | Conjupro Biotherapeutics, Inc. | 26 mi |
| Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC) | Phase 3 | Amgen | 26 mi |
| ALTO-100 in Bipolar Disorder With Depression (BD-D) | Phase 2 | Alto Neuroscience | 26 mi |
| Screening for AL Amyloidosis in Smoldering Multiple Myeloma | — | Tufts Medical Center | 27 mi |
| Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer | Phase 3 | Surgimab | 27 mi |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Krystal Biotech, Inc. | 27 mi |
| Artificial Intelligence-Powered Support For Quality Of Life Improvement In Participants With Cancer | N/A | Case Comprehensive Cancer Center | 27 mi |
| Decreasing Chemotherapy Induced Distress Using Immersive Virtual Reality in Patients With Cancer | N/A | Case Comprehensive Cancer Center | 27 mi |
| Groundbreaking Renal Assist Device Intervening to ENhance cardioThoracic Surgery Outcomes | N/A | 3ive Labs | 27 mi |
| Trial to Evaluate Safety And Effectiveness of Mechanical Circulatory Support in Patients With Advancing Heart Failure | N/A | Abbott Medical Devices | 27 mi |
| Multi-center Collaborative to Enhance Quality and Outcomes in the Management of Cardiogenic Shock | — | STAVROS G DRAKOS | 27 mi |
| Cardiogenic Shock Working Group Registry | — | Tufts Medical Center | 27 mi |
| HEMOTAG® Assessment for Short-term Outcomes of Heart Failure | N/A | Aventusoft, LLC. | 27 mi |
| Global Cardio Oncology Registry | — | The Cleveland Clinic | 27 mi |
| A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs | Phase 1/2 | Krystal Biotech, Inc. | 27 mi |
| A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer | Phase 2 | Wayshine Biopharm, Inc. | 27 mi |
| First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors | Phase 1/2 | DualityBio Inc. | 28 mi |
| A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib as a New Treatment for Colorectal Cancer. | Phase 2 | Kahr Bio Australia Pty Ltd | 28 mi |
| DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors | Phase 2 | DualityBio Inc. | 28 mi |
| A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors | Phase 1 | Shanghai Henlius Biotech | 29 mi |
| A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection | Phase 3 | Taiho Oncology, Inc. | 29 mi |
| To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | Phase 2 | Abion Inc | 29 mi |
| A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer | Phase 3 | Pfizer | 29 mi |
| Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes | Phase 3 | Kailera | 29 mi |
| Visugromab in Cachexia International Trial | Phase 2/3 | CatalYm GmbH | 29 mi |
| Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | Phase 3 | Boehringer Ingelheim | 29 mi |
| Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | Phase 3 | Merck Sharp & Dohme LLC | 29 mi |
| Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | Phase 1/2 | AbbVie | 29 mi |
| A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer | Phase 2/3 | Pfizer | 29 mi |
| Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | Phase 3 | Merck Sharp & Dohme LLC | 29 mi |
| A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers | Phase 1/2 | Pfizer | 29 mi |
| A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer | Phase 3 | Pfizer | 29 mi |
| A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | Phase 2/3 | AbbVie | 29 mi |
| Integrated Cancer Repository for Cancer Research | — | University of Nebraska | 29 mi |
| A Study of HS-20110 in Participants With Advanced Solid Tumors | Phase 1 | Hansoh BioMedical R&D Company | 31 mi |
| Beamion PANTUMOR-1: A Study to Test Whether Zongertinib Helps People With Advanced Cancers With HER2 Alterations | Phase 2 | Boehringer Ingelheim | 31 mi |
| Miro3D Wound Matrix Study for Diabetic Foot Ulcers and Wound Healing | N/A | Reprise Biomedical, Inc. | 31 mi |
| Study of WAL0921 in Patients With Glomerular Kidney Diseases | Phase 2 | Walden Biosciences | 31 mi |
| Study of Miro3D Wound Matrix for Healing Wounds and Ulcers in Outpatient Care | N/A | Reprise Biomedical, Inc. | 31 mi |
| LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2 | Phase 3 | Tenax Therapeutics, Inc. | 31 mi |
| A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2) | Phase 3 | Generate Biomedicines | 31 mi |
| A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors) | Phase 2 | Hoffmann-La Roche | 31 mi |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | Phase 1 | OncoNano Medicine, Inc. | 31 mi |
| A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 3 | Celgene | 32 mi |
| Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations | Phase 3 | SWOG Cancer Research Network | 32 mi |
| A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer | Phase 2 | Jazz Pharmaceuticals | 32 mi |
| Real World Evidence with the Debritom+ TM Novel Micro Water Jet Technology At a Single Wound Center | N/A | Medaxis, LLC | 32 mi |
| Study of SGR-1505 in Mature B-Cell Neoplasms | Phase 1 | Schrödinger, Inc. | 33 mi |
| PTT-936 Alone or in Combination in Patients With Locally Advanced or Metastatic Solid Tumors | Phase 1/2 | Pyrotech Therapeutics, Inc. | 33 mi |
| A First-in-Human, Phase 1/2 Study of LAT010 in Patients With Advanced Solid Tumors (LIGHTSPEED-1) | Phase 1/2 | Latticon Antibody Therapeutics, Inc | 33 mi |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors | Phase 1 | Shanghai Allink Biotherapeutics Co., Ltd. | 33 mi |
| Dynamic Light Scattering Ocular Measurement in the Detection of Dementia | — | MD Stem Cells | 34 mi |
| Neurologic Stem Cell Treatment Study | N/A | MD Stem Cells | 36 mi |
| Cantharidin Application in Patients With Common Warts (Verruca Vulgaris) (COVE-2) | Phase 3 | Verrica Pharmaceuticals Inc. | 37 mi |
| A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | Phase 3 | Loxo Oncology, Inc. | 37 mi |
| An Open-Label Pilot Study of VTX2735 in Recurrent Pericarditis | Phase 2 | Zomagen Biosciences Ltd. | 37 mi |
| Effects of Torso Weighting on Muscle Activation During Balance Tests in Individuals With and Without Multiple Sclerosis | N/A | University of St. Augustine for Health Sciences | 37 mi |
| The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies | Phase 1/2 | AVM Biotechnology Inc | 40 mi |
| Development and Analysis of a Stool Bank for Cancer Patients | — | Persephone Biosciences | 42 mi |
| Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer | Phase 1/2 | Cantex Pharmaceuticals | 42 mi |
| Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis | Phase 3 | Janssen Research & Development, LLC | 42 mi |
| Pulsed Electromagnetic Field Treatment With Dementia Patients | N/A | Herrick Medical LLC | 42 mi |
| Brain NAD in Alzheimer's Disease | — | Florida Atlantic University | 42 mi |
| Digital Detection of Dementia (D Cubed) Studies: D3 | N/A | Indiana University | 42 mi |
| Study to Evaluate Efficacy and Safety of Inclisiran in Children With Heterozygous Familial Hypercholesterolemia | Phase 3 | Novartis Pharmaceuticals | 42 mi |
| Focused Orticumab Research for Treating Inflammation in Coronary Arteries | Phase 2 | Abcentra | 42 mi |
| Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: | — | Supernus Pharmaceuticals, Inc. | 42 mi |
| A Study of AAV2-GDNF in Adults With Moderate Parkinson's Disease (REGENERATE-PD) | Phase 2 | AskBio Inc | 42 mi |
| Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD) | Phase 2 | Denali Therapeutics Inc. | 42 mi |
| Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) | Phase 3 | Amgen | 42 mi |
| Comparison of Breast Cancer Screening With CESM to DBT in Women With Dense Breasts | N/A | American College of Radiology | 42 mi |
| A Beta-only IL-2 ImmunoTherapY Study | Phase 1/2 | Medicenna Therapeutics, Inc. | 42 mi |
| Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies | Phase 1 | TopAlliance Biosciences | 42 mi |
| JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer | Phase 3 | University of Texas Southwestern Medical Center | 42 mi |
| A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | Phase 2/3 | AbbVie | 42 mi |
| QTX3544 in Patients With Advanced Solid Tumors With KRAS G12V Mutations | Phase 1 | Quanta Therapeutics | 43 mi |
| BIOTRONIK Conduction System Pacing With the Solia Lead - Solia CSP S | N/A | Biotronik, Inc. | 43 mi |
| A Study of JNJ-78278343 in Combination With Either JNJ-63723283 (Cetrelimab), Taxane Chemotherapy, or Androgen Receptor Pathway Inhibitors for Metastatic Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | 43 mi |
| A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression Treated With Intravenously (IV) Infused Mirvetuximab Soravtansine | Phase 2 | AbbVie | 43 mi |
| A Study of DS9051b in Participants With Advanced or Metastatic Adrenocortical Carcinoma and Metastatic Castration-resistant Prostate Cancer | Phase 1 | Daiichi Sankyo | 43 mi |
| A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201) | Phase 2 | Nurix Therapeutics, Inc. | 43 mi |
| A Study of Pasritamig (JNJ-78278343) in Combination With JNJ-86974680 for Treatment of Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | 43 mi |
| A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation | Phase 1/2 | D3 Bio (Wuxi) Co., Ltd | 43 mi |
| First-in-Human Study of DS-3939a in Participants With Advanced Solid Tumors | Phase 1/2 | Daiichi Sankyo | 43 mi |
| ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors | Phase 1/2 | Adagene Inc | 43 mi |
| A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors. | Phase 1 | Whitehawk Therapeutics, Inc. | 43 mi |
| Prospective Evaluation of the Pulse Biosciences nPulse™ Vybrance™ Percutaneous Electrode System | N/A | Pulse Biosciences, Inc. | 43 mi |
| A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors | Phase 1/2 | Astellas Pharma Global Development, Inc. | 43 mi |
| Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia | N/A | University of Colorado, Denver | 43 mi |
| A Study of JNJ-78278343 in Combination With JNJ-95298177 for Treatment of Prostate Cancer | Phase 1 | Janssen Research & Development, LLC | 43 mi |
| A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination | Phase 1/2 | Selecxine | 43 mi |
| A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors | Phase 1 | ArriVent BioPharma, Inc. | 43 mi |
| A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors | Phase 1 | Erasca, Inc. | 43 mi |
| Phase 1 Study of ACR-2316 in Specific Advanced Solid Tumors | Phase 1 | Acrivon Therapeutics | 43 mi |
| A Phase 1/2 Study of STP938 for Adult Subjects With Relapsed/Refractory B-Cell and T-Cell Lymphomas | Phase 1/2 | Step Pharma, SAS | 43 mi |
| A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC) | Phase 1/2 | Halda Therapeutics OpCo, Inc. | 43 mi |
| A Study of PYX-201 in Advanced Solid Tumors | Phase 1 | Pyxis Oncology, Inc | 43 mi |
| Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer | Phase 3 | Genmab | 43 mi |
| A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies | Phase 1 | Accutar Biotechnology Inc | 43 mi |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | Phase 1 | Genentech, Inc. | 43 mi |
| A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer | Phase 3 | Ferring Pharmaceuticals | 43 mi |
| A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers | Phase 1 | Janssen Research & Development, LLC | 43 mi |
| A Study of sEphB4-HSA in Kaposi Sarcoma | Phase 2 | Vasgene Therapeutics, Inc | 43 mi |
| A Study of DS5361b in Participants With Advanced Solid Tumors | Phase 1 | Daiichi Sankyo | 43 mi |
| A Study of JNJ-95437446 in Participants With Advanced-Stage Solid Tumors | Phase 1 | Janssen Research & Development, LLC | 43 mi |
| A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Clinical Activity of RO7673396 in Participants With Advanced Solid Tumors Harboring Rat Sarcoma Viral Oncogene Homolog (RAS) Mutation(s) | Phase 1 | Hoffmann-La Roche | 43 mi |
| A Study of YL242 in Subjects With Advanced Solid Tumors | Phase 1/2 | MediLink Therapeutics (Suzhou) Co., Ltd. | 43 mi |
| A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | Phase 1 | Bristol-Myers Squibb | 43 mi |
| Safety and Tolerability Study of GIM-122 in Subjects With Advanced Solid Malignancies | Phase 1/2 | Georgiamune Inc | 43 mi |
| Phase 1a/b Study of ZL-6201 Safety, PK, and Preliminary Efficacy in Sarcoma and Selected Tumors | Phase 1 | Zai Lab (Shanghai) Co., Ltd. | 43 mi |
| Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance | N/A | University of Colorado, Denver | 43 mi |
| Observational Study to Examine the Procedural and Outcomes of AF Ablation Assisted by STAR Apollo™ Mapping System | — | Kansas City Heart Rhythm Research Foundation | 43 mi |
| SPHERE Per-AF Post-Approval Study | — | Medtronic Cardiac Ablation Solutions | 43 mi |
| Safety and Effectiveness of Left Bundle Branch Area Pacing Versus Conventional Cardiac Resynchronization Therapy in Heart Failure | N/A | Boston Scientific Corporation | 43 mi |
| The Long-term Safety and Effectiveness Evaluation of the QDOT MICRO System Use in Conjunction With VISITAG SURPOINT Module for the Treatment of Symptomatic Drug Refractory Paroxysmal Atrial Fibrillation. | — | Heart Rhythm Clinical and Research Solutions, LLC | 43 mi |
| Post Approval Study2: Hintermann Series H3 Total Ankle Replacement System | N/A | DT MedTech, LLC | 43 mi |
| A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors | Phase 1 | Alterome Therapeutics, Inc. | 43 mi |
| First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer | Phase 1 | Accent Therapeutics | 43 mi |
| A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors | Phase 1/2 | Apollo Therapeutics Ltd | 43 mi |
| A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors | Phase 1 | NiKang Therapeutics, Inc. | 43 mi |
| A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer | Phase 1 | MBQ Pharma | 43 mi |
| Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors | Phase 1/2 | Tango Therapeutics, Inc. | 43 mi |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation | Phase 1 | Incyte Corporation | 43 mi |
| A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer | Phase 1 | Sutro Biopharma, Inc. | 43 mi |
| Safety/Efficacy Study of CID-078 in Patients With Advanced Solid Tumor Malignancies | Phase 1 | Circle Pharma | 43 mi |
| Phase 1 Study of OP-3136 in Advanced or Metastatic Solid Tumors | Phase 1 | Olema Pharmaceuticals, Inc. | 43 mi |
| A Study of ZL-1310 in Subjects With Small Cell Lung Cancer | Phase 1 | Zai Lab (Shanghai) Co., Ltd. | 43 mi |
| A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors | Phase 1 | Angiex, Inc. | 43 mi |
| DermaSensor Postmarket Surveillance Study | N/A | DermaSensor, Inc. | 43 mi |
| FX Shoulder Solutions Retrospective / Prospective Clinical Study | — | FX Shoulder Solutions | 45 mi |
| A Clinical Study to Evaluate the Effects of RO7795068 in Participants With Obesity or Overweight and Type 2 Diabetes | Phase 3 | Hoffmann-La Roche | 48 mi |